



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁷ : C12N 15/31, C07K 14/315, 16/12, A61K 31/70, 39/09, G01N 33/53, 33/68, C12Q 1/68</p>	A2	<p>(11) International Publication Number: WO 00/06738</p> <p>(43) International Publication Date: 10 February 2000 (10.02.00)</p>
<p>(21) International Application Number: PCT/GB99/02452</p> <p>(22) International Filing Date: 27 July 1999 (27.07.99)</p> <p>(30) Priority Data: 9816336.3 27 July 1998 (27.07.98) GB 60/125,329 19 March 1999 (19.03.99) US</p> <p>(71) Applicant (for all designated States except US): MICROBIAL TECHNIQS LIMITED [GB/GB]; 20 Trumpington Street, Cambridge CB2 1QA (GB).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): LE PAGE, Richard, William, Falla [GB/GB]; University of Cambridge, Dept. of Pathology, Tennis Court Road, Cambridge CB2 1QP (GB). WELLS, Jeremy, Mark [GB/GB]; Actinova Ltd., 12 Pembroke Avenue, Denny End Industrial Centre, Waterbeech, Cambridge CB5 9PB (GB). HANNIFFY, Sean, Bosco [IE/GB]; University of Cambridge, Dept. of Pathology, Tennis Court Road, Cambridge CB2 1QP (GB). HANSBRO, Philip, Michael [GB/GB]; University of Cambridge, Dept. of Pathology, Tennis Court Road, Cambridge CB2 1QP (GB).</p>	<p>(74) Agents: CHAPMAN, Paul, William et al.; Kilburn & Strobe, 20 Red Lion Street, London WC1R 4PJ (GB).</p> <p>(81) Designated States: CN, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published Without international search report and to be republished upon receipt of that report.</p>	
<p>(54) Title: NUCLEIC ACIDS AND PROTEINS FROM STREPTOCOCCUS PNEUMONIAE</p> <p>(57) Abstract</p> <p>Novel proteins from <i>Streptococcus pneumoniae</i> are described, together with nucleic acid sequences encoding them. Their use in vaccines and in screening methods is also described.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

NUCLEIC ACIDS AND PROTEINS FROM STREPTOCOCCUS PNEUMONIAE

The present invention relates to proteins derived from *Streptococcus pneumoniae*, nucleic acid molecules encoding such proteins, the use of the nucleic acid and/or proteins as antigens/immunogens and in detection/diagnosis, as well as methods for screening the proteins/nucleic acid sequences as potential anti-microbial targets.

Streptococcus pneumoniae, commonly referred to as the pneumococcus, is an important pathogenic organism. The continuing significance of *Streptococcus pneumoniae* infections in relation to human disease in developing and developed countries has been authoritatively reviewed (Fiber, G.R., *Science*, **265**: 1385-1387 (1994)). That indicates that on a global scale this organism is believed to be the most common bacterial cause of acute respiratory infections, and is estimated to result in 1 million childhood deaths each year, mostly in developing countries (Stansfield, S.K., *Pediatr. Infect. Dis.*, **6**: 622 (1987)). In the USA it has been suggested (Breiman *et al.*, *Arch. Intern. Med.*, **150**: 1401 (1990)) that the pneumococcus is still the most common cause of bacterial pneumonia, and that disease rates are particularly high in young children, in the elderly, and in patients with predisposing conditions such as asplenia, heart, lung and kidney disease, diabetes, alcoholism, or with immunosuppressive disorders, especially AIDS. These groups are at higher risk of pneumococcal septicaemia and hence meningitis and therefore have a greater risk of dying from pneumococcal infection. The pneumococcus is also the leading cause of otitis media and sinusitis, which remain prevalent infections in children in developed countries, and which incur substantial costs.

25

The need for effective preventative strategies against pneumococcal infection is highlighted by the recent emergence of penicillin-resistant pneumococci. It has been reported that 6.6% of pneumococcal isolates in 13 US hospitals in 12 states were found

to be resistant to penicillin and some isolates were also resistant to other antibiotics including third generation cyclosporins (Schappert, S.M., *Vital and Health Statistics of the Centres for Disease Control/National Centre for Health Statistics*, 214:1 (1992)). The rates of penicillin resistance can be higher (up to 20%) in some hospitals (Breiman *et al*, J. Am. Med. Assoc., 271: 1831 (1994)). Since the development of penicillin resistance among pneumococci is both recent and sudden, coming after decades during which penicillin remained an effective treatment, these findings are regarded as alarming.

For the reasons given above, there are therefore compelling grounds for considering improvements in the means of preventing, controlling, diagnosing or treating pneumococcal diseases.

Various approaches have been taken in order to provide vaccines for the prevention of pneumococcal infections. Difficulties arise for instance in view of the variety of serotypes (at least 90) based on the structure of the polysaccharide capsule surrounding the organism. Vaccines against individual serotypes are not effective against other serotypes and this means that vaccines must include polysaccharide antigens from a whole range of serotypes in order to be effective in a majority of cases. An additional problem arises because it has been found that the capsular polysaccharides (each of which determines the serotype and is the major protective antigen) when purified and used as a vaccine do not reliably induce protective antibody responses in children under two years of age, the age group which suffers the highest incidence of invasive pneumococcal infection and meningitis.

A modification of the approach using capsule antigens relies on conjugating the polysaccharide to a protein in order to derive an enhanced immune response, particularly by giving the response T-cell dependent character. This approach has

been used in the development of a vaccine against *Haemophilus influenzae*, for instance. There are, however, issues of cost concerning both the multi-polysaccharide vaccines and those based on conjugates.

5 A third approach is to look for other antigenic components which offer the potential to be vaccine candidates. This is the basis of the present invention. Using a specially developed bacterial expression system, we have been able to identify a group of protein antigens from pneumococcus which are associated with the bacterial envelope or which are secreted.

10

Thus, in a first aspect the present invention provides a *Streptococcus pneumoniae* protein or polypeptide having a sequence selected from those shown in table 1.

15 In a second aspect, the present invention provides a *Streptococcus pneumoniae* protein or polypeptide having a sequence selected from those shown in table 2.

A protein or polypeptide of the present invention may be provided in substantially pure form. For example, it may be provided in a form which is substantially free of other proteins.

20

As discussed herein, the proteins and polypeptides of the invention are useful as antigenic material. Such material can be "antigenic" and/or "immunogenic". Generally, "antigenic" is taken to mean that the protein or polypeptide is capable of being used to raise antibodies or indeed is capable of inducing an antibody response in
25 a subject. "Immunogenic" is taken to mean that the protein or polypeptide is capable of eliciting a protective immune response in a subject. Thus, in the latter case, the protein or polypeptide may be capable of not only generating an antibody response but, in addition, a non-antibody based immune response.

The skilled person will appreciate that homologues or derivatives of the proteins or polypeptides of the invention will also find use in the context of the present invention, ie as antigenic/immunogenic material. Thus, for instance proteins or polypeptides which include one or more additions, deletions, substitutions or the like are encompassed by the present invention. In addition, it may be possible to replace one amino acid with another of similar "type". For instance replacing one hydrophobic amino acid with another.

One can use a program such as the CLUSTAL program to compare amino acid sequences. This program compares amino acid sequences and finds the optimal alignment by inserting spaces in either sequence as appropriate. It is possible to calculate amino acid identity or similarity (identity plus conservation of amino acid type) for an optimal alignment. A program like BLASTx will align the longest stretch of similar sequences and assign a value to the fit. It is thus possible to obtain a comparison where several regions of similarity are found, each having a different score. Both types of identity analysis are contemplated in the present invention.

In the case of homologues and derivatives, the degree of identity with a protein or polypeptide as described herein is less important than that the homologue or derivative should retain the antigenicity or immunogenicity of the original protein or polypeptide. However, suitably, homologues or derivatives having at least 60% similarity (as discussed above) with the proteins or polypeptides described herein are provided. Preferably, homologues or derivatives having at least 70% similarity, more preferably at least 80% similarity are provided. Most preferably, homologues or derivatives having at least 90% or even 95% similarity are provided.

In an alternative approach, the homologues or derivatives could be fusion proteins, incorporating moieties which render purification easier, for example by effectively

tagging the desired protein or polypeptide. It may be necessary to remove the "tag" or it may be the case that the fusion protein itself retains sufficient antigenicity to be useful.

- 5 In an additional aspect of the invention there are provided antigenic/immunogenic fragments of the proteins or polypeptides of the invention, or of homologues or derivatives thereof.

10 For fragments of the proteins or polypeptides described herein, or of homologues or derivatives thereof, the situation is slightly different. It is well known that is possible to screen an antigenic protein or polypeptide to identify epitopic regions, ie those regions which are responsible for the protein or polypeptide's antigenicity or immunogenicity. Methods for carrying out such screening are well known in the art. Thus, the fragments of the present invention should include one or more such epitopic regions or be
15 sufficiently similar to such regions to retain their antigenic/immunogenic properties. Thus, for fragments according to the present invention the degree of identity is perhaps irrelevant, since they may be 100% identical to a particular part of a protein or polypeptide, homologue or derivative as described herein. The key issue, once again, is that the fragment retains the antigenic/immunogenic properties.

20

Thus, what is important for homologues, derivatives and fragments is that they possess at least a degree of the antigenicity/immunogenicity of the protein or polypeptide from which they are derived.

- 25 Gene cloning techniques may be used to provide a protein of the invention in substantially pure form. These techniques are disclosed, for example, in J. Sambrook *et al Molecular Cloning* 2nd Edition, Cold Spring Harbor Laboratory Press (1989). Thus, in a third aspect, the present invention provides a nucleic acid molecule

comprising or consisting of a sequence which is:

- (i) any of the DNA sequences set out in Table 1 or their RNA equivalents;
- 5 (ii) a sequence which is complementary to any of the sequences of (i);
- (iii) a sequence which codes for the same protein or polypeptide, as those sequences of (i) or (ii);
- 10 (iv) a sequence which has substantial identity with any of those of (i), (ii) and (iii);
- (v) a sequence which codes for a homologue, derivative or fragment of a protein as defined in Table 1.

15

In a fourth aspect the present invention provides a nucleic acid molecule comprising or consisting of a sequence which is:

- (i) any of the DNA sequences set out in Table 2 or their RNA equivalents;
- 20 (ii) a sequence which is complementary to any of the sequences of (i);
- (iii) a sequence which codes for the same protein or polypeptide, as those sequences of (i) or (ii);
- 25 (iv) a sequence which has substantial identity with any of those of (i), (ii) and (iii); or

- (v) a sequence which codes for a homologue, derivative or fragment of a protein as defined in Table 2.

5 The nucleic acid molecules of the invention may include a plurality of such sequences, and/or fragments. The skilled person will appreciate that the present invention can include novel variants of those particular novel nucleic acid molecules which are exemplified herein. Such variants are encompassed by the present invention. These may occur in nature, for example because of strain variation. For example, additions, substitutions and/or deletions are included. In addition, and particularly when utilising
10 microbial expression systems, one may wish to engineer the nucleic acid sequence by making use of known preferred codon usage in the particular organism being used for expression. Thus, synthetic or non-naturally occurring variants are also included within the scope of the invention.

15 The term "RNA equivalent" when used above indicates that a given RNA molecule has a sequence which is complementary to that of a given DNA molecule (allowing for the fact that in RNA "U" replaces "T" in the genetic code).

20 When comparing nucleic acid sequences for the purposes of determining the degree of homology or identity one can use programs such as BESTFIT and GAP (both from the Wisconsin Genetics Computer Group (GCG) software package) BESTFIT, for example, compares two sequences and produces an optimal alignment of the most similar segments. GAP enables sequences to be aligned along their whole length and finds the optimal alignment by inserting spaces in either sequence as appropriate.
25 Suitably, in the context of the present invention when discussing identity of nucleic acid sequences, the comparison is made by alignment of the sequences along their whole length.

Preferably, sequences which have substantial identity have at least 50% sequence identity, desirably at least 75% sequence identity and more desirably at least 90 or at least 95% sequence identity with said sequences. In some cases the sequence identity may be 99% or above.

5

Desirably, the term "substantial identity" indicates that said sequence has a greater degree of identity with any of the sequences described herein than with prior art nucleic acid sequences.

10

It should however be noted that where a nucleic acid sequence of the present invention codes for at least part of a novel gene product the present invention includes within its scope all possible sequence coding for the gene product or for a novel part thereof.

15

The nucleic acid molecule may be in isolated or recombinant form. It may be incorporated into a vector and the vector may be incorporated into a host. Such vectors and suitable hosts form yet further aspects of the present invention.

20

Therefore, for example, by using probes based upon the nucleic acid sequences provided herein, genes in *Streptococcus pneumoniae* can be identified. They can then be excised using restriction enzymes and cloned into a vector. The vector can be introduced into a suitable host for expression.

25

Nucleic acid molecules of the present invention may be obtained from *S.pneumoniae* by the use of appropriate probes complementary to part of the sequences of the nucleic acid molecules. Restriction enzymes or sonication techniques can be used to obtain appropriately sized fragments for probing.

Alternatively PCR techniques may be used to amplify a desired nucleic acid sequence. Thus the sequence data provided herein can be used to design two primers for use in PCR so that a desired sequence, including whole genes or fragments thereof, can be targeted and then amplified to a high degree.

5

Typically primers will be at least 15-25 nucleotides long.

As a further alternative chemical synthesis may be used. This may be automated.

Relatively short sequences may be chemically synthesised and ligated together to provide a longer sequence.

10

There is another group of proteins from *S.pneumoniae* which have been identified using the bacterial expression system described herein. These are known proteins from *S.pneumoniae*, which have not previously been identified as antigenic proteins.

15

The amino acid sequences of this group of proteins, together with DNA sequences coding for them are shown in Table 3. These proteins, or homologues, derivatives and/or fragments thereof also find use as antigens/immunogens. Thus, in another aspect the present invention provides the use of a protein or polypeptide having a sequence selected from those shown in Tables 1-3, or homologues, derivatives and/or fragments thereof, as an immunogen/antigen.

20

In yet a further aspect the present invention provides an immunogenic/antigenic composition comprising one or more proteins or polypeptides selected from those whose sequences are shown in Tables 1-3, or homologues or derivatives thereof, and/or fragments of any of these. In preferred embodiments, the immunogenic/antigenic composition is a vaccine or is for use in a diagnostic assay.

25

In the case of vaccines suitable additional excipients, diluents, adjuvants or the like

may be included. Numerous examples of these are well known in the art.

It is also possible to utilise the nucleic acid sequences shown in Tables 1-3 in the preparation of so-called DNA vaccines. Thus, the invention also provides a vaccine
5 composition comprising one or more nucleic acid sequences as defined herein. DNA vaccines are described in the art (see for instance, Donnelly *et al*, *Ann. Rev. Immunol.*, 15:617-648 (1997)) and the skilled person can use such art described techniques to produce and use DNA vaccines according to the present invention.

10 As already discussed herein the proteins or polypeptides described herein, their homologues or derivatives, and/or fragments of any of these, can be used in methods of detecting/diagnosing *S.pneumoniae*. Such methods can be based on the detection of antibodies against such proteins which may be present in a subject. Therefore the present invention provides a method for the detection/diagnosis of *S.pneumoniae*
15 which comprises the step of bringing into contact a sample to be tested with at least one protein, or homologue, derivative or fragment thereof, as described herein. Suitably, the sample is a biological sample, such as a tissue sample or a sample of blood or saliva obtained from a subject to be tested.

20 In an alternative approach, the proteins described herein, or homologues, derivatives and/or fragments thereof, can be used to raise antibodies, which in turn can be used to detect the antigens, and hence *S.pneumoniae*. Such antibodies form another aspect of the invention. Antibodies within the scope of the present invention may be monoclonal or polyclonal.

25 Polyclonal antibodies can be raised by stimulating their production in a suitable animal host (e.g. a mouse, rat, guinea pig, rabbit, sheep, goat or monkey) when a protein as described herein, or a homologue, derivative or fragment thereof, is injected into the

animal. If desired, an adjuvant may be administered together with the protein. Well-known adjuvants include Freund's adjuvant (complete and incomplete) and aluminium hydroxide. The antibodies can then be purified by virtue of their binding to a protein as described herein.

5

Monoclonal antibodies can be produced from hybridomas. These can be formed by fusing myeloma cells and spleen cells which produce the desired antibody in order to form an immortal cell line. Thus the well-known Kohler & Milstein technique (*Nature* 256 (1975)) or subsequent variations upon this technique can be used.

10

Techniques for producing monoclonal and polyclonal antibodies that bind to a particular polypeptide/protein are now well developed in the art. They are discussed in standard immunology textbooks, for example in Roitt *et al*, *Immunology* second edition (1989), Churchill Livingstone, London.

15

In addition to whole antibodies, the present invention includes derivatives thereof which are capable of binding to proteins etc as described herein. Thus the present invention includes antibody fragments and synthetic constructs. Examples of antibody fragments and synthetic constructs are given by Dougall *et al* in *Tibtech* 12 372-379 (September 1994).

20

25

Antibody fragments include, for example, Fab, F(ab')₂ and Fv fragments. Fab fragments (These are discussed in Roitt *et al* [*supra*]). Fv fragments can be modified to produce a synthetic construct known as a single chain Fv (scFv) molecule. This includes a peptide linker covalently joining V_H and V_L regions, which contributes to the stability of the molecule. Other synthetic constructs that can be used include CDR peptides. These are synthetic peptides comprising antigen-binding determinants. Peptide mimetics may also be used. These molecules are usually conformationally

restricted organic rings that mimic the structure of a CDR loop and that include antigen-interactive side chains.

5 Synthetic constructs include chimaeric molecules. Thus, for example, humanised (or primatised) antibodies or derivatives thereof are within the scope of the present invention. An example of a humanised antibody is an antibody having human framework regions, but rodent hypervariable regions. Ways of producing chimaeric antibodies are discussed for example by Morrison *et al* in PNAS, 81, 6851-6855 (1984) and by Takeda *et al* in Nature. 314, 452-454 (1985).

10

Synthetic constructs also include molecules comprising an additional moiety that provides the molecule with some desirable property in addition to antigen binding. For example the moiety may be a label (e.g. a fluorescent or radioactive label). Alternatively, it may be a pharmaceutically active agent.

15

Antibodies, or derivatives thereof, find use in detection/diagnosis of *S.pneumoniae*. Thus, in another aspect the present invention provides a method for the detection/diagnosis of *S.pneumoniae* which comprises the step of bringing into contact a sample to be tested and antibodies capable of binding to one or more proteins described herein, or to homologues, derivatives and/or fragments thereof.

20

In addition, so-called "Affibodies" may be utilised. These are binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain (Nord *et al* ,) Thus, Small protein domains, capable of specific binding to different target proteins can be selected using combinatorial approaches.

25

It will also be clear that the nucleic acid sequences described herein may be used to detect/diagnose *S.pneumoniae*. Thus, in yet a further aspect, the present invention

provides a method for the detection/diagnosis of *S.pneumoniae* which comprises the step of bringing into contact a sample to be tested with at least one nucleic acid sequence as described herein. Suitably, the sample is a biological sample, such as a tissue sample or a sample of blood or saliva obtained from a subject to be tested.

- 5 Such samples may be pre-treated before being used in the methods of the invention. Thus, for example, a sample may be treated to extract DNA. Then, DNA probes based on the nucleic acid sequences described herein (ie usually fragments of such sequences) may be used to detect nucleic acid from *S.pneumoniae*.

- 10 In additional aspects, the present invention provides:

- (a) a method of vaccinating a subject against *S.pneumoniae* which comprises the step of administering to a subject a protein or polypeptide of the invention, or a derivative, homologue or fragment thereof, or an immunogenic composition of the
15 invention;
- (b) a method of vaccinating a subject against *S.pneumoniae* which comprises the step of administering to a subject a nucleic acid molecule as defined herein;
- 20 (c) a method for the prophylaxis or treatment of *S.pneumoniae* infection which comprises the step of administering to a subject a protein or polypeptide of the invention, or a derivative, homologue or fragment thereof, or an immunogenic composition of the invention;
- 25 (d) a method for the prophylaxis or treatment of *S.pneumoniae* infection which comprises the step of administering to a subject a nucleic acid molecule as defined herein;

- (e) a kit for use in detecting/diagnosing *S.pneumoniae* infection comprising one or more proteins or polypeptides of the invention, or homologues, derivatives or fragments thereof, or an antigenic composition of the invention; and
- 5 (f) a kit for use in detecting/diagnosing *S.pneumoniae* infection comprising one or more nucleic acid molecules as defined herein.

Given that we have identified a group of important proteins, such proteins are potential targets for anti-microbial therapy. It is necessary, however, to determine
10 whether each individual protein is essential for the organism's viability. Thus, the present invention also provides a method of determining whether a protein or polypeptide as described herein represents a potential anti-microbial target which comprises antagonising, inhibiting or otherwise interfering with the function or expression of said protein and determining whether *S.pneumoniae* is still viable.

15

A suitable method for inactivating the protein is to effect selected gene knockouts, ie prevent expression of the protein and determine whether this results in a lethal change. Suitable methods for carrying out such gene knockouts are described in Li
20 *et al* , *P.N.A.S.*, 94:13251-13256 (1997) and Kolkman *et al* , 178:3736-3741 (1996).

In a final aspect the present invention provides the use of an agent capable of antagonising, inhibiting or otherwise interfering with the function or expression of a protein or polypeptide of the invention in the manufacture of a medicament for use in
25 the treatment or prophylaxis of *S.pneumoniae* infection.

As mentioned above, we have used a bacterial expression system as a means of identifying those proteins which are surface associated, secreted or exported and

thus, would find use as antigens.

The information necessary for the secretion/export of proteins has been extensively studied in bacteria. In the majority of cases, protein export requires a signal peptide to be present at the N-terminus of the precursor protein so that it becomes directed to the translocation machinery on the cytoplasmic membrane. During or after translocation, the signal peptide is removed by a membrane associated signal peptidase. Ultimately the localization of the protein (i.e. whether it be secreted, an integral membrane protein or attached to the cell wall) is determined by sequences other than the leader peptide itself.

We are specifically interested in surface located or exported proteins as these are likely to be antigens for use in vaccines, as diagnostic reagents or as targets for therapy with novel chemical entities. We have therefore developed a screening vector-system in *Lactococcus lactis* that permits genes encoding exported proteins to be identified and isolated. We provide below a representative example showing how given novel surface associated proteins from *Streptococcus pneumoniae* have been identified and characterized. The screening vector incorporates the staphylococcal nuclease gene *nuc* lacking its own export signal as a secretion reporter.

Staphylococcal nuclease is a naturally secreted heat-stable, monomeric enzyme which has been efficiently expressed and secreted in a range of Gram positive bacteria (Shortle, *Gene*, 22:181-189 (1983); Kovacevic *et al.*, *J. Bacteriol.*, 162:521-528 (1985); Miller *et al.*, *J. Bacteriol.*, 169:3508-3514 (1987); Liebl *et al.*, *J. Bacteriol.*, 174:1854-1861 (1992); Le Loir *et al.*, *J. Bacteriol.*, 176:5135-5139 (1994); Poquet *et al.*, *J. Bacteriol.*, 180:1904-1912 (1998)).

Recently, Poquet *et al.* ((1998), *supra*) have described a screening vector incorporating the *nuc* gene lacking its own signal leader as a reporter to identify exported proteins in Gram positive bacteria, and have applied it to *L. lactis*. This

vector (pFUN) contains the pAM β 1 replicon which functions in a broad host range of Gram-positive bacteria in addition to the ColE1 replicon that promotes replication in *Escherichia coli* and certain other Gram negative bacteria. Unique cloning sites present in the vector can be used to generate transcriptional and translational fusions between cloned genomic DNA fragments and the open reading frame of the truncated *nuc* gene devoid of its own signal secretion leader. The *nuc* gene makes an ideal reporter gene because the secretion of nuclease can readily be detected using a simple and sensitive plate test: Recombinant colonies secreting the nuclease develop a pink halo whereas control colonies remain white (Shortle, (1983), *supra*; Le Loir *et al.*, (1994), *supra*).

Thus, the invention will now be described with reference to the following representative example, which provides details of how the proteins, polypeptides and nucleic acid sequences described herein identified as antigenic targets.

We describe herein the construction of three reporter vectors and their use in *L. lactis* to identify and isolate genomic DNA fragments from *Streptococcus pneumoniae* encoding secreted or surface associated proteins.

The invention will now be described with reference to the examples, which should not be construed as in any way limiting the invention. The examples refer to the figures in which:

Figure 1: shows the results of a number of DNA vaccine trials; and

Figure 2: shows the results of further DNA vaccine trials.

EXAMPLE 1

(i) Construction of the pTREP1-nuc series of reporter vectors

(a) Construction of expression plasmid pTREP1

The pTREP1 plasmid is a high-copy number (40-80 per cell) theta-replicating gram positive plasmid, which is a derivative of the pTREX plasmid which is itself a derivative of the previously published pIL253 plasmid. pIL253 incorporates the broad Gram-positive host range replicon of pAM β 1 (Simon and Chopin, *Biochimie*, 70:559-567 (1988)) and is non-mobilisable by the *L. lactis* sex-factor. pIL253 also lacks the *tra* function which is necessary for transfer or efficient mobilisation by conjugative parent plasmids exemplified by pIL501. The Enterococcal pAM β 1 replicon has previously been transferred to various species including *Streptococcus*, *Lactobacillus* and *Bacillus* species as well as *Clostridium acetobutylicum*, (Oultram and Klaenhammer, *FEMS Microbiological Letters*, 27:129-134 (1985); Gibson *et al.*, (1979); LeBlanc *et al.*, *Proceedings of the National Academy of Science USA*, 75:3484-3487 (1978)) indicating the potential broad host range utility. The pTREP1 plasmid represents a constitutive transcription vector.

The pTREX vector was constructed as follows. An artificial DNA fragment containing a putative RNA stabilising sequence, a translation initiation region (TIR), a multiple cloning site for insertion of the target genes and a transcription terminator was created by annealing 2 complementary oligonucleotides and extending with Tfl DNA polymerase. The sense and anti-sense oligonucleotides contained the recognition sites for NheI and BamHI at their 5' ends respectively to facilitate cloning. This fragment was cloned between the XbaI and BamHI sites in pUC19NT7, a derivative of pUC19 which contains the T7 expression cassette from pLET1 (Wells *et al.*, *J. Appl. Bacteriol.*, 74:629-636 (1993)) cloned between the EcoRI and HindIII sites. The resulting construct was designated pUCLEX. The complete expression cassette of pUCLEX was then removed by cutting with HindIII and blunting followed by cutting with EcoRI before cloning into EcoRI and SacI (blunted) sites of pIL253 to generate the vector pTREX (Wells and Schofield, *In*

Current advances in metabolism, genetics and applications-NATO ASI Series, H 98:37-62 (1996)). The putative RNA stabilising sequence and TIR are derived from the *Escherichia coli* T7 bacteriophage sequence and modified at one nucleotide position to enhance the complementarity of the Shine Dalgarno (SD) motif to the
5 ribosomal 16s RNA of *Lactococcus lactis* (Schofield *et al.* pers. coms. University of Cambridge Dept. Pathology.).

A *Lactococcus lactis* MG1363 chromosomal DNA fragment exhibiting promoter activity which was subsequently designated P7 was cloned between the EcoRI and
10 BglII sites present in the expression cassette, creating pTREX7. This active promoter region had been previously isolated using the promoter probe vector pSB292 (Waterfield *et al.*, *Gene*, 165:9-15 (1995)). The promoter fragment was amplified by PCR using the Vent DNA polymerase according to the manufacturer.

15 The pTREP1 vector was then constructed as follows. An artificial DNA fragment which included a transcription terminator, the forward pUC sequencing primer, a promoter multiple -cloning site region and a universal translation stop sequence was created by annealing two overlapping partially complementary synthetic
oligonucleotides together and extending with sequenase according to manufacturers
20 instructions. The sense and anti-sense (pTREP_F and pTREP_R) oligonucleotides contained the recognition sites for EcoRV and BamHI at their 5' ends respectively to facilitate cloning into pTREX7. The transcription terminator was that of the *Bacillus penicillinase* gene, which has been shown to be effective in *Lactococcus* (Jos *et al.*, *Applied and Environmental Microbiology*, 50:540-542 (1985)). This was considered
25 necessary as expression of target genes in the pTREX vectors was observed to be leaky and is thought to be the result of cryptic promoter activity in the origin region (Schofield *et al.* pers. coms. University of Cambridge Dept. Pathology.). The forward pUC primer sequencing was included to enable direct sequencing of cloned DNA fragments. The translation stop sequence which encodes a stop codon in 3

different frames was included to prevent translational fusions between vector genes and cloned DNA fragments. The pTREX7 vector was first digested with EcoRI and blunted using the 5' - 3' polymerase activity of T4 DNA polymerase (NEB) according to manufacturer's instructions. The EcoRI digested and blunt ended pTREX7 vector was then digested with Bgl II thus removing the P7 promoter. The artificial DNA fragment derived from the annealed synthetic oligonucleotides was then digested with EcoRV and Bam HI and cloned into the EcoRI(blunted)-Bgl II digested pTREX7 vector to generate pTREP. A *Lactococcus lactis* MG1363 chromosomal promoter designated P1 was then cloned between the EcoRI and BglII sites present in the pTREP expression cassette forming pTREP1. This promoter was also isolated using the promoter probe vector pSB292 and characterised by Waterfield *et al.*, (1995), *supra*. The P1 promoter fragment was originally amplified by PCR using vent DNA polymerase according to manufacturers instructions and cloned into the pTREX as an EcoRI-BglII DNA fragment. The EcoRI-BglII P1 promoter containing fragment was removed from pTREP1 by restriction enzyme digestion and used for cloning into pTREP (Schofield *et al.* pers. coms. University of Cambridge, Dept. Pathology.).

(b) PCR amplification of the *S. aureus* nuc gene.

The nucleotide sequence of the *S. aureus* nuc gene (EMBL database accession number V01281) was used to design synthetic oligonucleotide primers for PCR amplification. The primers were designed to amplify the mature form of the nuc gene designated nucA which is generated by proteolytic cleavage of the N-terminal 19 to 21 amino acids of the secreted propeptide designated Snase B (Shortle, (1983), *supra*). Three sense primers (nucS1, nucS2 and nucS3, Appendix 1) were designed, each one having a blunt-ended restriction endonuclease cleavage site for EcoRV or SmaI in a different reading frame with respect to the nuc gene. Additionally BglII and BamHI were incorporated at the 5' ends of the sense and anti-sense primers

respectively to facilitate cloning into BamHI and BglII cut pTREP1. The sequences of all the primers are given in Appendix 1. Three nuc gene DNA fragments encoding the mature form of the nuclease gene (NucA) were amplified by PCR using each of the sense primers combined with the anti-sense primer described above. The
5 nuc gene fragments were amplified by PCR using *S. aureus* genomic DNA template, Vent DNA Polymerase (NEB) and the conditions recommended by the manufacturer. An initial denaturation step at 93 °C for 2 min was followed by 30 cycles of denaturation at 93 °C for 45 sec, annealing at 50 °C for 45 seconds, and extension at 73 °C for 1 minute and then a final 5 min extension step at 73 °C. The
10 PCR amplified products were purified using a Wizard clean up column (Promega) to remove unincorporated nucleotides and primers.

(c) Construction of the pTREP1-nuc vectors

15 The purified nuc gene fragments described in section b were digested with Bgl II and BamHI using standard conditions and ligated to BamHI and BglII cut and dephosphorylated pTREP1 to generate the pTREP1-nuc1, pTREP1-nuc2 and pTREP1-nuc3 series of reporter vectors. General molecular biology techniques were carried out using the reagents and buffer supplied by the manufacture or using
20 standard conditions(Sambrook and Maniatis, (1989), *supra*). In each of the pTREP1-nuc vectors the expression cassette comprises a transcription terminator, lactococcal promoter P1, unique cloning sites (BglII, EcoRV or SmaI) followed by the mature form of the nuc gene and a second transcription terminator. Note that the sequences required for translation and secretion of the nuc gene were deliberately excluded in
25 this construction. Such elements can only be provided by appropriately digested foreign DNA fragments (representing the target bacterium) which can be cloned into the unique restriction sites present immediately upstream of the *nuc* gene.

In possessing a promoter, the pTREP1-nuc vectors differ from the pFUN vector described by Poquet *et al.* (1998), *supra*, which was used to identify *L. lactis* exported proteins by screening directly for Nuc activity directly in *L. lactis*. As the pFUN vector does not contain a promoter upstream of the *nuc* open reading frame the cloned genomic DNA fragment must also provide the signals for transcription in addition to those elements required for translation initiation and secretion of Nuc.

This limitation may prevent the isolation of genes that are distant from a promoter for example genes which are within polycistronic operons. Additionally there can be no guarantee that promoters derived from other species of bacteria will be recognised and functional in *L. lactis*. Certain promoters may be under stringent regulation in the natural host but not in *L. lactis*. In contrast, the presence of the P1 promoter in the pTREP1-nuc series of vectors ensures that promoterless DNA fragments (or DNA fragments containing promoter sequences not active in *L. lactis*) will still be transcribed.

(d) Screening for secreted proteins in *S. pneumoniae*

Genomic DNA isolated from *S. pneumoniae* was digested with the restriction enzyme Tru9I. This enzyme which recognises the sequence 5'- TTAA -3' was used because it cuts A/T rich genomes efficiently and can generate random genomic DNA fragments within the preferred size range (usually averaging 0.5 - 1.0 kb). This size range was preferred because there is an increased probability that the P1 promoter can be utilised to transcribe a novel gene sequence. However, the P1 promoter may not be necessary in all cases as it is possible that many Streptococcal promoters are recognised in *L. lactis*. DNA fragments of different size ranges were purified from partial Tru9I digests of *S. pneumoniae* genomic DNA. As the Tru 9I restriction enzyme generates staggered ends the DNA fragments had to be made blunt ended before ligation to the EcoRV or SmaI cut pTREP1-nuc vectors. This was achieved by the partial fill-in enzyme reaction using the 5'-3' polymerase

activity of Klenow enzyme. Briefly Tru9I digested DNA was dissolved in a solution (usually between 10-20 μ l in total) supplemented with T4 DNA ligase buffer (New England Biolabs; NEB) (1X) and 33 μ M of each of the required dNTPs, in this case dATP and dTTP. Klenow enzyme was added (1 unit Klenow enzyme (NEB) per μ g of DNA) and the reaction incubated at 25°C for 15 minutes. The reaction was stopped by incubating the mix at 75°C for 20 minutes. EcoRV or SmaI digested pTREP-nuc plasmid DNA was then added (usually between 200-400 ng). The mix was then supplemented with 400 units of T4 DNA ligase (NEB) and T4 DNA ligase buffer (1X) and incubated overnight at 16°C. The ligation mix was precipitated directly in 100% Ethanol and 1/10 volume of 3M sodium acetate (pH 5.2) and used to transform *L. lactis* MG1363 (Gasson, 1983). Alternatively, the gene cloning site of the pTREP-nuc vectors also contains a BglII site which can be used to clone for example Sau3AI digested genomic DNA fragments.

L. lactis transformant colonies were grown on brain heart infusion agar and nuclease secreting (Nuc⁺) clones were detected by a toluidine blue-DNA-agar overlay (0.05 M Tris pH 9.0, 10 g of agar per litre, 10 g of NaCl per liter, 0.1 mM CaCl₂, 0.03 % wt/vol. salmon sperm DNA and 90 mg of Toluidine blue O dye) essentially as described by Shortle, 1983, *supra* and Le Loir *et al.*, 1994, *supra*). The plates were then incubated at 37°C for up to 2 hours. Nuclease secreting clones develop an easily identifiable pink halo. Plasmid DNA was isolated from Nuc⁺ recombinant *L. lactis* clones and DNA inserts were sequenced on one strand using the NucSeq sequencing primer described in Appendix 1, which sequences directly through the DNA insert.

25 Isolation of Genes Encoding Exported Proteins from *S. pneumoniae*

A large number of gene sequences putatively encoding exported proteins in *S. pneumoniae* have been identified using the nuclease screening system. These have

now been further analysed to remove artefacts. The sequences identified using the screening system have been analysed using a number of parameters.

1. All putative surface proteins were analysed for leader/signal peptide sequences using the software programs Sequencher (Gene Codes Corporation) and DNA Strider (Marck, *Nucleic Acids Res.*, 16:1829-1836 (1988)). Bacterial signal peptide sequences share a common design. They are characterised by a short positively charged N-terminus (N region) immediately preceding a stretch of hydrophobic residues (central portion-h region) followed by a more polar C-terminal portion which contains the cleavage site (c-region). Computer software is available which allows hydropathy profiling of putative proteins and which can readily identify the very distinctive hydrophobic portion (h-region) typical of leader peptide sequences. In addition, the sequences were checked for the presence of or absence of a potential ribosomal binding site (Shine-Dalgarno motif) required for translation initiation of the putative nuc reporter fusion protein.

2. All putative surface protein sequences were also matched with all of the protein/DNA sequences using the publicly databases [OWL-proteins inclusive of SwissProt and GenBank translations]. This allows us to identify sequences similar to known genes or homologues of genes for which some function has been ascribed. Hence it has been possible to predict a function for some of the genes identified using the LEEP system and to unequivocally establish that the system can be used to identify and isolate gene sequences of surface associated proteins. We should also be able to confirm that these proteins are indeed surface related and not artifacts. The LEEP system has been used to identify novel gene targets for vaccine and therapy.

3. Some of the genes identified proteins did not possess a typical leader peptide sequence and did not show homology with any DNA/protein sequences in the database. Indeed these proteins may indicate the primary advantage of our screening method, i.e. the isolation of atypical surface-related proteins, which may

have been missed in all previously described screening protocols or approaches based on sequence homology searches.

5 In all cases, only partial gene sequences were initially obtained. Full length genes were obtained in all cases by reference to the TIGR *S.pneumoniae* database (www@tigr.org). Thus, by matching the originally obtained partial sequences with the database, we were able to identify the full length gene sequences. In this way, as described herein, three groups of genes were clearly identified, ie a group of genes encoding previously unidentified *S.pneumoniae* proteins, a second group exhibiting 10 some homology with known proteins from a variety of sources and a third group which encoded known *S.pneumoniae* proteins, which were, however, not known as antigens.

15 Example 2: Vaccine trials

pcDNA3.1+ as a DNA vaccine vector

pcDNA3.1+

20 The vector chosen for use as a DNA vaccine vector was pcDNA3.1 (Invitrogen) (actually pcDNA3.1+, the forward orientation was used in all cases but may be referred to as pcDNA3.1 here on). This vector has been widely and successfully employed as a host vector to test vaccine candidate genes to give protection against pathogens in the literature (Zhang, *et al.*, Kurar and Splitter, Anderson *et al.*). The 25 vector was designed for high-level stable and non-replicative transient expression in mammalian cells. pcDNA3.1 contains the ColE1 origin of replication which allows convenient high-copy number replication and growth in *E. coli*. This in turn allows rapid and efficient cloning and testing of many genes. The pcDNA3.1 vector has a large number of cloning sites and also contains the gene encoding ampicillin 30 resistance to aid in cloning selection and the human cytomegalovirus (CMV) immediate-early promoter/enhancer which permits efficient, high-level expression of the recombinant protein. The CMV promoter is a strong viral promoter in a wide range of cell types including both muscle and immune (antigen presenting) cells. This is important for optimal immune response as it remains unknown as to which 35 cells types are most important in generating a protective response *in vivo*. A T7 promoter upstream of the multiple cloning site affords efficient expression of the

modified insert of interest and which allows *in vitro* transcription of a cloned gene in the sense orientation.

5 Zhang, D., Yang, X., Berry, J. Shen, C., McClarty, G. and Brunham, R.C. (1997) "DNA vaccination with the major outer-membrane protein genes induces acquired immunity to *Chlamydia trachomatis* (mouse pneumonitis) infection". *Infection and Immunity*, 176, 1035-40.

10 Kurar, E. and Splitter, G.A. (1997) "Nucleic acid vaccination of *Brucella abortus* ribosomal L7/L12 gene elicits immune response". *Vaccine*, 15, 1851-57.

15 Anderson, R., Gao, X.-M., Papakonstantinou, A., Roberts, M. and Dougan, G. (1996) "Immune response in mice following immunisation with DNA encoding fragment C of tetanus toxin". *Infection and Immunity*, 64, 3168-3173.

Preparation of DNA vaccines

20 Oligonucleotide primers were designed for each individual gene of interest derived using the LEEP system. Each gene was examined thoroughly, and where possible, primers were designed such that they targeted that portion of the gene thought to encode only the mature portion of the gene protein. It was hoped that expressing those sequences that encode only the mature portion of a target gene protein, would facilitate its correct folding when expressed in mammalian cells. For example, in the majority of cases primers were designed such that putative N-terminal signal peptide sequences would not be included in the final amplification product to be cloned into the pcDNA3.1 expression vector. The signal peptide directs the polypeptide precursor to the cell membrane via the protein export pathway where it is normally cleaved off by signal peptidase I (or signal peptidase II if a lipoprotein). Hence the signal peptide does not make up any part of the mature protein whether it be displayed on the surface of the bacteria surface or secreted. Where an N-terminal leader peptide sequence was not immediately obvious, primers were designed to target the whole of the gene sequence for cloning and ultimately, expression in pcDNA3.1.

35 Having said that, however, other additional features of proteins may also affect the expression and presentation of a soluble protein. DNA sequences encoding such features in the genes encoding the proteins of interest were excluded during the design of oligonucleotides. These features included:

- 40
1. LPXTG cell wall anchoring motifs.
 2. LXXC lipoprotein attachment sites.
 3. Hydrophobic C-terminal domain.

4. Where no N-terminal signal peptide or LXXC was present the start codon was excluded.

5. Where no hydrophobic C-terminal domain or LPXTG motif was present the stop codon was removed.

5
Appropriate PCR primers were designed for each gene of interest and any and all of the regions encoding the above features was removed from the gene when designing these primers. The primers were designed with the appropriate enzyme restriction site followed by a conserved Kozak nucleotide sequence (in most cases (NB except in occasional instances for example ID59) GCCACC was used. The Kozak sequence facilitates the recognition of initiator sequences by eukaryotic ribosomes) and an ATG start codon upstream of the insert of the gene of interest. For example the forward primer using a BamH1 site the primer would begin
10 GCGGGATCCGCCACCATG followed by a small section of the 5' end of the gene of interest. The reverse primer was designed to be compatible with the forward primer and with a NotI restriction site at the 5' end in most cases (this site is TTGCGGCCGC) (NB except in occasional instances for example ID59 where a XhoI site was used instead of NotI).

20 PCR primers

The following PCR primers were designed and used to amplify the truncated genes of interest.

25 ID5

Forward Primer 5'

CGGATCCGCCACCATGGGTCTAATTGAAGACTTAAAAAATCAA 3'

Reverse Primer 5' TTGCGGCCGCCAATGCTAGACTAAACACAAGACTCA 3'

30

ID59

Forward Primer 5' CGCGGATCCATGAAAAAATCTATTCAATTTTATAGCA 3'

Reverse Primer 5' CCCTCGAGGGCTACTTCCGATACATTTTAAACTGTAGG
35 3'

ID51

40 Forward Primer 5' CGGATCCGCCACCATGAGTCATGTCGCTGCAAATG 3'

Reverse Primer 5' TTGCGGCCGCATACCAAACGCTGACATCTACG 3'

ID29

Forward Primer 5' CGGATCCGCCACCATGCAAAAAGAGCGGTATGGTTATG
3'

5 Reverse Primer 5' TTGCGGCCGCACCCCCATTCTTAATCCCTT 3'

ID50

Forward Primer 5'
10 CGGATCCGCCACCATGGAGGTATGTGAAATGTCACGTAAA 3'
Reverse Primer 5' TTGCGGCCGCTTTTACAAAGTCAAGCAAAGCC 3'

Cloning

15 The insert along with the flanking features described above was amplified using PCR
against a template of genomic DNA isolated from type 4 *S. pneumoniae* strain 11886
obtained from the National Collection of Type Cultures. The PCR product was cut
with the appropriate restriction enzymes and cloned in to the multiple cloning site of
20 pcDNA3.1 using conventional molecular biological techniques. Suitably mapped
clones of the genes of interested were cultured and the plasmids isolated on a large
scale (> 1.5 mg) using Plasmid Mega Kits (Qiagen). Successful cloning and
maintenance of genes was confirmed by restriction mapping and sequencing ~ 700
base pairs through the 5' cloning junction of each large scale preparation of each
construct.

25


Strain validation

A strain of type 4 was used in cloning and challenge methods which is the strain
from which the *S. pneumoniae* genome was sequenced. A freeze dried ampoule of a
30 homogeneous laboratory strain of type 4 *S. pneumoniae* strain NCTC 11886 was
obtained from the National Collection of Type Strains. The ampoule was opened and
the cultured re suspended with 0.5 ml of tryptic soy broth (0.5% glucose, 5%
blood). The suspension was subcultured into 10 ml tryptic soy broth (0.5% glucose,
5% blood) and incubated statically overnight at 37°C. This culture was streaked on
35 to 5% blood agar plates to check for contaminants and confirm viability and on to
blood agar slopes and the rest of the culture was used to make 20% glycerol stocks.
The slopes were sent to the Public Health Laboratory Service where the type 4
serotype was confirmed.

40 A glycerol stock of NCTC 11886 was streaked on a 5% blood agar plate and
incubated overnight in a CO2 gas jar at 37°C. Fresh streaks were made and optochin
sensitivity was confirmed.

Pneumococcal challenge

5 A standard inoculum of type 4 *S. pneumoniae* was prepared and frozen down by passing a culture of pneumococcus 1x through mice, harvesting from the blood of infected animals, and grown up to a predetermined viable count of around 10^9 cfu/ml in broth before freezing down. The preparation is set out below as per the flow chart.



|
V

5 All subsequent challenges - use standard inoculum to effective dose

An aliquot of standard inoculum was diluted 500x in PBS and used to inoculate the mice.

10 Mice were lightly anaesthetised using halothane and then a dose of 1.4×10^5 cfu of pneumococcus was applied to the nose of each mouse. The uptake was facilitated by the normal breathing of the mouse, which was left to recover on its back.

S. pneumoniae Vaccine trials

15 Vaccine trials in mice were carried out by the administration of DNA to 6 week old CBA/ca mice (Harlan, UK). Mice to be vaccinated were divided into groups of six and each group was immunised with recombinant pcDNA3.1 + plasmid DNA containing a specific target-gene sequence of interest. A total of 100 μ g of DNA in
20 Dulbecco's PBS (Sigma) was injected intramuscularly into the tibialis anterior muscle of both legs (50 μ l in each leg). A boost was carried using the same procedure 4 weeks later. For comparison, control groups were included in all vaccine trials. These control groups were either unvaccinated animals or those administered with non-recombinant pcDNA3.1 + DNA (sham vaccinated) only,
25 using the same time course described above. 3 weeks after the second immunisation, all mice groups were challenged intra-nasally with a lethal dose of *S. pneumoniae* serotype 4 (strain NCTC 11886). The number of bacteria administered was monitored by plating serial dilutions of the inoculum on 5% blood agar plates. A
30 problem with intranasal immunisations is that in some mice the inoculum bubbles out of the nostrils, this has been noted in results table and taken account of in calculations. A less obvious problem is that a certain amount of the inoculum for each mouse may be swallowed. It is assumed that this amount will be the same for each mouse and will average out over the course of inoculations. However, the
35 sample sizes that have been used are small and this problem may have significant effects in some experiments. All mice remaining after the challenge were killed 3 or 4 days after infection. During the infection process, challenged mice were monitored for the development of symptoms associated with the onset of *S. pneumoniae* induced-disease. Typical symptoms in an appropriate order included piloerection, an increasingly hunched posture, discharge from eyes, increased lethargy and
40 reluctance to move. The latter symptoms usually coincided with the development of a moribund state at which stage the mice were culled to prevent further suffering. These mice were deemed to be very close to death, and the time of culling was used

to determine a survival time for statistical analysis. Where mice were found dead, the survival time was taken as the last time point when the mouse was monitored alive.

5 Interpretation of Results

A positive result was taken as any DNA sequence that was cloned and used in challenge experiments as described above which gave protection against that challenge. Protection was taken as those DNA sequences that gave statistically significant protection (to a 95% confidence level ($p < 0.05$)) and also those which were marginal or close to significant using Mann-Whitney or which show some protective features for example there were one or more outlying mice or because the time to the first death was prolonged. It is acceptable to allow marginal or non-significant results to be considered as potential positives when it is considered that the clarity of some of the results may be clouded by the problems associated with the administration of intranasal infections.

Results

Trials 1-6 (see figure 1)

Mouse number	Mean survival times (hours)									
	Unvacc control (1)	pcDNA 3.1+ (1)	ID5 (1)	Unvacc control (2)	ID59 (2)	Unvacc control (5)	ID59 (5)	Unvacc control (6)	ID51 (6)	
1	47.5	61.0	61.0	49.0	55.0	58.0	55.3	71.6*	50.0	
2	57.0	47.5	61.0	51.0	55.0	75.0	98.0	60.7	99.9T	
3	47.5	50.5	57.0	49.0	55.0	48.0	58.5	98.5	53.6	
4	47.5	50.5	72.0	55.0	69.5	46.7	55.3	(101.2)*T	99.9	
5	77.0	72.0	47.5	49.0	74.0	58.0	53.5	60.7	59.4	
6	57.0	50.5	mouse died	49.0	mouse died	75.0	98.0	50.8	50.0*	
Mean	55.6	55.3	59.7	50.3	61.7	60.1	69.8	68.4	68.8	
sd	11.5	9.4	8.8	2.4	9.3	12.5	21.9	18.3	24.4	
p value 1	-	-	0.1722	-	0.0064	-	0.2862	-	<36.0	
p value 2	-	-	0.2565	-	-	-	-	-	-	

* - bubbled when dosed so may not have received full inoculum.

T - terminated at end of experiment having no symptoms of infection.

Numbers in brackets - survival times disregarded assuming incomplete dosing

p value 1 refers to significance tests compared to unvaccinated controls

p value 2 refers to significance tests compared to pcDNA3.1 + vaccinated controls

Statistical Analyses.

5 Trial 1 - None of the other groups had significantly longer survival times than the controls. The survival times of the unvaccinated and pcDNA3.1 control groups were not significantly different. One of the mice from ID5 was an outlying result and the mean survival times for ID5 were extended but not significantly so.

Trial 2 - The group vaccinated with ID59 had significantly longer survival times than the unvaccinated control group.

10 Trial 5 - The group vaccinated with ID59 again survived for an average of almost 10 hours longer than the controls but the results were not quite statistically significant.

Trial 6 - The group vaccinated with ID51 did not have survival times significantly higher than unvaccinated controls ($p = < 36.0$), however, there were 2 outlying mice in the vaccinated group.

15

Vaccine trials 7 and 8 (See figure 2)

Mouse number	Mean survival times (hours)			
	Unvacc control (7)	ID29 (7)	Unvacc control (8)	ID50 (8)
1	59.6	73.1	45.1	60.6
2	47.2	54.8	50.8	60.6
3	59.6	59.3	60.4	51.1
4	70.9	54.8*	55.2	60.6
5	68.6*	59.3	45.1	60.6
6	76.0	54.8	45.1	60.6
Mean	63.6	59.35	50.2	59.1
sd	10.3	7.1	6.4	3.9
p value 1	-	<39.0	-	0.0048

* - bubbled when dosed so may not have received full inoculum.

20 T - terminated at end of experiment having no symptoms of infection.

Numbers in brackets - survival times disregarded assuming incomplete dosing
p value 1 refers to significance tests compared to unvaccinated controls

Statistical Analyses.

- 5 Trial 7 - The ID29 vaccinated group showed prolonged times to the first death. T
Trial 8 - The group vaccinated with ID50 survived significantly longer than
unvaccinated controls.

Appendix I - Oligonucleotide primers

nucS1

Bgl II Eco RV

5 5'- cgagatctgatatctcacaaacagataacggcgtaaataag -3'

nucS2

Bgl II Sma I

10 5'- gaagatcttccccgggatcacaaacagataacggcgtaaataag -3'

nucS3

Bgl II Eco RV

5'- cgagatctgatatccatcacaaacagataacggcgtaaataag -3'

15 nucR

Bam HI

5'- cgggatccttatggacctgaatcagcgttgtc -3'

NucSeq

20 5'- ggatgcittgttcaggtgtatc -3'

pTREPF

5'- catgatatcggtacctcaagctcataatgtccggcaatggtgtgggctttttgttttagcggataa
caatttcacac -3'

25

pTREPR

5'- gcggatccccgggcttaattaatgttaaactagtcgaagatctcgcgaattctcctgtgtgaaatt
gttatccgcta -3'

30

pUCF

5'- cgccagggttttccagtcacgac -3'

VR

5'- tcagggggcgaggacctatg -3'

35

V1

5'- tcgtatgttgtgtggaattgtg -3'

V₂

5'- tccggctcgtatgttgtggaattg -3'

TABLE 1

5	<u>ID4 1200 bp</u>
10	<p>ATGAGAAATATGTGGGTGTAATCAAGGAAACCTATCTTCGACATGTGAGTCATGGAGTTCTTCTTTATGGTGA TTTCGCCGTTCTCTTTTAGGAATCTCTGTAGGAATTGGGCATCTCCAAGGTTCTTCTATGGCTAAAAATAATAA AGTGGCAGTAGTGACAAACAGTGCCATCTGTAGCAGAAGGACTGAAGAATGTAATGGTGTTAACTTCGACTATAA AGACGAAGCAAGTGCCAAAGAAGCAATTAAGAAGAAAAATTAAGGTTATTTGACCATTGATCAAGAAGATA GTGTTCTAAAGGCAGTTTATCATGGCGAAACATCGCTTGAAAATGGAATTAATTTGAGGTTACAGGTACACTCA ATGAACTGCAAAATCAGCTTAATCGTTCAACTGCTTCTTGTCTCAAGAGCAGGAAAAACGCTTAGCGCAGACAA TTCAATTCACAGAAAAGATTGATGAAGCCAAGGAA/ATAAAAAAGTTTATTCAAACAATTGCAGCAGGTGCCTTAG GATTTCTTTCTTTATATGATTCTGATTACCTATGCGGGTGTAAACAGCTCAGGAAGTTGCCAGTGAAAAAGGCCACAA AATTATGGAAGTCGTTTTCTAGCATAAGGGCAAGTCACTATTTCTATGCGCGGATGATGGCTCTGTTCTAGTG 15 ATTGTAACGCATATTGGGATCTATGTTGTAGGTGGTCTGGCTGCCGTTTGTCTTTAAAGATTGCCATCTTGGC TCAGTCTGGTATTTGGATCACTTGGGAGATGCTATCTCACTGAATACCTTGCTCTTTATTTTGATCAGTCTTTCA TGTACGTAGTCTTGGCAGCCTTCTAGGATCTATGGTTTCTCGTCTGAGGACTCAGGAAAGCCTTGTCGCTTT GATGATTTTGATTATGGGTGGTTTTTTGGAGTGACAGCTCTAGGTGCAGCTGGTGACAATCTCTCTGAAGATT 20 GGTCTTATATCCCTTTATTTGACCTTCTTTATGCGGTTTGAACGATTAATGACTATGCGGGGGAGCAGAAG CATGGATTTCACCTTGCTATTACAGTGATTTTGGCGTGGTAGCAACAGGATTTATCGGACGCATGTATGCTAGTCT CGTTCTTCAAACGGATGATTTAGGGATTGGAACCTTTAAACGTGCCTTATCTTATAAATAG</p>
25	<p>MRNMWVVIKETYLRHVESWSFFFMVISPFLFLGISVGIGHLQGSSMAKNNKVAVVTVPSVAEGLKNVNGVNFYKD EASAKEAIKEEKLKGYLTIDQEDSVLKAVYHGETSLENGIKFEVTGTLNELQNLRSTASLSQEKEKRLAQTIQFTEKI DEAKENKKFIQTIAAGALGFFLYMILITYAGVTAQEVASEKGTKIMEVVFSSIRASHYFYARMMALFLVILTHIGYVVG GLAAVLLFKDLPLAQSGILDHLGDAISLNTLLFILSLFMYVVLAAFLGSMVSRPEDSGKALSPLMILMGFFGVLTALG AAGDNLLLKIGSYIPFISTFFMPFRTINDYAGGAEAWISLAITVFAVVATGFIGRMYASLVLTQDDLGWTKFRALSYK Z</p>
30	<u>ID5 1125 bp</u>
35	<p>CCTGGGAAAGTCTTGAAAATTATGATAGAATGGTGGGAAGGAAAAATTCAGGAGAGTAGTAGTGACTCAAAATGTT GAAAGTCTTCTCGTATCCATTGTAATCAGTGACATACAATGAAGAAAAATATCTGCCTGGTCTAATTGAAGACTTAA AAAATCAAACCTATCCTAAAGAGGATATTGAAATCTATTTATAAATGCTATGTCCACAGATGGGACCACAGCTA TCATTAGCAATTTATAAAGGAAGATACAGAGTTAACTCAATTAGATTGTATAACAATCCTAAGAAAAATCAAG CTAGTGGTTTTAAACCTGGGAGTTAAACATTTCTGAGGGGACCTTATTTAAAAATTTGATGCTCATTCAAAAGTTAC TGAGACTTTTGAATGAACAATGTGGCTATTATCAACAAGGTGAATTTGTCTGTTGGGGGGCCTAGACCGACGATT GTCGAAGGAAAAAGGAAAAATGGGCAGAGACCTTGCACTTGTGAGGAAAAATATGTTTGGCAGTAGCATTGCCAAT TATCGAAATAGTTCTGAGGATAGATATGTTCTTCTATTTTTCATGGAATGTATAAACGAGAGGTTTTCCAGAAGG 40 TTGGTTTGTAGTAAATGAGCAACTTGGCCGAAGTAAATGATATTCAATTATAGAATTCGAGAATATGGTTATAA AATCCGCTATAGCCCAAGTATTCTATCTTATCAGTATATTCGACCAACATTCAAGAAAAATGCTGCATCAAAAGTAT TCAAATGGTTTGTGGATTGGCTTGACAAGTCATGTTTCAAGTTAAGTGTATCATTATTTCACTATGTTCTTGTGTT ATTGTTTTTGAAGTCTTGTGTTTGTCTAGCATTGTTACCGATCACATTGCTATTCATAACTTTACTATTAGGTGCTT 45 ATTTTCTACTTTTGTCACTACTCTTGTGCTGCTTTATTAACCAATAAAAAATGGATTCTAATTGTGATGCCCTTT ATTTTATTTTCCATTCACTTTGCTTATGGCCTTGGGACGATTGTAGGTTAATTAGAGGATTTAAATGGAAGAAGG AGTACAAGAGAACAATAATTTATTTGGATAAAATAAGCCAATAAATCAAAATATGCTATAA</p>
50	<p>PGKVLKIMIEWWKEKFRVTVQNVESLLVSVISAYNEEKYLPGLIEDLNQTYPKEDIEILFINAMSTDGTTAIIQQFIK EDTEFNSIRL YNNPKKNQASGFNLGVKHSVGDILKIDAHSKVTETFMNNVAIIQQGEFVCGGPRPTIVEGKGKWAET LHLVEENMFSSIANYRNSSEDYVSSIFHGMKREVFKVGLVNEQLGRTEENDIHYRIREYGYKIRYSPSILSYQYIRP TFKKMLHQKYSNGLWIGLTSHVQFKCLSLFHYVPCFLVLSLVFSLALLPITFVFTLLLGAYFLLSLLTLLKHKRNGF LIVMPFILFSIHFAVGLGTIVGLIRGFKWKKEYKRTUUYLDKISQINQNMZ</p>
55	<u>ID11 696 bp</u>
60	<p>ATGATGAAAGAACAAAATACGATAGAAATCGATGTATTTCAATTAGTTAAAAGCTTGTGGAAACGCAAGCTAATG ATTTAATAGTGGCACTTGTGACAGGTGCGGGGGCTTTTGCATATAGCACTTTTATTGTTAAGCCAGAATATACGA GTACCACGCGAATTTACGTAGTGAATCGCAATCAAGGAGACAAGCCGGGGTTGACAAATCAGGATTTGCAGGCAG GAACCTATCTGGTAAAAGACTACCGTGAGATTATCTTTTCGAGGATGTTTGGAGGAAGTTGTTCTGATTGAA ACTAGATTTGACGCCAAAAGGTTTGGCTAATAAAAAATTAAGTGACAGTACCAAGTTGATACCCGTATTGCTCTATT TCAGTTAATGATCGAGTCTCTGAAGAGGCAAGCCGATCGCTAACTCTTTGAGAGAAGTAGCTGCTCAAAAAATT ATCAGTATTACTCGTGTCTGACGTGACAACACTGGAGGAGGCAAGGCCGGCGATATCCCCGTCTCGCCAAAT ATTAACGCAATACACTAATTGGTTTTTTGGCAGGGGTGATTGGAAGTATAGTCTTCTATCTTGAACCTTTT</p>

GGATACTCGTGTGAAACGTCGGAAGATATCGAAAATACATTGCAGATGACACTTTTGGGAGTTGTGCCAACTT
GGGTAAGTTGAAATAG

5 MMKEQNTTEIDVFQLVKSLWKRKLMILVALVTGAGAFAYSTFIVKPEYTSSTRJYVVRNQGDKPGLTNQDLQAGTYL
VKDYREILSQDVL EEVSDLKLDLTPKGLANKIKVTPVDTRIVSISVNDRVPEEASRIANSLEVAQAQKIISITRVSDVT
TLEEARPAISPSPNIKRNTLIGFLAGVIGT SVIVLHLELLDTRVKRPEDIENTLQMTLLGVVPLNGLKLZ

ID12 555 bp

10 ATGGTAAAAGTAGCAGTTATATTAGCTCAGGGCTTTGAAGAAATTGAAGCCTTGACAGTTGTAGATGTCTTGCGTC
GAGCCAATATCACATGTGATATGGTTGGTTTTGAAGAGCAAGTAACGGGTTGCGATGCAATCCAAGTAAGAGCAG
ATCATGTCTTTGATGGAGATTTATCAGACTATGATATGATTGTTCTTCTCGGAGGTATGCCTGGTTCTGCACATTTA
CGTGATAATCAGACCTTGATTCAAGAATTGCAAGCTTCGAGCAAGAAGGGAAGAACTAGCAGCCATTTGTGCG
15 GCACCAATTGCCCTCAATCAAGCAGAGATTTGAAAAATAAGCGATACACTTGTTATGACGGCGTTCAAGAGCAA
ATCCTTGATGGTCACTACGTCAAGGAAACAGTAGTGGTAGTGGTCAGTTGACAACCAAGTCGGGGTCTTCAACA
GCCCTTGCCCTTGCTACGAGTTGGTGAGCAACTAGGAGGGGACGCAGAGAGTTTACGAACAGGAATGCTCTAT
CGAGATGTCCTTGGTAAAAATCAGTAA

20 MVKVAVILAQGFEEIEALTVVDLRRANITCDMVGFEQVTGSHAIQVRADHVFDDGLSDYDMIVLPGMMPGSAHLR
DNQTLIQELQSFEQEGKLAICAAPIALNQAEILNKRYTCYDGVQEQILDGHYVKETVVVDGQLTTSRGPSTALAF
YELVEQLGGDAESLRGMLYRDVFGKNQZ

ID27 306 bp

25 GTGGTAGGGATGGTAGAACCAAACTAGAAAGCCTTATAAAAGATCTTTACAATCATGCTCGACATGATTTGAGT
GAAGATTTAGTTGCTGCTCTCCTAGAGACTACTAAAAAAGCTCTACTACAAATGAGCAATTGCAGGCAGTTGCTC
TCTCAGGCCTGGTCAATCGTGAATTGCTCCTAAATCCCAACATCCAGCACCTGAGTTGCTCAACTTGGCTCGCTT
TGTCAAAAGAGAAGAAGCCAAGTACAGAGGAAGTCCGACTTCTGCGCTTATGTATGAGGAAGTCTTTAAAAATGCT
30 TTGA

30 MVMGVPEPNLESLLKDLYNHARHDLSEDLVAALLETTKKLPTTNEQLQAVRLSGLVNRLLLLNPKHPAPELLNLARFVK
REEAKYRGATATSALMYEELFKMLZ

ID29 945 bp

35 TTGTTCTTAAAAAAGGAAAAGAGAGGTAATCAGCATGCGTAAATGGACAAAAGGATTTCTCATCTTTGGTGTGGTG
ACTACCGTTATCGGCTTTATCCTGCTTTTTGTAGGTATCCAATCTGACGGGAATAAGAGCCTACTTTCCATGTCCAA
AGAACCTGTCTATGATAGCCGTACGGAAAAGCTAACCTTTGGCAAGGAAGTCGAAAACCTAGAAATTACTCTCCA
40 CCAACACACGCTCACCATCACAGACTCTTTGATGATCAAAATCCACATTTCTTACCATCCATCTCTTTGCTCAC
CATGATCTTATACCAATCAGAACGATAGAACTCTGAGTCTCACTGATAAGAACTGTCTGAACTCCGTTTCTCT
CTTCTGGAATTGGTGGGATTCTTCATATCGCAAGTAGCTACTCTAGTCTGTTTTGAAGAAGTTATCTCCGACTACC
AAAAGGGAGAACTCTAAAAGGGATCAACATCTCAGCCAATCGCGGACAAAACCAATCATAAATGCTAGCCTTGA
AAATGCGACCTCAATACAAACAGCTATATCCTCCGAATTGAAGGAAGTCGTATCAAAAACAGTAACTCACAAAC
GCCCAATATCGTTAATATCTTTGATACAGTTCTTACAGATAGTCAAGTCAACAGAGAAATCACTTCCACGCT
45 GAAAATATCCAAGTCCATGGCAAGGTTGAAGTCACTGCTGCAAGATTATCTCAGAAATCATCCTAGACCAGAAAGAA
AGCCAACGAATTAAGTGGGACATCTCAAGCAACTATGGTTCTATCTTCCAATTACAAAGAGAAAAGCCTGAATCA
AGAGGTACGGAATTAAGCAACCTTACAAAAGTAAAAAAGCGATGTCAAGGATCAACTCATTGCGAGATCTGAT
GATAATATTGATCTAATATCCACACCAAGCAGACGTTGA

50 MFLKKEREVISMRKWTGKFLIFGVVTTVIGFILLFVGIQSDGIKSLSMSKEPVYDSRTEKLTFGKEVENLEITLHQHTLTI
TDSFDDQIHISYHPSLSAHDLTINQNDRTLSTDKKLSETPFLSSGIGGILHIASSYSSRFEEVILRLPKGRITLKGINISANR
GQTTINASLENATLNTNSYILRIEGRISRIKNSKLTTPNIVNIFDVTLDTSQLESTENHFHAENIQVHGKVELTAKDYLRIL
QKESQRINWDISSNYGSIFQFTREKPESRGTELSNPYKTEKTDVKDQLIARSDDNIDLISTPSRRZ

55 ID30 879 bp

ATGAAACAAGAATGGTTTGAAGTAATGATTTTGTAAAAACAACAAGCAAGAACAAGCCTGAAGAGCAAGCTCA
AGAGGTTGCAGACAAGGCTGAAGAAACGATAGCCGATCTCGATACACCAATTGAAAAAAATCTCAGTTAGAGG
AGGAAGTCCCTCAAGCTGAAGTCGAATTGGAAAGCCAGCAAGAAGAGAAAAATTGAAGCTCCTGAAGACAGTGAA
60 GCGAGAACAGAAATAGAAGAAAAGAGGCATCTAATTCTACTGAAGAAGAGCCAGACCTTTCTAAGAAAAACAGA
AAAAGTCACTATAGCTGAAGAGAGCCAAGAGCTCTTCTCAGCAAAAAGCAACCAAGAAAGGCCACTTCTTAT
CAGTAAATCTTTAGAAAGTCTTATATCCCCGACCAAGCTCCAAAATCTAGGGATAAATGGAAGAGCAAGTGCT
TGATTTTTGGTCTTGGCTAGTGGAAGCGATCAAAATCTCTACAAGTAAGTTGGAAACAAGTATCACACACAGTTAC
ACAGCCTTTCTCTTGCTCATTCTGTTTTCTGCATCTTCTTTTCTTTAGTATCTATCATCAACATGCTTACTAT
65 GGACATATAGCAAGCATTAAACAGTCGCTTCCCTGAGCAGCTAGCTCCTTAACTCTTTTTCTATCATCTCTATCCT

- AGTAGCGACAACACTCTTCTTTCTTTTCATTCTCTTGGGTAGTTTCGTTGTGAGACGATTTATCCACCAGGAAAAAG
GACTGGACGCTAGACAAGGTTCTCCAACAATATAGTCAACTCTTGGCAATTCCAATCTCCTCACTGCTATTGCTAG
TTTCTTTGCTTTCTTTGATAGCCTACGATTACAGCCCTCTTGTGTGTGA
- 5 MKQEWESNDFVKTSSKNKPEEQAEVADKAEETIADLDTPIEKNTQLEEEVPQAEVELESQOEEKIEAPEDSEARTEIE
EKKASNSTEEEPDLSEKETEKVIAEESQEALPQQKATTKPELLSKSLESPIPDQAPKSRDKWKEQVLDWFWSVLVEAKS
PTSKLETSITHSYTAFLLLLFSASSFFSIYHIKHAYYGHASINSRFEQLAPLTLFSIISILVATTLFFFSFLLGFSVVRRIH
QEKDWLTKVLLQYSQLLAIPISLLLLVSLLSLIA YDLQPSVZ
- 10 ID105 990 bp
- ATGCAACTCGCTTCTTCGGTCTACTCATTGTTCTGCTGGTACAATTTGTTCTTAAAAAAGGAAAGAGAGGTAATCA
GCATGCGTAAATGGACAAAAGGATTTCTCATCTTTGGTGTGGTACTACGCTTATCGGCTTTATCCTGCTTTTTGTA
GGTATCCCAATCTGACGGGATTAAGAGCCTACTTTCCATGTCCAAAGAACCTGTCTATGATAGCCGTACGGAAAAAG
15 CTAACCTTTGGCAAGGAAGTCGAAAACCTAGAAATTACTCTCCACCAACACACGCTCACCATCACAGACTCTTTC
GATGATCAAATCCACATTTCTTACCATCCATCTCTTCTGCTCACCATGATCTTATCACCATCAGAACGATAGAA
CTCTGAGTCTCACTGATAAGAACTGTCTGAACTCCGTTTCTCTCTTCTGGAATTGGTGGGATTCTTCATATCGC
AAGTAGTACTCTAGTCGTTTTGAAGAAGTTATTCTCGACTACAAAAGGGAGAACTCTAAAAGGGATCAACAT
20 CTCAGCCAATCGCGGACAAACCACCATCATAAATGCTAGCCTTGAAGATGCGACCCTCAATACAAACAGCTATAT
CCTCCGAATTGAAGGAAGTCGTATCAAAAACAGTAACTCACAACGCCCAATATCGTTAATATCTTTGATACAGTT
CTTACAGATAGTCAGTAGTCAACAGAGAATCACTTCCACGCTGAAAAATCCTCAAGTCCATGGCAAGGTTGAA
CTGACTGCCAAAGATTATCTCAGAATCATCTAGACCAAGAAAGCCAAACGAATTAAGTGGGACATCTCAAGC
AACTATGTTTCTATCTTCCAATTCAAGAGAAAAGCCTGAATCAAGAGGTACGGAATTAAGCAACCCCTTACAAA
25 ACTGAAAAAACCGATGTCAAGGATCAACTCATTGCGAGATCTGATGATAATATTGATCTAATATCCACACCAAGC
AGACGTTGA
- MQLASSVYSLFVWYNLFLKKEREVISMRKWTGFLIFGVVTTVIGFILLFVGIOQSDGIKSLLSMSKEPVYDSRTEKLTFG
KEVENLEITLHQHTLTITDSFDDQIHISYHPSLSAHHDLTINQNDRTLSLTDKKLSETPFLSSGIGGILHIASSYSSRFEEVIL
30 RLPKGRITLKGINISANRGQTTIHNASLENATLNTSYILRIEGSRKNSKLTTPNIVNIFDTVLTDQLESTENHFHAENIQV
HGKVELTAKDYLRILDQKESQRINWDISSNYGSIFQFTREKPESRGTELSNPYKTEKTDVKDQLIARSDDNIDLISTPSRR
Z
- ID107 -78bp
- 35 ATGATATGTAAAAATGAAGCAGGGAGGGAGCAGGGCGTGCTGGGGATGGAGAGTGGGGGAGGGACGCTGCTATTT
TAATC
- 40 MICKMKQGGSRACWGWVRVGEGRCYFN
- ID109 714 bp
- CGATAAAGAGGCCTTGAGTAATCTCAATTTGCAGATTGAAAATGGAGAGATTATGGGCTTGATTGGTCATAATGG
45 GGCTGGAAAAATCGACCACTATAAAATCCCTAGTCAGTATCAITTCACCCAGCAGTGGTGGTATTTTGGTAGACGGT
CAGGAGTTATCGGAAAAATCGCTTGGCTATTAAACGAAAGATTGGCTACGTAGCAGACTCGCCTGACTTATTTTAC
GCTTAACGGCCAATGAATTTTGGGAATTGATCGCCTCATCTATGATCTGAGTAGATCTGACTTGGAGGCTAGTCT
AGCTAGGCTATTGAACGTTTTTGATTTGCTGAAAATCGCTATCAGGTTATTGAACTCTTCTCACGGAATGCGT
50 CAGAAAGTCTTTGTCTATCGGAGCACTCTGTCTGATCCCGATATTGGGTTTTGGACGAACCCCTGACTGGTTTTGG
ATCCCAGGCTGCCTTTGATTGAAACAGATGATGAAGGAACATGCACAAAAAGGGAAGACAGTCTTGTTTTCAA
CTCATGTCCTAGAGGTGGCAGAGCAAGTCTGTGATCGGATTGCCATTTTGAAGAAAGGGGCATTGATTATTGTGG
TAAGGTAGAGGACTTGAGGAAAGACCACCCAGACCACTTTGGAAAGTATCTACCTTAGTCTTGCTGGTAGAAA
AGAGGAGGTTGCGGATGCGTCTCAAGGTCATTA
- 55 DKEALSNNLQIENGEMGLIGHNGAGKSTTIKSLVSISSPSSGRILVDGQELSENRLAIKRKIGYVADSPDLFLRLTANEF
WELIASSYDLSRSDLEASLARLLNVDFEAENRYQVIETLSHGMROKVFVIGALLSDPDIWVLDPLTGLDPQAAFDLKQ
MMKEHAQKGTVLFSTHVLEVAEQVCDRIAILKKGHLIYCGKVEDLRKDHPDQSLSIYLSLAGRKEEVADASQGHZ
- 60 ID112 360 bp
- ATGGCTTTGTTTTTTCAGAGAGAGGAGCAGTACGGAAGACACCAATGGCAAGTCCAATAATGAGACCTATGATGGTT
CCGACGATAGAGATTAAAAGAGTGATACCAGCACCACGCAAGAGTTGTTGCCAGTTTTTTCAGAAAGAAATTTAGCA
ACTTGGCTAAAGAACTACTGCTAGTCTCTTCAGTTGTTGTAGCTTCGGCAGGTTGTTCTTGTATCATACGATCCA
65 TCAAGGCAACTTGGTCATCTTTGAAATGGTTTCAATGCTGGCATTGATTGGCTAATACGATTGTCATTTTACGA
AGCCCGATAGCGATAGCTGTATCTTCTTCCCAAGTTTGAACCAGGTTCTACTTGA

MALFSEGA VRKTPMASPIMRPMVPTIEIKRVIPAPRKSCQFSEIRLATWLKLLLVSSVVVASAGCSLIIRSIKATWSS
FEMVSM LALIWLRISFLRSPIAIAVSSSPVLKPGSTZ

5 ID 128 - 3.43

ATGAAATTTAGTAAAAATATATAGCAGCTGGATCAGCTGTTATCGTATC
CTTGAGTCTATGTGCCTATGCACTAAACCAGCATCGTTCGAGGAAAAATA
10 AGGACAATAATCGTGTCTCTTATGTGGATGGCAGCCAGTCAAGTCAGAAA
AGTGAAAACCTTGACACCAGACCAGGTTAGCCAGAAAGGAATTCAGGC
TGAGCAAAATTGTAATCAAAATTACAGATCAGGGCTATGTAACGTACACG
GTGACCACTATCATTACTATAATGGGAAAGTTCCTTATGATGCCCTCTTT
AGTGAAGAAGCTCTTGATGAAGGATCCAACTATCAACTTAAAGACGCTGA
TATTGTCAATGAAGTCAAGGGTGGTTATATCATCAAGGTCGATGAAAAAT
15 ATTAGTGTCTACCTGAAAAGATGCAGCTCATGCTGATAATGTTCCGAATAAA
GATGAAATCAATCGTCAAAAAAAGAACATGTCAAAGATAATGAGAAGGT
TAACTCTAATGTTGCTGTAGCAAGGTCTCAGGGACGATATACGACAAATG
ATGGTTATGTCTTTAATCCAGCTGATATTATCGAAGATACGGGTAATGCT
TATATCGTTCCTCATGGAGGTCACTATCACTACATTCCCAAAAGCGATTT
20 ATCTGCTAGTGAATTAGCAGCAGCTAAAGCACATCTGGCTGGAAAAATA
TGCAACCGAGTCAGTTAAGCTATTCTTCAACAGCTAGTGACAAATAACACG
CAATCTGTAGCAAAAGGATCAACTAGCAAGCCAGCAATAAATCTGAAAA
TCTCCAGAGTCTTTTGAAGGAACTCTATGATTACCTAGCGCCCAACGTT
ACAGTGAATCAGATGGCCTGGTCTTTGACCCTGCTAAGATTATCAGTCGT
25 ACACCAATGGAGTTGCGATTCCGCATGGCGACCATACCACTTTATTCC
TTACAGCAAGCTTTCTGCCTTAGAAGAAAAGATTGCCAGAATGGTGCCTA
TCAGTGGAACTGGTCTACAGTTTCTACAAATGCAAAACCTAATGAAGTA
GTGTCTAGTCTAGGCAGTCTTTCAAGCAATCCTTCTTCTTAACGACAAG
TAAGGAGCTCTCTTACAGCATCTGATGGTTATATTTTAAATCCAAAAGATA
30 TCGTTGAAGAAAACGGCTACAGCTTATATTGTAAGACATGGTGATCATTTC
CATTACATTCCAAAATCAAATCAAATGGGCAACCGACTCTTCCAAACAA
TAGTCTAGCAACACCTTCTCCATCTCTTCCAATCAATCCAGGAACCTTCA
ATGAGAAAACATGAAGAAGATGGATACGGATTGATGCTAATCGTATTATC
35 GCTGAAGATGAATCAGGTTTTGTCATGAGTCACGGAGACCACAATCATT
TTTCTTCAAGAAGGACTTGACAGAAGAGCAAATTAAGGTGCGCAAAAAA
TTTAG

MKFSKKYIAAGSAVIVSLSLCAYALNQHRSQENKDNRRVSYVDGSQSSQK
40 SENLTPDQVSQKEGIAEQIVIKITDQGYVTSBGDHYHYNGKVPYDALF
SEELLMKDPNYQLKDADIVNEVKGYYIIVKVDGKYVYVYKDAHADNVRTK
DEINRQKQEHVKDNEKVNSNVAVARSQGRYTTNDGYVFNPAHIEDTGNA
YIVPHGGHYHYIPKSDLSASELAAAKAHLAGKNMQPSQLSYSSTASDNNT
QSVAKGSTSKPANKSENLSLKLKYDSPAQRYSSEGLVFDPAKIISR
TPNGVAIPHGDHYHFIPYSKLSALEEKIARMVPISGTGSTVSTNAKPNEV
45 VSSLGSLSSNPSSLTTSKELSSASDGYIFNPKDIVEETATAYIVRHGDHF
HYIPKSNQIGQPTLPNNSLATPSPSLPINPGTSHEKHEEDGYGFDANRJI
AEDESGFVMSHGDHNYFFKKDLTEEQIKVRKNI*

TABLE 2

ID2 840 bp

5 ATGGGAATTGCTCTAGAAAATGTGAATTTTACATATCAAGAAGGTAAGTCCCTTAGCTTCAGCAGCTTTGTCGGATG
 TTTCTTTGACGATTGAAGATGGCTCTTATACAGCTTTAATTGGGCACACAGGTAGTGGTAAATCAACTATTTTACA
 ACTCTTAAATGGTTTATTGGTGCCAAAGTCAAGGGAGTGTGAGGGTTTTTGATACCTTAATCACTCGACTTCTAAA
 AATAAAGATATTTCGTCAAATTAGAAAACAGGTTGGCTTGGTATTTTCAGTTTGCTGAAAATCAGATTTTGAAGAAA
 10 CGGTTTTGAAGGACGTTGCTTTTGGACCCGCAAAATTTTGGAGTTTCTGAAGAAGATGCTGTGAAGACTGCCGCTGA
 GAAACTGGCTCTGGTTGGAATTGATGAATCACTTTTGTATCGTAGTCCGTTTGAGCTGTGAGGGGACAAATGAGA
 CGTGTGGCATTGACGGCATACTTGCCATGGAGCCAGCTATATTAGTCTTAGATGAGCCACAGCTGGTCTAGATC
 CTCTAGGGAGAAAAGAGTTGATGACCCTGTTCAAAAACTCCACCAGTCAGGGATGACCATCGTCTTGGTAAACGC
 ATTTGATGGATGATGTTGCTGAATATGCGAATCAAGTCTATGTAATGGAAGGGGACGTTTGTAAAGGGGGGCA
 15 AACCAAGTGATGCTTTCAAGACGTTGTTTTATGGAAGAAGTTCAGTTGGGAGTACCTAAAAATTACGGCCTTTTG
 TAAACGATTGGCTGATAGAGGCGTGTCATTTAAACGATTACCGATTAAGATAGAGGAGTTCAAGGAGTCGCTAAA
 TGGATAG

MGIALENVNTFYQEGTPLASAALSDVSLTIEDGYSYALIGHTGSGKSTILQLLNGLLVPSQGSVRVFDLTITSTSKNKDIR
 20 QIRKQVGLVFQFAENQIFETVVKDVAFGPQNFVSEEDAVKTAREKLALVGIDSLFDRSPFELSGGQMRRVVAJAGILA
 MEPAILVLDEPTAGLDPLGRKELMTLFKKLHQSGMTIVLVTHLMDDVAEYANQVYVMEKGRLVKGKPSDVFQDVV
 FMEEVQLGVPKITAFCKRLADRGVSFKRLPIKIEEFKESLNGZ

ID 3 6360 bp

25 TACCCGGTAGTCTTAGCAGACACATCTAGCTCTGAAGATGCTTTAAACATCTCTGATAAAGAAAAAGTAGCAGAA
 AATAAAGAGAAAACATGAAAATATCCATAGTGCTATGGAACTTCACAGGATTTTAAAGAGAAAACAGCAGTC
 ATTAAGGAAAAAGAGTTGTTAGTAAAAATCCTGTGATAGACAATAACACTAGCAATGAAGAAGCAAAAAATCAA
 AGAAGAAAAATCCAATAAATCCCAAGGAGATTATACGGACTCATTGTGTAATAAAACACAGAAAATCCCAAAAA
 30 AGAAGATAAAGTTGTCTATATTGCTGAATTTAAAGATAAAGAATCTGGAGAAAAAGCAATCAAGGAACATCCAG
 TCTTAAGAATACAAAAGTTTTATATACTTATGATAGAATTTTAAACGGTAGTGCCATAGAAACAACTCCAGATAAC
 TTGGACAAAATTAACAAATAGAAAGTATTTTCATCGGTTGAAAGGGGACAAAAAGTCCAACCCATGATGAATCAT
 GCCAGAAAAGGAAATTGGAGTTGAGGAAGCTATTGATTACCTAAAGTCTATCAATGCTCCGTTTGGGAAAAATTTT
 GATGGTAGAGGTATGGTCAATTTCAAAATTCGATCTGGAACAGATTATAGACATAAGGCTATGAGAAATCGATGAT
 35 GATGCCAAAGCCTCAATGAGATTTAAAAAGAAGACTTAAAGGCACTGATAAAAAATTATTGGTTGAGTGATAAAA
 ATCCCTCATGCGTTCAATTATTATAATGGTGGCAAAATCACTGTAGAAAAATATGATGATGGAAGGGATTATTTTG
 ACCCAGATGGGATGCATATTGACGGGATTCTTGCTGGAAATGATACTGAACAAGACATCAAAAACTTAAACGGCA
 TAGATGGAATTGCACCTAATGCACAAATTTCTCTTACAAAATGTATTCTGACGCAGGATCTGGGTTTGGGGTGA
 TGAACAATGTTTCATGCTATTGAAGATTCTATCAACACACACGTTGATGTTGTTTCGGTATCATCTGGTTTTACA
 40 GGAACAGGTCCTGTAGGTGAGAAAATATTGGCAAGCTATTCCGGCATTAAAGAAAGCAGGCATTCCAATGGTTGTC
 GCTACGGGTAACATATGCGACTTCTGCTTCAAGTTCTTATGCGGATTAGTAGCAAAATAATCATCTGAAAATACCG
 AACTGGAAATGTAAACAGAACTGCAGCAGATGAAGATGCGATAGCGGTCGTTCTGCTAAAAATCAAAACAGTTG
 AGTTTGATAAAGTTAAACATAGGTGGAGAAAGTTTTAAATACAGAAATATAGGGGCTTTTTCGATAAGAGTAAAA
 TCACAACAATGAAGATGGAACAAAAGCTCTAGTAAATTTAAATTTGTATATATAGGCAAGGGGCAAGACCAAG
 45 ATTTGATAGGTTTGGATCTTAGGGGCAAAATGTCAGTAATGGATAGAATTTATACAAAGGATTAAAAAATGCTTT
 TAAAAAGCTATGGATAAGGGTGCACGCCCATTTATGGTTGTAATACTGTAATTAATCAATAGAGATAATTG
 GACAGAGCTTCCAGCTATGGGATATGAAGCGGATGAAGGTAATAAGTCAAGTGTTTTCAATTCAGGAGATGA
 TGGTGTAAAGCTATGGAACATGATTAATCCTGATAAAAAAACTGAAGTCAAAAGAAATAATAAGAAAGATTTTAA
 AGATAAATTGGAGCAATCTATCCAATTGATATGGAAGTTTTAATTCCAACAACCGAATGTAGGTGACGAAAA
 50 AGAGATTGACTTTAAGTTTGCACCTGACACAGACAAAGAACTCTATAAAGAAGATATCATCGTTCCAGCAGGATC
 TACATCTTGGGGGCAAGAATAGATTACTTTTAAACCCGATGTTTCAGCACCTGGTAAAAATATTAATCCACG
 CTTAATGTTATTAATGGCAATCAACTATGGCTATATGTCAGGAAGTATGAGGCACTCCAATCGTGGCAGCTT
 CTACTGTTTTGATTAGACCGAAATTAAGGAAATGCTTGAAGACCTGTATTGAAAACTTAAAGGGAGATGACA
 AAATAGATCTTACAAGTCTTCAAAAAATGCGCTACAAAAATCTGCGCGACCTATGATGGATGCAACTTCTTGGAA
 55 AAGAAAAAGTCAATACTTTGCATCACCTAGACAACAGGGAGCAGGCCTAATTAATGTGGCCAATGCTTTGAGAA
 ATGAAGTTGTAGCACTTCAAAAACTGATTCTAAAGGTTTGGTAAACTCATATGTTTCCATTTCTTTAAAGA
 AATAAAAGGTGATAAAAAATCTTACAATCAAGCTTCAATATACATCAAAACAGACCTTTGACTTTTAAAGTTTCA
 GCATCAGCGATAACTACAGATTCTTAACTGACAGATTAATACTTGTGAAACATATAAAGATGAAAAATCTCCA
 GATGGTAAGCAAAATTGTTCCAGAAATTCACCCAGAAAAAGTCAAAGGAGCAAAATATCACATTGAGCATGATACT
 60 TTCATATAGGCGCAAAATCTAGCTTTGATTGTAATGCGGTTATAAATGTTGGAGAGGCCAAAAACAAAAATAAA
 TTTGTAGAATCATTATTCTATTGAGTCAAGTGAAGCGATGGAAGCTTAAACTCCAGCGGGAAGAAAAATAAAC
 TTCCAACCTTCTTGTGATGCCTCTAATGGGATTGCTGGGAATTGGAACCAACCAATCTTTGATAAATGGG
 CTTGGGAAGAAAGGTTCAAGATCAAAACACTGGGAGGTTATGATGATGATGGTAAACCGAAAAATCCAGGAACCT
 65 TAAATAAGGGAATTGGTGGAGAACATGGTATAAATTTAATCCAGCAGGAGTTATACAAAATAGAAAAAGATA
 AAAATACAACATCCCTGGATCAAAATCCAGAATTATTGCTTTCAATAACGAAGGATCAACGCTCCATCAATCA
 GTGGTTCTAAGATTGCTAACATTTATCCTTTAGATTCAAAATGGAAATCCTCAAGATGCTCAACTTGAAGAGGATT

5 AACACCTTCTCCACTTGTATTAAGAAGTGCAGAAGAAGGATTGATTTCAATAGTAAATACAAATAAAGAGGGAGA
AAATCAAAGAGACTTAAAGTCATTTCCGAGAGAACACTTTATTAGAGGAATTTTAAATTTCTAAAAGCAATGATGC
AAAGGGAATCAAATCATCTAACTAAAAGTTTGGGTGACTTGAAGTGGGATGGACTCATCTATAATCTAGAGG
TAGAGAAGAAAAATGCACCAGAAAGTAAGGATAATCAAGATCTGCTACTAAGATAAGAGGTCAATTTGAACCGAT
10 TGGCGAAGGTCAATATTTCTATAAAATTTAAATATAGATTAACTAAAGATTACCATGGCAGGTTTCTATATTCCT
GTAAAAATTGATAACACCGCCCTAAGATTGTTTCCGTTGATTTTCAAATCCTGAAAAAATTAAGTTGATTACAA
AGGATACTTATCATAAGGTAAAAGATCAGTATAAGAATGAAACGCTATTTCGAGAGATCAAAAAGAACATCCTG
AAAAATTTGACGAGATTGCGAACGAAGTTTGGTATGCTGGCGCCGCTCTTGTTAATGAAGATGGAGAGGTTGAAA
15 AAAATCTTGAAGTAACTACGCAGGTGAGGGTCAAGGAAGAAATAGAAAACTTGATAAAGACGGAATACCATTT
ATGAAATTAAGGTGCGGGAGATTAAAGGGAAAAATCATTGAAGTCATTGCATTAGATGGTTCTAGCAATTTCA
CAAAGATTCATAGAATTAATTTGCTAATCAGGCTGATGAAAAGGGGATGATTTCTATTATCTAGTAGATCCTGA
TCAAGATTCATCTAAATATCAAAAGCTTGGCGAGATTGCGAATCTAAATTTAAAAATTTAGGAAATGGAAAAAGA
GGGTAGTCTAAAAAAGATACAACTGGGTAGAATCATCATCAAGAAAAATGAAGAGTCTATTAAAGAAAAAT
15 CTAGTTTTACTATTGATAGAAATATTTCAACAATTAGAGACTTTGAAAAATAAGACTTAAAGAAATCATTAAAAA
GAAATTTAGAGAAGTTGATGATTTTACAAGTGAAGTGGTAAAGAGATGGAGGAATACGATTATAAATACGATGA
TAAAGGAAATATAATAGCCTACGATGATGGGACTGATCTAGAATATGAACTGAGAACTTGACGAAATCAAATC
AAAAATTTATGGTGTCTAAGTCCGTCTAAAGATGGGACTTTGAAATCTTGAAAGATAAGTAATGTTTCTAAA
AATGCCAAGGTATATTATGGGAATAACTATAAATCTATAGAAATCAAAGCGACCAAGTATGATTTCCACTCAAAA
20 ACGATGACATTTGATCTATACGCTAATATTATGATATTGTTGGATGGATTAGCTTTTGAGGAGATATGAGATTAT
TTGTTAAAGATAATGATCAGAAAAAGCTGAAATTAATTAAGATGCCTGAAAAAATTAAGGAAATCAAAATCAG
AATATCCCTATGTATCAAGTTATGGGAATGTCAATAGAATTAGGGGAAGGAGATCTTCAAAAAACAAACAGACA
ATTTAACTAAAAATGGAATCTGGTAAAAATCTATTCTGATTGAGAAAAACAAATATCTGTTAAAGGATAATATCAT
TCTAAGAAAAAGGCTATGCACTAAAAGTGACTACCTATAATCTGGAAAAACGGATATGTTAGAAGGAAATGGAGT
25 CTATAGCAAGGAAGATATAGCAAAAAATACAAAAGGCCAATCTAATCTAAGAGCCCTTTGAGAAACAAATTTA
TGCTGATAGTAGAAATGTTGAAGATGGAAGAAGTACCAATCTGTATTAAATGTCGGCTTTGGACGGCTTTAAACATT
ATAAGGTATCAAGTGTGTACATTTAAAAATGAACGATAAAGGGGAAGCTATCGATAAAGACGGAATCTTGTGACA
GATTCCTTCTAACTTGTATTATTTGGTAAGGATGATAAAGAATACACTGGAGAGGATAAGTTCAATGTGAAGGATA
TAAAGAAAGATGGCTCCATGTTATTTATTGATACCAACCAAGTAAACCTTTCAATGGATAAGAACTACTTTAATCC
30 ATCTAAATCTAATAAAATTTATGTACGAAATCCAGAATTTTATTTAAGAGGTAAGATTTCTGATAAGGGTGGTTTT
AACTGGGAATTGAGAGTTAATGAATCGGTTGTAGATAATTATTTAATCTACGGAGATTACACATTGATAACACTA
GAGATTTAATATTAAGCTGAATGTTAAAGACGGTGACATCATGGACTGGGAATGAAAGACTATAAAGCAAAACG
GATTTCCAGATAAGGTAACAGATATGGATGGAATGTTTATCTTCAAACTGGCTATAGCGATTGTAATGCTAAAGC
AGTTGGAGTCCACTATCAGTTTTATATGATAATGTTAAACCCGAAGTAAACATTGATCCTAAGGGAAATACTAGT
35 ATCGAATATGCTGATGGAATCTGTAGTCTTAAACATCAATGATAAAGAAATAATGGATTGATGGTGAGATT
CAAGAACCAATATTTATATAAATGGAAGAAATATACATCATTTAATGATATTAAACAAATAATAGACAAACA
CTAAACATTAAGATTGTTGTAAGATTTTGAAGAAATACAAACCGTAAAAGAATTCAATTTAAATAAAGATACG
GGAGAGGTAAGTGAATTAACCTCATAGGGAATCTGTGACCATTCAAAATGGAAGAAATGAGTTCAACGATA
GQDQDLIGLDLRGKIAVMDRIYTKDLKNAFFKAMDGARAIMVNTVNYNDRDNWTELPAMGYEADGKTSQVFSI
40 TTTCTGGTTTCGAAGGTAAAAAGACGCTGGCTATGTTATTAATCTATCAAAAGATACCTTTATAAAACCTGATT
CAAGAAAAATAGAGGAGAAAAAGGAGGAAGAAATAAACCTACTTTTGATGTATCGAAAAAGAAAGATAACCCAC
AAGTAAACCATAGTCAATTAATGAAAGTACAGAAAAAGAGGATTTACAAAGAGAAGAGCATTACAAAAATCT
GATTCAACTAAGGATGTTACAGCTACAGTCTTGATAAAAAACAATATCAGTAGTAAATCAACTAACAATCCT
AATAAGTTGCCAAAAACTGGAACAGCAAGCGGAGCCAGACACTATTAGCTGCCGAATAATGTTTATAGTAGGA
45 ATTTTTCTGGATTGAAGAAAAAAATCAAGATTAA

50 YPVLADTSSSEDALNISDKEKVAENKEKHENIHSAMETSQDFKEKKTAVIKEKEVVSKNPVIDNNTSNEEAKIKEENS
KSQGDYDTSFVNKNTENPKKEDKVYVIAEFKDKESGEKAJELSSLKNTKVLTYDRIFNLSAIETTPDNLKDIKQIEG
SVERAQKVQPMNHNHARKEIGVEEADYLSINAPFGKNFDRGMVISNIDTGTDRHKAMRIDDAKASMRFKKEDL
KGTDKNYWLSDKIPHAFNYNNGGKITVEKYDDGRDYDFPHGMHAGILAGNDTEQDIKNFNIGDGLAPNAQIFSYKMY
SDAGSGFAGDETMFHAIEDSIKHNVDSVSVSSGFTGTGLVGEKYWQAIRALRKAGIPMVVATGNVYATSASSSWDLVA
NNHLKMTDTGNVTRTAHEDAIASAKNQTFEDKVNIIGGESFKYRNIGAFFDKSKITTNEDGTPKPSKLFVYIGK
55 GQDQDLIGLDLRGKIAVMDRIYTKDLKNAFFKAMDGARAIMVNTVNYNDRDNWTELPAMGYEADGKTSQVFSI
SGDDGVKLVNMINPDKKTEVKRNKEDFKDKLEQYYPIDMESFNSNKPVNGDEKIDFKFAPDTPKELYKEDIIVPAG
STSWGPRIDLLKPDVSAAPGKNIKSTLNVINGKSTYGYMSGTSMATPIVAASTVLIRPKLEMLERPVKLNKLGDDKIDL
TSLTKIALQNTARPMMDATSWKEKSQYFASPRQAGLINVANALRNEVVATFKNTDSKGLVNSYGSISLKEIKGDKK
YFTIKLHNTSNRPLTFKVSASAITDSDLRLKLDDETYKDEKSPDGKQIVPEIHPKVKGANITFEHDTFTIGANSSFDLN
AVINVGEAKNKNKFVESFIHFESVEAMEALNSSGKKINFQPSLSMPLMGFAGNWNHEPILDKWAWEEGSRSKTLGGYD
DDGPKPIPGTLNKGIGGEHGDKNFNPAGVIQNRKDKNTTSLDQNPFLFAFNNEGINAPSSSGSKIAMYPPLDSNGNPQDA
60 QLEGLTPSPVLRSAAEGLISIVNTNKEGENQRDLKVISREHFIRGILNSKSNDAKGKSSKLKVWGDLYWDLGYNPRG
REENAPESKDNQDPATKIRGQFEPIAEGQYFYKFKYRLTKDYWPQVSYIPVKIDNTAPKIVSVDFSNPEKIKLITKDTYHK
VKDQYKNETLFARDQKEHPEKFDEIANEVWYAGAALVNEDEGEVEKNLEVTYAGEGQGRNRKLDKDGNTTYEIKGAG
DLRGKIEIIVALLDSSNFTKIHRIKFANQADEKGMISYLYLVDPPQDSSKYQKLGEIAESKFKNLNGKEGSLKKDDTTGVE
HHHQENEEISIEKSSFTIDRNISTIRDENKDLKKLKKKREVDDETSETGRMEEYDYKYDDKGNIIAYDDGTDLEYE
TEKLDEIKSKIYGLVSPSKDGHFEILGKISNVSKNAKYVYGNKYKSIEIKATKYDFHSKTMTFDLYANINDIVDGLAFAG
65 DMRLFVKDNDQKKAIEKIRMPKIKETKSEYPYVSSYGNVIELGEGDLSKNKPDNLTKMESCKIYSDSEKQYLLKDNII

5 LRKGYALKVTTYNPCKTDMLEGNVYSKEDIAKIQKANPNLRLALSETTIYADSRNVEDGRSTQSVLMSALDGFNIHRYQ
VFTFKMNDKGEAIDKGNLVTDSKLVLFGKDDKEYTGEDKFNVEAIKEDGSMFLFIDTKPVNLSMDKNYFNPSKSNKI
YVRNPEFYLRGKISDKGGFNWELRVNESVVDNYLIYGDLDHIDNTRDFNKLNVKDDIMDWGMKDYKANGFPDKVTD
MDGNVYLQTYSDLNKAVGVHYQFLYDNVKEPVNIDPKGNTSIEYADGKSVFNINDKRNNGFDGEIQEQHIYINGK
EYTSFNDIKQIDKTLNKKIVVKDFARNTTVKEFILNKDTEVSELKPHRVTVTIQNGKEMSSITVSEEDFILPVYKGELEK
GYQFDGWEISGFEGKKDAGYVINLSKDTFKPVFKIEEKKEEENKPTFDVSKKCDNPQVNHSQLNESHKREDLQREEH
SQKSDSTKDVATVLDKNNISSKSTTNNPNKLPKTGTASGAQTLLAAGIMFIVGIFLGLKKKNQDZ

10 ID6 597 bp

CTTGAATTAATAAAAAACGTCATGCGACTAAGCATTTTACTGATAAGCTTGTGATCCCAAAGATGTGCGTACGG
CTATCGAAATTGCAACCTTAGCGCCAAAGCGCCACACAGCCAGCCTTGGAAATTTGTGGTGGTACGTGAGAAAA
ATGCTGAATCGGCAAGTTAGCTTATGGTTCCAAATTTGAAACAGGTATCATCAGCGCCTGTAACCATTTGCTTTGTT
TACAGATACGGACTTAGCCAAACGTGCTCGTAAGATTGCCCGTGTGGTGGTGAATAACTTTTCTGAAGAGCAA
15 CTTCAATATTTTATGAAAAATCTGCCAGCTGAGTTTGCCCGTTACAGTGAGCAACAAGTCAGCGACTACCTAGCTC
TCAATGCAGGTTTGGTTGCCATGAACTTGGTTCTGCTTACAGACCAAGGAATTGGTTCTAACATTATTTCTGG
TTTTGACAAATCAAAAGTTAATGAAGTTTGGAAATCGAAGACCGTTTCCGCCAGAACTCTTGATCACAGTGGGT
TATACAGACGAAAAATTTGGAACCAAGCTACCGCTTCCAGTAGATGAAATCATCGAGAAAAGATAG

20 LELNKKRHATKHFTDKLVDPKDVRTAIEIATLAPSAHNSQPWKFFVVREKNAELAKLAYGSNFEQVSSAPVTIALFTDT
DLAKRARKIARVGGANNFSEEQLQYFMKNLPAEFARYSEQVSDYLALNAGLVAMNLVLAITDQIGSNILGFDKSK
VNEVLEIEDRFRPELLITVGYTDEKLEPSYRLPVDEIEKRZ

25 ID7 1401 bp

ATGACAGCAATTGATTTTACAGCAGAAAGTAGAAAAACGCAAGAAGACCTCTTGGCTGACTTGTAGCCTTTTG
GAAATCAATTTCAGAACGTGATGACAGCAAGGCTGATGCCAGCATCCATTGGGCGCTGGTCCAGTAAAAGCCTTG
GAGAAATTCCTTGAAATCGCAGACCGCGATGGCTACCCAACTAAGAATGTTGATAACTATGCAGGACATTTTGTAG
TTTGGTGATGGAGAAGAAGTTCTCGGAATCTTTGCCCATATGGATGTGGTGCCTGCTGGTAGCGGTTGGGACACAG
30 ACCCTTACACACCAACTATCAAAGATGGTCGCCTTTATGCGCGCGGGGCTTCGGACGATAAGGGTCTACAAACAG
CTTGTTACTATGGTTTGAATCATCAAAGAATTGGGTCTTCCAACCTTCTAAGAAAAGTTTCGCTTCATCGTTGGAAC
AGACGAAGAATCAGGCTGGGCAGACATGGACTACTTTGAGCAGCTAGGACTTGCCAAACCAGATTTTCGGTTT
CTCACCAGATGCTGAATTTCCAATCATCAATGGTGAAAAAGGAAATATCAGGGAATACCTCCACTTTGCAGGAGA
AAATACAGGTGTTGCCCGCTTTCACAGCTTTACAGGTGGTTACGTGAAAATATGGTACCAGAATCAGCAACAGC
35 AGTCGTTTCAGGTGACTTGGCTGACTTGAAGCTAACTAGATGCCTTTGTTGCAGAACACAACTTAGAGGAGA
ACTCCAAGAAGAAGCTGGCAAATACAGGTGACGATCATTTGGTAAATCAGCCACCGGTGCTATGCCTGCTTCAGG
TGTCAATGGCGCAACTTACCTTGCCCTCTTCTCAGCCAGTTTGGCTTTGCTGGTCCAGCCAAAGACTACCTTGAC
ATCGCAGGTAAAATTTCTTTGAACGATCATGAGGGTGAAAAATCTTAAGATTGCTCATGTGGATGAAAAGATGGGT
GCTCTTTCTATGAATGCCGGCGCTTTCACACTTCGATGAAACAAGTGTGATAATACCATTGCCCTCAACATCGCT
40 ATCCAAAAGGAACAAGTCCAGAACAAATCAAGTCAATCCTTGAAAACTTGCCAGTTGTTTCTGTTAGCCTGCTGA
ACAGGTCACACGCCTCACTATGTGCCAATGGAAGATCCACTGTGCAACCTTGTGAAATATCTATGAAAAACA
AACTGGCTTTAAAGGTGATGAACAAGTATCGGTGGTGAACCTTTGGTGGCTGCTAGAACCGGGAGTTGCCTA
CGGTGCTATGTTCCAGACTCGATTGATACCATGCACCAAGCCAATGAATTTATCGCCTTGGATGATCTTTCCGA
GCAGCAGCAATTTATGCCGAAGCTATTTACGAATTGATCAAAATA

45 MTAIDFTAEEVKRKEDLLADLFSLEINSEDRDSDKADAQHPFGPGPVKALEKFLIADRDGYPTKNVDNYAGHFEGD
GEEVLGIFAHMDVVPAGSGWDTDPYTPTKDGRLYARGASDDKGPPTACYYGLKIIEKLGTPSKKVRVFGTDEESGW
ADMDYYFEHVGLAKPDFGFSPDAEFPIINGEKNITEYLHFAGENTGVARLHSFTGGLRENMPESATAVVSGDLADL
QAKLDAFVAEHKLRGELQEEAGKYKVTIIGKSAHGAMPASGVNGATYLLFLSQFGFAGPAKDYLDIAGKILLNDHEG
-50 ENLKIAHVDEKMGALSMNAGVFHFDETSADNTIALNIRYPKGTSPQIKSILENLPPVSVSLSEHGHTPHYVPMEDPLVQ
TLLNIYEKQTFKGHEQVIGGGTFRLLERGVAYGAMFPDSIDTMHQANEFIALDDLFRAAIYAEIYELIKZ

ID8 1617 bp

55 GTGTATACTATTATAAAATCAAATATAAAAAATTTAGTTTATTAACGATATTTATTGTTGCTGGTCAATTATTGCT
AATTTATGCAGCAACTATTAATGCTCTGGTGTGAATGAATTAATTGCGATGAATTTAGAGCGGTTTTGAAATTG
TCAATCTACCAAATGATTGTCTGGTGTGGGATAATTTCTTGACTGGGTAGTGAAAAATATCAGGTGAAAGTGA
TCCAAGAGTTTTAATCTAGAGATTGCAAAATAGAGTTGCCACAGACATCTAACTCTACCTATCAAGAAATTTTCATG
TAAATCATCAGGAACATATCTTTCGTGGCTAAATAATGATGTTGAGACTTTAAATGATCAGGCGTTTAAACAATTT
60 TTTTATAGTAATAAAGGAATTTCTGGTACTATATTGCAAGTTGACTCTTAATCACTATCAATTGGTCATTGACTGT
AGCCACCTTGTGTTTCAATTAATGATTATGCTACTGTACCAAAAAATCTTTCATCGAAAAATGCGAGAAGTTAGTCTA
AATTTAACTAACCAAAATGAAGCTTTTTTAAATCTAGTGAGACTATATTGAATGGATTTGATGTTTAGCGTCTCT
TGAATCTTTTATATGATTGCTTAAGAAAAATTAAGAAAGCAGGAATTTATTAAGATGGTTATACAAGAAAAA
CAACTGTAGAAACGTTAGCAGGCGCTATTAGCTTCTTCTCAATATTTTTTTTTCAGATATCTCTCGTTTTTTTAA
65 GGCTATCTTGAATAAAGGAATAGTGAAAAATGGTACTATTGAAGCAATAGGAGCACTAACAGGTGTTATTTTT

ACAGCGCTAGGTGAATTAGGAGGTCAATTATCCTCTATTATTGGTACGAAGCCTATTTTTTAAAAATTGTATTCAA
TTAATCCAATTGAGTCAAATAAAATGAATGATATCGAACCAATGAGGTGAATAGAGATTTCCGTTATATGAAG
CAAAAAATATTTGCTATAAGTATGGAGATAAAGAAAATTTAAAAAACTTAAATTTTTGTTTCAACGTAATGAAAA
GTATTTAATTTAGGTGAAAGTGGAAAGCGGGAATCTACATTATTAATAATTATTGAATGGCTTTTGAGAGATTAT
5 AGTGGAGAATTGCGATTCTGCGGGGATGATATAAAAAAACTCCTATTATAATATGGTTTCGAATGTTCTATATG
TAGATCAAAAAGCTTATTGTTTGAAGGTACGATTAGAGATAATTTTTATTGGAAGAAAAATTACTGATGAAGA
AATACTACAGTCTTTAGAGCAAGTTGGTTTGAGTGTAAGATTTTCTAATAACATTTTAGATTATTATGTTGGT
10 GATGATGGGAGATTACTGTGAGGAGGCGAGAAACAAAAAATTACTTAGCTAGAGGGCTAATTAGAAAAAGAA
AATAGTATTAATTGACGAGGGAACCTCTGCTATCGATAGGAGAACTTCGTTAGCGATTGAACGTAAGATATTAGA
TAGAGAGGATTTGACTGTCAATTATTGTTACCCATGCTCCGCATCCGGAACCTAAACAATATTTACTAAGATATAT
CAATTTCCAAAGGATTTTATTTAA

MYTIKSNKKFSLLTIFIVAGQLLLIYAATINALVLNELIAMNLERFLKLSIYQMIWVCGIIFLDWVVKNYQVEVIQEFNL
EIRNRVATDISNSTYQEFHKSXSGTYLSWLNNDVQTLNDQAFKQLFLVIKGISGTIFAVVTLNHYHWSLTVATLFSLMIM
15 LLVPKIFASKMREVSLLNTQNEAFLKXSETILNGFDVLSLNLVYLPKKIKEAGILLKMMVIQRKTTVETLAGAISFFLNI
FFQISLVFLTGYLAIKGIVKIGTIEAIGALTGVFTALGELGGQLSSIIGTKPIFLKLYSINPIESNKMNDIEPNEVNRDFPLYE
AKNICYKYGDKEILKNLNFQORNEKYLILGESGSGKSTLLKLLNGFLRDYSGELRFGDDIKKTSYLNMYVSNVLYVDQ
KAYLFEGTIRDNILLEENYTDDEILQSLEQVGLSVKDFPNNILDYVVGDDGRLLSGGQKQKITLARGLIRNKKIVLIDEGT
20 SAIDRRTSLAIERKILDREDLTVIIVTHAPHELKQYFTKIYQFPKDFIZ

ID9 705 bp

ATAACAGTTAAACAGATTATGGACGAAATAGCCGTTTCAGATATGACTGCAAGGCGCTATTTACAGGAATTAGCT
GATAAAGATTTGCTGATTCTGTGTCATGGTGGAGCTGAAAAAATTCGAACCAACTCCCTTTTGACTAATGAGCGAT
25 CAAATATTGAAAAACAAGCCCTCCAAACGGCAGAAAAACAAGAAATAGCCCATTTTGACAGGCAGTCTAGTAGAA
GAAAGAGAAACTATTTTCATTGGACCGAGGAACAACATTAGAGTTTTTTCGCGGTGAGTTGCCTATTGACAATATCC
CGCTCGTAACCAACAGTCTACCTGTTTTCTGATTTAAGCGAAGCAAAAAATTAACAGATTGATTTTAAATAGGTGG
AAATTATCGCGATATTACAGGTGCTTTTGTGGTACATTGACCTACAAAAATCTCTAATCTCCAATTTTCTAAAG
30 GCTTTCTGTTAGCTGTAATGGTATTCAAAACGGAGCTCTAGCTACTTTAGCGAGGAAGAGGGAGAGGCTCAACGC
ATCGCTTTAAATAATTCTAATAAAAAATATTTACTCGCAGATCATAGCAAGTTCAATAAGTTTGATTTTTATCTTT
TTATAATGTATCAAACTTTGATACTATTGTTTACAGATTCTAAACTAAGTGATTCAATCCTTTTTAAGCTATCTAAAC
ACATTAAGTCATCAAGCCTTAA

ITVKQIMDEIAVSDMTARRYLQELADKDLLIRVHGAELRNTNSLLTNNERSNIEKQALQTAEKQEIHFAGSLVEERETI
35 FIGPQTTLFFARELPIDNIRVVTNSLPVFLILSERKLTDLILIGGNYRDITGAFVGTLLQNLNLQFSKAFVSCNGIQNGA
LATFSEEEGEAQRIALNNSNKKYLLADHSKFNKDFYTFYVNSNLDITVSDSKLSDSILFKLSKHVKIPZ

ID10 483 bp

ATGACTGAGTTTTGTTAGATCTTCTCTAGAACCCATTAACTAGCTCGTTGGACCTACTACTATCACTTGAAAC
AGCTAGACAAAAACAGATAAAGACCAAGAGCTTAAACTGAAATTCATCCATCTTTATCGAACACAAGGGAAAT
40 ATGCTTATCGCCGGGTTCATTTAGAACTAAGAAATCGTGTTATCTGGTAAATCATAAAAAGAGTTCAAGGCTTGA
GAAAGTACTCAATTTACAAGCTAAATGCGAAAGAAACGAAATATTTCTCTCATAAAGGAGACGTTGGTAAAGAA
GGCAGAGAATCTCATTCAAGCCCAATTTGAAGGCTCTAAAACAATGGAAGAGTGCTACACAGATGTGACTGAATT
45 TGCCATTCCAGCAAGTACTCAAAAGCTTTAGCTATCACCAGTTTATGATGGCTTTAACAGCGAAATATTGCTTTT
AATCTTTCTTGTTCGCTAATTTAGAATAA

MTEFSLDLLLEAIKLARWYTYHLLKQLDKTDKQDELKTEIQSIFIEHKGNYA YRRVHLELRNRGYLVNHKRVQGLMK
50 VLNLQAKMRKKRYSSHKGDVGKKAENLIQAQFEGSKTMEKCYTDVTEFAIPASTQKLYLSPVLDGFNSEHAFNLSCS
PNLEZ

ID14 1266 bp

CCAGGATTTGGTACCGTTGCAAGTGGTGTGCCTTTCTCTCTAAAGGAAAAATGGAGGAAAAATCAATCAATCAGCA
CATTAGATATCAAGTTGCTAAGGTATTGGTCAAGGATGAAGATGAAAAAATCGCTTGCTTGACAGCAGGGAAT
55 GACTTTAACTTTGTAACCAATGTGGATGATATTTATCAGACCAAGGATATTACTATCGTAGTGGAATTTGGGGC
GTATTGAGCCTGTCTAAACCTTTATCACTCGTGCCTTGGAAAGCTGGAAACACGTTGTTACTGCTAAACAAGGACCT
TTAGCTGTCCATGGCGCAGAATTGCTAGAAATCGCTCAAGCTAAACAGGTAGCACTTTACTACGAAGCAGCAGT
60 TGCTGGTGGGATTCCAATTTCTGCTACTTTAGCAAAATTCCTTGGCTTCTGATAAAATTACGCGCGTGTCTGGAGTA
GTCAACCGAACTTCCAATTCATGGTGACCAAGATGGTGAAGAAGGCTGGTCTTACGATGATGCTCTTGGCGAA
GCACAACGTCTAGGATTTGCAGAAAGCGATCCGACGAATGACGTAGATGGGATTGATGCAGCTACAAGATGGTT
ATTTTGAAGCAATTTGCTTTGGCATGAAGATTGCTTTGATGATGATGCCACAAGGGAATCCGCAATATCACAC
CAGAAGACGTAGCTGTAGCTCAAGAGCTTGTTACGTAGTGAAATTTGGTTGGTTCTATTGAGGAACTTCTTCAGG
65 TATTGCTGCAGAGTGACTCCAACCTTCTACCTAAAGCGCACCCACTTGCTAGTGTGAATGGCGTAATGAACGCT
GTCTTTGTAGAATCTATCGGTATTGGTGAGTCTATGTAACGACCAAGGTGCGGGTCAAAAACCAACTGCAACA

AGTGTGTGAGCTGATATTGTCGATCGTTGCGTCGTTGAATGATGGTACTATTGGCAAAGACTTCAACGAATATA
GCCGTGACTTGGTCTTGGCAAATCCTGAAGATGTCAAAGCAAACACTATTCTCAATCTTGGCTCTAGACTCAAA
AGGTCAAGGTCTTGAAGTGTGGTCAAAATCTTCAATGCTCAAGATAATTTCTTTAAGCAAATCCTTCAAGATGGCAAA
GAGGGTGAAGCAAGGCGGTGCTGTTATCATCACACAAGATTAAATAAGCCGAGCTTGAAATGTCTCAGCTGAA
TTGAAGAAGGTTTCAGAAATCGACCTCTTGAATACCTTCAAGGTGCTAGGAGAATAA

10

PGFGTVASGVFLLKENGKKINQSAHSDIKVAKVLVKDEDEKNRLLAAGNDFNFVTNVDDILSDQDITTVVELMGRIE
AKTIFITRALEAGKHVTVANKDLLAVHGAELLEIAQKAAVLYEEAAVAGGIPILRTLANSLLDSDKTRVLGVVNGTSNF
MYTKMVEEGVSYDDALAEQKRLGFAESDPTNDVGDAAYKYMVLQSQAFGMKIAFDNDVAHKGRINTPDEVAVAE
LGYVVKLVGSIEETSSGIAAEVTPFLPKAHPASVNGVMNAVFVESIGIESMYGYPGAGQKPTATSVADIVIRVRL
NDGTIGKDFNEYSRDLVLNAPNEDVKANYFYSLALDSDKQVLKLAEIFNAQDSFKQLQDGKEGDKARVVITHKINKA
QLENYSAELKKVSEFDLLNTFKVLKZY

15

ID16 1725 bp

20

ATGAAACACCTATTATCTTACTTCAAACCTACATCAAGGAATCAATTTTAGCCCCCTTGTTCAAGCTGTTAGAAG
CTGTTTTTGTAGCTCTTGGTTCCCATGGTGATTGCTGGGATTGTTGACCAATCTTTACCTCAGGGAGATCAAGGTCA
TCTCTGGATGCAGATTGGCCTCTCTTATCTTTGCGATAATTGGCGTTTATAGTGGCCTTGATAGCTCAATTTTACT
CAGCAAAAGCAGCAGTAGGTTCTGCTAAGGAATTGACAAACGATCTTATCGTCATATTCTTCTTGCCCAAGG
CAGCAGAGACCGTCTGACAACTTCTAGTTTGGTCACTCGCTTGACTTCGGATACCTACCAGATTACAGATCGGTAT
AATCAATTCCTGCGTCTCTTTTACGAGAGCCCATATCGTTTTTGGTGCCATTTTATGCGCTTATCGAATCTCAGC
TGAGTTGACTTCTGGTTCTTAGTCTTGTTGCCATTTTGACCAATTGTCATTGTAGGGTTATCTCGATTGGTCAATC
CTTTCTACAGTAGTCTCAGAAAGAAAAACGGACCAACTGGTTTCAGAAAGACGCCGCAATTCGAAGGATCGGG
TTATTCGTGCTTTTGGTCAAGAAAAACGAGAGTTACAGATTTTTCAAACCTTAACCAAGTTTATGCTAGATTACA
AGAAAAGACAGGTTTCTGGTCTAGTTTATTAAACACCTTGACCTATCTGATTGTCAATGGAACCTCTCTCGTTATT
ATCTGGCAAGGCTATATTTCAATTCAAGGAGGAGTCTCAGTCAAGGTGCTCTTATGCTCTTATCAATTACCTCT
TACAGATTTTTGGTGAATTGGTCAAGCTAGCCATGTTGTATCAATTCCTCAACGAGTCTTATCTCAGTCAAGCG
AATCGGAAGTCTTTGTTGAGGCTCCAGAGGATATCCATTACAGAGTTAGAACAAAAGCAAGCTACCAGAGATAA
GGTTTTCAAGTCCAAGATTGACCTTTACTATCTGATCTGAGCGGCCAGCCTTCTCTGAGATACATTTCTTTGAT
ATGACTCAAGGACAAATTTAGTATATCATCGGGGGAATCGTTCTGGTAAATCAAGCTTGGTGCACCTTACTTG
GACTTTATCCAGTAGACAAGGGGAACATTGACCTTTATCAAAATGGAGCTAGTCTCTTAATTGGAGCAGTGGC
GGTCTTGGATTGCCTATGTACTCTAAAGGTTGCAAGCTTTTAAAGGAACCATTCGTTCCAACCTTGACTCTAGGTTT
CAATCAAGAAGATTCTGACCGAGAACTCTGGCAGGCTTTGGAGATTGCGCAAGCTAAGGATTTTGCAGTGAAAA
GGAAGGACTCTTGATGCTCTAGTTGAGGACGGGGGGCGAAATTTCTCAGGTGGACAAAAACAAAGATTGTCTAT
CGCCCGAGCAGTCTTGCGCCAGGCTCCGTTTCTATCCTAGATGATGCAACCTCGGCACCTGGATACCTATACAGAG
TCCAAGCTCTTGAAGGCTATTAGAGAAAAATTTCCAAAACAGGAGCTTAAGTTTGATCTCTCAACGAACCTCAACTT
TACAGATGGCGGACAGGATTTCTCTCTTGGAAAAAGGTGAGTTGCTAGTCTTGTGGCAAGCAGGATGACTTGATGA
AATCCAGCCAAGTCTATTGTGAAATCAATGCATCCCAACATGGAAAGGAGGACTAG

40

MKHLIS YFKPYKESILAPFLKLEAVFELLVPMVIAVQDSSLPGQDQGHLMWQIGLLIFLIVGVTLVALLAQFYFSKA
 AVGSAKELTNDLRYHILSLPKDSDRLTSSLVRTLSDTYQIQTGNGHFLRLFLRAPIIVFGAIFMA YRISAE LTFWFLV
 VAILTTIVGLSRLVNPFFYSRLRKKTDQLVQETRQQLQGMVRVIRAFGQEKRELQIFQFTLNQVYARLQEKTFWSSLLTPL
 TYLVNGTLLVVIUQGYISIQGGVLSCGALLIALINYLQILVELVKLAMLINSNQSYISVKRIEYFVEAPEDHISELEQKQ
 ATIRNDVLQVQELTFTYYPDAAPQSLRYISYFDMTQGOILGUGGTSGSKSSLVQLLLGLYPVDKGNIDLQNGRSPNLNEQ
 WRSWIA YVPQKVELFKGTIRSNLTLGFNQEVSDQELWQALEIAQAKDFVSEKEGLLDALVEAGGRNFSGGQKQRLSIA
 RAVLRQAPFLILDDATSLDPTTESKLLKAIRENFPMNTSLILISQRTSTLQMAQDQILLLEKGELLA VGKHDDLKMSQVYC
 EINASOHQEDZ

45

ID18 1224 bB

- 50

ATGAAACGTTCTCTCGACTCAAGAGTCGATTACAGTTTGCTCTTGCCAGTATTTTTTCTACTGGTCATCGGTGTGGT
GGCTATCTATATAGCCGTTAGTCATGATTATCCCAATAATTTCTGCCCATTTTGGGACGAGCGTGCCTGGTATT
GCGTTGGGGCTGTGATGTGGTTTGTGGTATCGTCTTAAACAGAAATTTCTTGGAAAGTGACCCCTTCTGAT
TATTTTAGGCTTGGGACTTATGATCTTGCCGATTGTATTTTATAATCCAAAGCTTAGTTGCATCAACGGGTGCCAAA
AAGTGGGTATCAATAAATGGAATTACCTTATCCCAACCGTCAGAATTTATGAAGATATCCTATATCCTCATTTGG
CTCGTGTCAATTGCTCAATTTACAAAGAAACATAAGGAATGGAGACGACGCGTCCGCTGGAATCTTTTGTAATTT
CTGGATGATTCTCTTACCATTCCAGTCTAGTCTCTTATAGCACTTCAAAGTGACTTGGGGACGGCTTTGGTTTTG
TAGCCATTTTCTCAGGAATCGTTTATTATCAGGGGTTTCTTGGAAAAATTTATTCCTGAGTATTGTGACTGCTGTA
ACAGGAGTTGCTGGTTTCTAGCTATCTTTATTAGCAAGGACGAGAGCTTTTCTCAGCAATTGGAATGCCGCA
CCTACCAAATTAATCGGATTTTGGCTTGGCTCAATCCCTTGAGTTTGCCCAAAACAAGACTTACCAGCAGGCTCA
AGGGCAGATGGCATTTGGGAGTGTTGGCTTATTTGGTCAGGGAATTAATGCTTCAAGTCTGCTTATCCAGTTCGA
GAGTCAGATAGTATTTTACGGTATTCTTCAGAAGATTTTGGCTTTATGGCTCTGCTCTGTTATTGCGCTCTATCT
CATGTGATTTACCGTATGTTGAAGATTACTCTTAAATCAAAATACCAGTTCTACACTTATATTTCCACAGGTTTGA
TTATGATGTTTGCTCTCCACATCTTGAAGATATCGGTGCTGTGACTGGAATCTTCTTTGACGGGATTTCCCTGT
CCTTTCATTTTCGCAAGGGGATCAGCTATTACAGTAATCTGATTTGGTGTGGTTTGTCTTTATCGATGAGTAAAC

GACTAATCTAGCTGAAGAAAAGAGCGGAAAAGTCCCATTCAAACGGAAAAAGGTTGTATTAACAAATTAATA
A

5 MKRSLDSRVDYSLLLPVFFLLVIGVVAIYIVSHDYPNNILPILGQQVAVIALGLVIGFVVMLEFNLWKVTPFLYILGL
GLMILPIVFNPSLVASTGAKNWVSINGITLFPQSEFMKISYILMLARVIVQFTKKHKEWRRTVPLDFLLIFWMILFTIPVL
VLLALQSDLGTALVFVAIFSGIVLLSGVSWKIIIPVFVTAVTGVAGFLAIFISKDGRAFLHQIGMPTYQINRILAWNLPFEF
AQTTTQQAQGGQIAGSGGLFGQGFNASNLLIPVRESDMIFTVIAEDFGFISVSVIALYLMILYRMLKITLKSNNQPYTY
10 ISTGLIMMLLFHIFENIGAVTGLLPLTGIPLPFISQGGSAIISNLIGVLLLSMSYQTNLAEEKSGKVPFKRKKVVLQKQKZ

ID22 987 bp

ATGGTGGCTAAGAAAAAATCTTATTTTTATGTGGTCTTTTCTCTTGGAGGTGGTGCAGAGAAGATTCTATCAA
CCATTGTTTCAAATCTGGATCCAGAAAAGTATGATATTGATATTCTTGAAATGGAGCACTTTGACAAGGGATATGA
15 ATCTGTTCCAAAGCATGTACGCATTTTAAATCCCTTCAAGATTATCGCCAAACCAGATGGTTACGAGCTTTTGTG
TGGAGAAATGAGAATTTATTTTCAAGACTGACTCGTCTGTTGCTTGTAAAAGATGATTATGATGTTGAAGTTCTT
TTACCATTATGAATCCACCAGTGTGTTCTCTAAAAGAAGAGAAGTCAAGAAGATATCTTGGATTCTATGGAAGTAT
TGAAGAACTTCTTAAGGATAGCTCTAAAAGAGAATCACATAGAAGCCAGTTGGATGCTGCGAATACAATTGTAGG
GATTTCAAAAAAGACCAGCAATTCTATCAAGGAAGTTTATCCAGATTATACTTCTAAATTACAGACAATCTACAAT
20 GGATATGATTTTCAAGTATTTCTAGAAAAATCTCAAGAGAAGATCGATATCGAGATTGCTCCTCAAAGTATCTGTA
CTATCGGACGGATTGAGGAAAAAAGGGTCTGACCGTGTAGTGAAGTGATACGATTATTACACCAAGAGGGAA
AAAACTATCATCTCTATTTTATCGGGGCTGGTGATATGGAAGAGGAACTGAAAAACAGAGTCAAAGAGTATGGGA
TTGAGGACTATGTACATTTCTTGGTTATCAAAAAAATCCTTATCAGTATCTATCTCAGACGAAAGTTCTTTGTCT
ATGTCTAAACAAGAAGTTTCTGGAGTGTATGTGGAGGCCTTGAGTCTGGGACTCCCTTTTATCTCTACGGACG
25 TTGGAGGGGCTGAGGAATTATCCCAAGAGGACGATTGGACAAATCATTGAGAGCAATCAAGAGGCAGCTCAG
CGGATTACTAATTACATGACTTCTGCCTCAAATTTGATGTCGATGAGGCTAGCCAAATTCATTCAACAATTTACAA
TTACAAAACAATCGAACAAGTAGAAAACTATTAGAGGAGTAG

30 MYAKKKILFFMWSFSLGGGAEEKILSTIVSNLDPEKYDIDILEMEHFDKGYESVPKHVRILKSLQDYRQTRWLRAFLWRM
RIYFPRLTRLLVKDDYDVEVSFTIMNPPLLFSKRREVKKISWIHGSIEELLKDSKRESHRSQLDAANTIVGISKTSNSIK
EVYPDYTSKLQTYNGYDFQTILEKSQEKIDIEIAPQSICTIGRIEENKGSDDRVEVIRLLHQEGKNYHLFYFAGAGMEEEL
KKRVKEYGIEDYVHFLGYQKNPYQYLSQTKVLLSMSKQEGFPGVYVEALSGLPFISTDVGGAEELSQEGRFQGNESNQ
EAAQAITYMTSASFVDEASQFIQQTITTKQIEQVEKLEEZ

ID23 1434 bp

35 ATGGAAGCTGCATTAATTAGTGTGATTGTGCCAGTCTATAATGTGGCGCAGTACCTAGAAAAATCGATAGCTTCCA
TTCAGAAGCAGACCTATCAAAATCTGGAATTAATCTTGTGATGATGGTGCAACAGATGAAAGTGGTGCCTTGTG
TGATTCAATCGCTGAACAAGATGACAGGGGTGTCAGTGCTTCATAAAAAGAACGAAGGATTGTCCGAAGCAGAAA
40 TGATGGGATGAAGCAGGCTCACGGGATTATCTGATTTTATTGACTCAGATGATTATATCCATCCAGAAATGATT
CAGAGCTTATATGAGCAATTAGTTCAAGAAGATGCGGATGTTTCGAGCTGTGGTGTCATGAATGTCTATGCTAATG
ATGAAAGCCACAGTCAGCCAATCAGGATGACTATTTGTCTGTGATTCTCAAACATTTCTAAAGGAATACCTCAT
AGGTGAAAAAATACCTGGGACGATTGCAATAAGCTAATCAAGAGACAGATTGCAACTGCCCTATCCTTTCTCTAA
GGGGTTGATTACGAAGATGCCTATTACCAATTTTATTGATTTAATCAAGTTGGCCAAGAAGTATGTGGTTAATCTAAA
45 CCCTATTATTACTATTTCCATAGAGGGGATAGTATTACGACCAAAACCCTATGCAGAGAAGGATTTAGCCTATATTG
ATATCTACCAAAAGTTTTATAATGAAGTTGTGAAAAACTATCCTGACTTGAAAGAGGTGCGTTTTTTCAGATTGGC
CTATGCCCACTTCTTTATTCTGGATAAGATGTTGCTAGATGATCAGTATAACAGTTTGAAGCCTATTCTCAGATT
CATCGTTTTTAAAGGCCATGCCTTTGCTATTTCTAGGAATCCAATTTTCCGTAAGGGGAGAAGAATTAGTGCTT
50 TGGCCTATTCTATAAATATTTCTTATATCGATTCTTATTACTGAAAAATATTGAAAAATCTAAAAAATTACATTA
G

55 METALISVIVPVYVNAQYLEKSIASIQKQTYQNLEIILVDDGATDESRLCDSIAEQDDRVSVLHKKNEGLSQARNRDM
KQAHGDYLFIDSDDYHPEMIQSLYEQLVQEDADVSSCGVMNVYANDESPQSANQDDYFVCDSTFLKEYLIGEKIPG
TICNLIKRIATALSFPKGLIYEDAYYHFDLIKAKKYVVNTKPYYYFHRGDSITTKPYAEKDLAYIDIYQKFYNEVV
KNYPDLKEVAFFRLAYAHFFILDKMLLDQYKQFEAYSQIHRFLKGHAFISRNPFRKGRRISALALFINISLYRFLLLK
NIEKSKKLHZ

ID24 735bp

60 ATGAGAATCAAAGAGAAAAACCAATAATATTAATGGAGGAATAAAAAATGTAAGTAAGCATTATGGTCATTCAATC
ATTCTCAAAGATATAAATTTTGCACCTAACAAGGGTGAAATTTGTTGGTCTAGCAGGGAGAAATGGAGTTGGTAAG
AGTACGTTGATGAAATTTCTTGTTCAGAATAATCAACCGACTTCAGGTAATATTATAAGCAGTGATAATGTTGGGT
ATTTAATCGAAGAACCAAAATATTTTATCTAAAAACAGGTTAGAGAATTTAAAAATTTTGTCAAATTTATATGG
65 TGTGACTACAATCAAGAAAGATTAGATGTTGATCCAAAGAGTTAGATTTGACTCAGTCTATTAAATAAAAAAGTA
AAGACCTATTCTTTGGGTACAAAACAAAAATAGCTTTGCTTCAACTCTCGTTACGGAACCTGATATATTGATT

TAGATGAACCGACTAATGGTTTAGATATTGAATCATCACAATAGTTTTAGCGGTTCTAAAAAATTAGCTTTACA
TGAAATGTGGGAATTTAATATCGAGTCATAAATTAGAAGACATTGAAGAAATTTGTGAGAGAGTTCTTTTCTTG
GAGAACGGGCTTTGACATTTCAAAAAGTAGGAAAAGATAGTCATAATTTCTTGTGAGATAGCTTTTTCATCAG
CTACAGATAGAGACATTTTCATTACCAACAAGAATTTGGGATATTGTTTAG

MRIKEKTNNINGGIKNVSKHYGHSILKDNFALNKEIVGLAGRNGVKGSTLMKILVQNNQPTSGNISSDNVGYLIEEP
KLFLSKTGLENLYLSNLYGVVDYNQERFRLIQELDLTQSIKKVKTYSLGTKQKLALLLTLVTEPDILILDEPTNGLDIE
SSQIVLAVLKKLALHENVGILISSHKLEDIEECERVLFLENGLLTFQKVGKDSHNFLEIAFSSATDRDIFITKQEFWDIVZ

ID25 1704bp

ATGACTGAATTAGATAAACGTCACCGCAGTAGCATTATGACAGCATGGTTAAATCACCTAACCGTGCTATGCTTC
GTGCGACTGGTATGACAGATAAGGACTTTGAAACATCGATTGTGGGAGTGATTTCGACTTGGGCGGAAAAATACAC
CATGTAACATTCACTTGCATGATTTGCGGAACTGGCTAAAGAAGGTGTCAAATCTGCAGGCGCTTGGCCTGTAC
AGTTTGGAAACATTACCGTAGCGGACGGGATCGCTATGGGAAACGCTGGTATGCGTTTCTCTCTAACATCTCGTGA
CATCATCGCGGACTCCATCGAGGCGGCTATGAGTGGTCACAACGTGGATGCCTTCGTGCTATCGGTGGCTGTGA
CAAGAACATGCCTGGATCTATGATTGCTATTGCTAATATGGATATCCAGCTATTTTCGCTATGGTGGAACATT
GCACCGGGAATCTTGATGGTAAAGATATCGACTTGGTTTCTGTCTTTGAAGGTATCGGAAAAATGGAACACCGT
GACATGACAGCTGAGGACGTGAAACGCTTGAATGTAATGCCTGCCCTGGCCTGGTGGTTGTGGTGGTATGTAT
ACTGCTAATACCATGGCAACTGCTATCGAAGTTCTAGGGATGAGTTTGCAGGGTCTCCTCTCACCCAGCTGAAT
CAGCTGATAAGAAAGAAGATATCGAAGCAGCAGGACGTGCTGTTGTAAGATGTTGGAACCTGGTCTCAAACCAT
CAGATATCTTGACTCGTGAAGCCTTTGAAGATGCTATCACTGTAACGATGGCTCTCGGTGGTTCTACAAACGCCAC
TCTTCACTTGGCTCGCCATTGCCCATGCCGCAATGTTGACTTGTCACTTGAGGACTTCAATACGATTCAAGAACGT
GTGCTCACTTGGCCGACTTGAAACCATCTGGTCAATGTTCTTCCAAGACCTCTACGAAGTCGGTGGTGTCCCTG
CGGTTATGAAGTATTTGTTGGCAATGGTTTCTTACGGAGATCGCATCACATGTAAGTGGTAAAGTGTAGCTGA
AAACTTGGCTGACTTTCAGACTTGAAGCTCCAGGCCAAAAAGTTATCATGCCACTTGAAAAATCCAAACGTGCGGA
TGGTCCGCTTATCATCTTGAACGGGAACCTTGTCTGACGGTGCAGTTGCCAAGGTATCAGGTGTTAAAGTGGCT
CGTCACGTTGGGCCAGCTAAGGTCTTTGACTCAGAAGAAGATGCGATTACGGCCGTTCTGACAGATGAAATCGTT
GATGGCGATGTAGTCGTTGTTCTGTTTGTGGACCTAAAGGTGGTCTGGTATGCTGAGATGCTATCACTTTCTTC
AATGATTGTTGGTAAAGGTGAGGAGATAAGGTGGCCTCTTGACGGACGGACGTTTCTGTTGGTACTTATGGT
CTGGTTGTTGGACATATCGCTCCTGAAGCTCAGGATGGTGGACCAATTGCCTATCTCCGTACCGGCGATATCGTTA
CGTTGGCAACAGATACCAAGAAATTTCTATGGCCGTATCCGAAGAAGAAGTTGAAAAACGCAAGGCAGAAAAA
ACCTTGGCAACACTTTACAGCCGTGGTGTCTCGGTAATATGCCACATCGTATCATCTGCTTACCGCGGAGCCG
TGACAGACTTCTGGAATATGGACAAGTCAGGTAATAATAA

MTELDKRHRSSYDSMVKSPNRLRATGMTDKDFETSIIVGVISTWAENTPCNIHLHDFGKLAKGKVSAGAWPVQFG
TITVADGIAMGTPGMRFLTSRDIIADSIIEAAMSGHNVDFAVIAIGGCDKNMPSMIAIANMDIPAIFYGGTIAPGNLDG
KDIDLVSFVFEIGIGKWNHGDMTAEDVKRLECNACPGPGCGGMYTANTMATAEVLGMSLPSSSHPAESADKKEDIE
AAGRAVVKMLELGLKPSDILTREAFAIDATVTMALGGSTNATLHLLAIAHAANVDLSLEDFTIQUERVPHLADLKPSGQ
YVFQDLVEVGGVPAVMKYLLANGFLHGDRTCTGKTVAENLADFADLTPGQKVMPLNPKRADGPLIILNGLNLPDG
AVAKVSGVKVRRHVGPAAKVFDESEDAIQAVALTDEIVDGDVVVRFVGPKGPGMPPEMLSLSSMIVGKGQGDVALLT
DGRFSGGTGYGLVVGHIAPEAQDGGPIALYLRGTDIVTVDQDTKEISMAVSEEELEKRAETTLPLYSRGLVGLKYAHIVSS
ASRGAVTDFWNMDKSGKKZ

ID26 274bp

ATGTTATAATAAAAAATAAGAAATTTAAGGAGAAATACAATATGTCAATTTTTATTGGAGGAGCATGGCCATATGC
AAACGGTTTCGTTACATATTGGTCACGCGGAGCGCTTTTACCGGGGATATTCTTGCAAGATACTATCGTCAGAA
GGGAGAGGAAGTTTTATATGTTTCTGGAAGTGATTGTAATGGAACCCCTATTCTATCAGAGCTAAAAAGAAAA
TAAGTCTGTGAAAGAAATTGCTGATTTTTATCATAAGGAATTTAATCCA

CYNKNKEFKENYMSIFIGGAWPYANGSLHIGHAAALLPGDILARYRQKGEEVLVYSGSDCNGTPISIRAKKENKSYK
EIADFYHKEFNP

ID28 1065bp

ATGACAACATTATTTTCAAAAATTAAGAAGTAACAGAAGTTGCTGCAGTCTCAGGTCATGAAGCGCCTGTCCGT
GCTTATCTTCGTGAAAAGTTGACACCGCATGTGGATGAAGTGGTGACAGATGGCTTGGGTGGTATTTTTGGTATCA
AACATTACAGAAGCTGTGGATGCACCGCGCTCTTGGTCTCTCATATGGACGAAGTTGGTTTTATGGTCAGCGA
AATCAAGCCAGATGGTACCTTCGGTGTCTGAGAAATCGGTGGCTGGAACCCCATGGTGGTTAGCAGCCAACGTTT
CAAACTCTTGACTCGTGATGGTCATGAAATTCCTGTGATTTTCAAGTTCTGTCTCCGCAATTTGACTCGTGAAAG
GGGGGACCAACCATGCCAGCCATTGCCGATATCGTTTTGATGGTGGTTTTGCGGACAAGGCTGAGGCAGAAAGT
TTTGGCATCCGTCCTGGTGATACCATTTGACAGATAGTTCTGCAATTTTGACAGCCAATGAAAAAATATCATCT
CAAAAGCTTGGGATAACCGCTACGGTGTCTCATGGTAAGCGAGCTAGCTGAAGCTTTATCGGGTCAAAAACCTCG
GCAATGAAGTCTATCTGGGTTCTAACGTCCAAGAAGAAGTTGGTCTGCGTGGCGCTCATACCTCTACAACCAAGTT

5 TGACCCAGAAGTCTTCCTCGCAGTTGATTGCTCACCAGCAGGTGATGTCTACGGTGGTCAAGGCAAGATTGGAGA
TGGAACCTTGATTGCTTTCTATGATCCAGGTCACTTGCTTCTCCAGGGATGAAGGATTTCTTTTGACAAACGGCT
GAAGAAGCTGGTATCAAGTACCAATACTACTGTGGTAAAGGCGGAACAGATGCAGGTGCAGCTCATCTGAAAAAT
GGTGGTGTCCCATCAACAATATCGGTGTCTGCGCTCGTTATATCCATTCTCACCAAACCTCTATGCAATGGATG
ACTTCTAGAAAGCGCAAGCTTTCTTACAAGCCTTGGTGAAGAAATTGGATCGTTCAACGGTTGATTGATTAACA
TTATTAA

10 MTLFSKIKEVTELAASVSGHEAPVRAYLREKLTPHVDEVVTDGLGGIFGIKHSEAVDAPRVLVASHMDEVGFMVSEIKP
DGTFRVVEIGWNPMVSVSSQRFKLLTRDGHEIPVISGSVPPHLTRGKGGTTPAJADIVFDGGFADKAEASFIRPGDT
IVPDSSAILTANEKNIISKAWDNRYGVLVSELAELSGQKLGNELYLSNVQEEVLRGAHTSTTKFDPFVFLAVDCS
PAGDVYGGQKIGDGLIRFYDPGHLLLPKMDFLLTAAEEAGIKYQYYCGKGGTDAGAAHLKNGVPSSTIGVCARY
IHSQTLTYAMDDFLEAQFLQALVKLDRSTVDLKHYZ

15 ID31 1182bp

ATGGAATTTTCTATGAAATCAGTCAAAGGACTACTCTTTATCATAGCTAGTTTTATCTTGACTCTTTTGACTTGGAT
GAACACTTCTCCCAATTATGATTCCAGGACTAGCTTTAAACAGCCTATCTCTGACTTTTATCTAGCCACTCGT
CTCCCACTACTAGAAAGCTGGTTTACAGTTTGGAGAAGGTCTACACCGTCCACAAATTCACAGCCTTTCTCTCAA
TCATCTCTACTAATCTTTATAACTTTAGTATGGGCGGTTTGTGGGGCTCTCGCTTAGCTGCTCAGTTTGGCAATCTT
20 GCCATCTATATCTTTGCCAGCATCATCCTTGTGCGCTATTTAGGCAAATACATCCAATACGAAGCTTGGCGATGGA
TTCACCGCCTGGTTTACCTAGCCTATATTTAGGACTCTTTCACATCTACATGATAATGGGCAATCGTCTCCTTACA
TTTAATCTTCTAAGTTTCTTGTGGTATGCTTGGCTTTTAAAGCTTACTAGCTGGTTTTATATCATTTTCTATAT
CAAAAGATTTCTTCCCTATCTAGGGAATAATACCATCTCAAACGCTTAAATCAGGATACTAGAGAAATTCAA
ATCCATCTTAGCAGACCTTTCAACTATCAATCAGGACAATTTGCCTTTCTAAAGATTTTCCAAGAAGGCTTTGAAA
25 GTGCTCCGCATCCCTTTTCTATCTCAGGAGGTCTGGTCAAACCTTTACTTTACTGTTAAACCTTCAGGCGACCA
TACCAAGAATATCTATGATAATCTTCAAGCCGGCAGCAAAGTAACCTAGACAGAGCTTACGGACACATGATCAT
AGAAGAAAGGACGAGAAATCAGGTTTGGATTGCTGGAGGTATTGGGATCACCCCTTCATCTCTACATCCGTGA
ACATCCTATTTTAGATAAAACAGGTTCACTTCTACTATAGCTTCCGTGGAGATGAAAATGCAGTCTACCTAGATTTA
CTCCGTAATCTAGCTCAGAAAAATCCTAATTTTGAATCCATCTAATCGACAGTACGAAAGACGGCTATCTTAAT
30 TTGAACAAAAAGAGTGCCCGAATGCAACCGTCTATATGTGTGGTCTATTTCTATGATGAAGGCACTTGCCA
AACAGATTAAGAAACAAATCCAAAAACAGAGCATATTTAC

MEFSMKSVMKGLLFIASFILTLTWMNTSPQFMIPGLALTSLSLTFILATRLPLESWFHSLEKVYTVHKFTAFLSIILLIFH
35 NFSMGGWLWGSRLAAQFNLAIYFASIILVAYLGKYQYEAWRWIHRLVYLA YILGLFHIYMMGNRLTLFNLLSLFVGS
YALLGLLAGFYIIFLYOKISFPYLGKITHLKLRLNHDTRIQLHSRPFNYQSQFAFLKIFQEGFESAPHPFISISGGHQTLY
FTVKTSGDHTKNIYDNLQAGSKVTLDRAYGHMIEEGRENQVWIAAGGIGTTFISYIREHPILDKQVHFYYSFRGDENAV
YLDLLRNYAQKNPNFELHLIDSTKDGYNFEQKEVPEHATVYMCGPISMMKALAKQKKQNPKEHY

40 ID32 900bp

ATGACTTTTAAATCAGGCTTTGTAGCCATTTTAGGACGTCCTCAATGTTGGGAAGTCAACCTTTTAAATCAGCTTA
TGGGGCAAAAGATTGCCATCATGAGTGACAAGGCGCAGACAACGCGCAATAAATCATGGGAATTTACACGACTG
ATAAGGAGCAAATTTGCTTTATCGACACACAGGGATTACAAAGCCTAAACAGCTCTCGGAGATTTCTATGGTTG
45 AGTCTGCCTACAGTACCTTTCGCGAAGTGGACACTGTTCTTTTATGGTGCCTGCTGATGAAGCGCGTGGTAAGGG
GGACGATATGATTATCGAGCGTCTCAAGGCTGCCAAGGTTCTGTGATTTTGGTGGTGAATAAATCGATAAGGTC
CATCCAGACCAGCTCTGTCTCAGATTGATGACTCCGTAATCAAATGGACTTTAAGGAAATTTGTTCCAATCTCAG
CCCTTCAGGGAATAACGTGTCTCGTCTAGTGATATTTTGAAGTGAATACTGGATGAAGGTTTCCAATATTTCCC
GTCTGATCAAATCAGACCATCCAGAACGTTTCTTGGTTTCAGAAATGGTTCGCGAGAAAGTCTTGACACCTAACT
50 CGTGAAGAGATTCCGATTCTGTAGCAGTAGTTGTTGACTCTATGAAACGAGACGAAGAGACAGACAAGGTTTAC
ATCCGTGCAACCATCATGGTCGAGCGCGATAGCCAAAAAGGATTATCATCGGTAAAGGTGGCGCTATGCTTAAAG
AAAATCGGTAGCATGGCCCGTCTGTATCGAACTCATGCTAGGAGACAAGGTCTCTAGAAACCTGGGTCAAG
GTCAAGAAAAACTGGCGCGATAAAAGCTAGATTTGGCTGACTTTGGCTATAATGAAAGAGAATACTAA

MTFKSGFVAILGRPNVGKSTFLNHVMGQKLAIMSDKAQTTNRNKIMGIYTTDEQIVFIDTPGIHKPKTALGDFMVESAYS
55 TLREVDTVLFMVPADDEARGKDDMIERLKAAPVPLVVKIDKVPDQLLSQIDDFRNQMDKFEIVPISALQGNVVS
RLVDILSENLDGFFQYFSDQITDHPERFLVSEMVREKVLHLTREIIPHSVA VVVDMSMKRDEETDKVHIRATIMVERDSQ
KGIHIGKGGAMLKKIGSMARRDIELMLGDKVFLETWVVKKNWRDKKLDLADFGYNERYZ

60 ID33 855bp

CTGCTTCTGTTTTTACAGAAGGAGGACTTATGCCTGAATTACCTGAGGTTGAAACCGTTTGTCTGGCTTAGAAA
AATTGATTATAGGAAAGAAGATTTTCAGTATAGAAATTCGCTACCCCAAGATGATTAAAGACGGATTTGGAAGAGT
TTCAAAGGGAATTCCTAGTCAGATTATCGAGTCAATGGGACGTCGTGAAAAATATTGCTTTTTTATCTGACAGA
65 CAAGGTCTTGATTTCCCATTTGCGGATGGAGGGCAAGTATTTTACTATCCAGACCAAGGACCTGAACGCAAGCAT
GCCCATGTTTTCTTCATTTTGAAGATGGTGGCAGCTTGTTTATGAGGATGTTTCGCAAGTTTGAACCATGGAAC

5 TCTTGGTGCCTGACCTTTTAGACGTCTACTTTATTTCTAAAAAATTAGGTCTGAACCAAGCGAAACAAGACTTTGA
TTTACAGGTCTTTCAATCTGCCCTTGCCAAGTCCAAAAAGCCTATCAAATCCCATCTCCTAGACCAGACCTTGGTA
GCTGGACTTGGCAATATCTATGTGGATGAGGTTCTCTGGCGAGCTCAGGTTTCATCCAGCTAGACCTTCCAGACTT
TGACAGCAGAAGAAGCGACTGCCATTCATGACCAGACCATTTGCTGTTTTGGGCCAGGCTGTTGAAAAAGGTGGCT
CCACCATTCGGACTTATACCAATGCCTTTGGGGAAGATGGAAGCATGCAGGACTTTCATCAGGTCTATGATAAGA
CTGGTCAAGAATGTGTACGCTGTGGTACCATTCATTGAGAAAAATCAACTAGGCGGACGTGGAACCCACTTTTGTCC
AAACTGTCAAAGGAGGGACTGA

10 MLLVFTEGGMLPELPEVETVCRGLEKLIQKISSIEIRPKMIKTDLEEFQRELPSQIHESMGRRGKYLLFYLTDKVLISHL
RMEGYFYYPDQGPERRKHAHVFFHFEDGGTLVYEDVRKFGTMELLVPDLLDVYFISKKLGPPESEQDFDLQVFSALA
KSKKPIKSHLLDQTLVAGLNIYVDEVLRQAQVHPARPSQTLTAEETAJHDQTLAVLQGAVEKGGSTIRTYTNAFGED
GSMQDFHQVYDKTGQECVRCGTIEKIQLGGRGTHFCPNCQRRDZ

15 ID34 633bp

15 TTGTCCAAACTGTCAAAGGAGGGACTGATGGGAAAAATCATCGGAATCACTGGGGGAATTGCCTCTGGTAAGTCA
ACTGTGACAAATTTTCTAAGACAGCAAGGCTTTCAAGTAGTGGATGCCGACGCAGTCGTCCACCAACTACAGAAA
CCTGGTGGTCGTCTGTTTGAGGCTCTAGTACAGCACTTTGGGCAAGAAATCATTCTTGAAAACGGAGAATCAATC
20 GCCCTCTCCTAGCTAGTCTCATCTTTTCAAATCCTGATGAACGAGAATGGTCTAAGCAAAATCAAGGGGAGATTAT
CCGTGAGGAACTGGCTACTTTGAGAGAACAGTTGGCTCAGACAGAGAAGAGATTTTCTTCATGGATATTCCTCTACTT
TTTGAGCAGGACTACAGCGATTGGTTTGTGAGACTTGGTGGTCTATGTGGACCGAGATGCCAAAGTGGAAACGC
TTAATGAAAAGGGACCAAGTTGTCCAAAGATGAAGCTGAGTCTCGTCTGGCAGCCCAAGTGGCCTTTAGAAAAAAG
AAAGATTTGGCCAGCCAGGTTCTTGATAATAATGGCAATCAGAACCAGCTTCTTAATCAAGTGCATATCCTTCTTG
25 AGGGAGGTAGGCAAGATGACAGAGATTAA

25 MSKLSKEGLMGKIIIGITGGIASGKSTVTNFLRQQGFQVVDADAVVHQLQKPGGRLFEALVQHFGQEIIENGENLNRPLL
ASLIFSNPDEREWSKIQGEIIEELATLREQLAQTEIFFMDIPLLFEQDYSDFWFAETWLVYVDRDAQVERLMKRDQLS
KDEAESRLAAQWPLEKKDLASQVLDNNGNQNQLLNQVHILLEGRQDDRDZ

30 ID35 1269bp

30 TTGATAATAATGGCAATCAGAACCAGCTTCTTAATCAAGTGCATATCCTTCTTGAGGGAGGTAGGCAAGATGACA
GAGATTAAGTGAAGGATAATCTGCGCATTGCCTGGTTTGGTAATTTCTGACAGGAGCCAGTATTTCTTTGGTTG
35 TACCTTTATGCCCATCTTCGTGGAATAATCTAGGTGTAGGGAGTCAGCAAGTCGCTTTTATGCAAGCTTAGCAAT
TTCTGTCTCTGCTATTTCCGCGCGCTCTTTCTCCTATTTGGGGTATTCTTGCTGACAAATACGGCCGAAAACCCA
TGATGATTGGGGCAGGCTTGTCTATGACTATCACTATGGGAGGCTTGGCCTTTGTCCCAAATATCTATTGGTTAAT
CTTTCTTCGTTTACTAAACGGTGTATTTGCAAGTGTGTTCTTAATGCAACGGCACTGATAGCCAGTCAGGTTCCA
AAGGAGAAATCAGGCTCTGCCTTAGGTACTTTGTCTACAGGCGTAGTTGCAGGTAAGTCTAACTGGTCCCTTTATTG
40 GTGGCTTTATCGCAGAAATATTGGCAATTCGTACAGTTTCTTACTGGTTGGTAGTTTCTATTCTTAGCTGCTATT
TGACTATTTGCTTTATCAAGGAAGATTTTCAACCAGTAGCCAAGGAAAAGGCTATTCCAAACAAAGGAATATTATAC
CTCGGTTAAATATCCCTATCTTTTGTCTCAATCTCTTTTAAACAGTTTGTCTATCCAAATTTTCAAGTCAATCGATTG
GCCCTATTTTGGCTCTTTATGTACGCGACTTAGGGCAGACAGAGAATCTTCTTTTGTCTCTGGTTTGATTGTGTCC
45 AGTATGGGCTTTTCCAGCATGATGAGTGCAGGAGTCATGGGCAAGCTAGGTGACAAGGTGGGCAATCATCGTCTC
TTGGTTGTGCGCCAGTTTATTCAGTCATCATCTATCTCTCTGTGCCAATGCCTCTAGCCCCCTTCAACTAGGACT
CTATCGTTTCTCTTTGGATTGGGAACCGGTGCCTTGATTCCCGGGGTTAATGCCCTACTCAGCAAAATGACTCCC
AAAGCCGGCATTTCGAGGGTCTTTGCCTTCAATCAGGTATTTCTTTATCTGGGAGGTGTTGTTGGTCCCATGGCAG
GTTCTGCAGTAGCAGGTCAATTTGGCTACCATGCTGCTTTTATGCGACAAGCCTTTGTGTTGCCTTTAGTTGTCTC
TTTAACCTGATTCAATTTGAAACATTATTAAGAAAGTAAAGGAAATCTAG

50 MIIMAIRTSFLIKCISFLREVGMTEINWKDNLRIA WFGNFLT GASISLVVFPMPFIVENLGVGSQQVAFYAGLAISVSAIS
AALFSPWIGILADKYGRKPMIRAGLAMTITMGLAFVFNLYWIFLRLNGVFAGFVPNATALIASQVPKEKSGSALG
TLSTGVVAGTLTGPFIGGFIAELFGIRTVFLLVGSFLAAILTICFIKEDFPVAKKEAIPTELFTSVKYPYLLNLFLTS
FVIQFSAQSIGPILALYVRDLGQTENLLFVSGLVSSMGFSSMMSAGVMGKLGDKVGNHRLLVVAQFYSVIYLLCANAS
55 SPLQLGLYRFLGLGTGALIPGVNALLSKMTPKAGISRVFAFNQVFFYLGGVVGPMAGSAVAGQFGYHAFYATSLCV
AFSCLFNLIQFRTLKVKEIZ

ID36 1311bp

60 ATGGCCCTACCAACTATTGCCATTGTAGGACGTCCCAATGTTGGGAAATCAACCCTATTTAATCGGATCGCTGGTG
AGCGAATCTCCATTGTAGAAGATGTCGAAGGAGTGACACGTGACCGTATTTATGCAACGGGTGAGTGGCTCAATC
GTTCTTTTATGACATGATTGATACAGGAGGAATTGATGATGTCGATGCTCCTTTTCATGGAACAAATCAAGCACCAGGC
AGAAATTGCCATGGAAGAAGCAGATGTTATCGTTTTTGTCTGTCTGGTAAGGAAGGAATTACTGATGCAGACGA
ATACGTAGCTCGTAAGCTTTATAAGACCCACAAACAGTTATCCTCGCAGTCAACAAGGTGGACAACCTGAGAT
GAGAAATGATATATATGATTCTATGCTCTCGGTTTGGGTGAACCATTCCTATCTCATCTGTCATGGAATCGGT
65 ACAGGGGATGTGCTAGATGCGATCGTAGAAAATCTTCAAATGAATATGAGGAAGAAAAATCCAGATGTCATTAAAG
TTTAGCTTGATTGGTCGTCTAACGTTGGAAAATCAAGCTTGATCAATGCTATCTTGGGAGAAGACCGTGTATTG

CTAGTCCTGTTGCTGGAACTCGTGATGCCATTGATACCCACTTTACAGATACAGATGGTCAAGAGTTTACCAT
GATTGATACGGCTGGTATGCGTAAGTCTGGTAAGGTTTATGAAAATACTGAGAAATACTCTGTTATGCGTGCCATG
CGTGCTATTGACCGTTTACAGATGTGGTCTTGATGGTCATCAATGCGGAAGAAGGCATTGCGTAGTACGACAAGCGT
5 ATCGCAGGATTTGCCCATGAAGCTGGTAAAGGGATGATTATCGTGGTCAACAAGTGGGATACGCTTGAAAAAGAT
AACCACACTATGAAAACTGGGAAGAAGATATCCGTGAGCAGTTCCAATACCTGCCTTACGCACCGATTATCTTT
GTATCAGCTTTAACCAAGCAACGTCTCCACAACTTCTGAGATGATTAAAGCAAATCAGCGAAAGTCAAAATACA
CGTATTCCATCAGCTGTCTTGAACGATGTCTATGGAATGCCATTGCCATCAACCCAAACGACAGACAAAGGA
10 AAACGTCTCAAGATTTTCTATGCGACCAAGTGGCAACCAACCAACCTTTGTATCTTTGTCAATGAAGAAAG
AACTCATGCACTTTTCTTACCTGCGTTTCTTGGAAAAATCAAATCGCAAGGCCTTTGTTTTGAGGGAACACCGAT
TCATCTCATCGCAAGAAACGCAATAA

MALPTIAIVGRPNVKGSTLFNRIAGERISTVEDVEGVTRDRIYATGEWLNRSFSMIDTGGIDDVDAPFMEQIKHQAEIAM
EEADVIVFVVSQKEGTTDADEYVARKLYKTHKPVILAVNKVDNPEMRNDIYDFYALGLGEPLPISSVHIGTGVDLDAI
15 VENLPNEYEEENPDVIFSLIGRPNVGKSSLINAILGEDRVIASPVAGTTRDAIDTHFTDGDGQEFMTIDTAGMRKSGKV
YENTEKYSVMRAMRAIDRSVVLMVINAEEGIREYDKRIAGFAHEAGKGMIIIVNKNWDTLEKDNHTMKNWEEDIREQ
FQYLPYAPIIFVSALTQRLHKLPEMIKQISESQNTRIPSAVLNDVIMDAIAINPTPTDKGKRLKIFYATQVATKPPTFVIFV
NEEELMHFSYLRFLNQIRKAFVFEGTPIHLIARKRKZ

ID37 714bp

20 ATGACAGAAACCATTAAATTGATGAAGGCTCATCTTCAGTGCGCAGGTTTTAAAGAGCAAGAAATCCCCAAGTA
GACTTAAATGAGATTTTGACAGCAGCCAGATGGCATCATCTTGAAGAATTCCAATCCTACTCTGTGATTGTGG
TACGAAGTCAAGAGAAGAAAGATGCCTTGTATGAATTGGTACCTCAAGAAGCCATTGCGCAGTCTGCTGTTTCTCT
TCTCTTTGTGCGAGATTGAAACCGAGCAGAAAAGGGAGCCGACTTCATACCGACACCTTCAACCCCAAGGTGT
25 GGAAGGTCTCTTGATTAGTTCGGTTCGATGCACTCTTGGTGGACAAAACGCCTTGTGGCAGCTGAAAGCTTGGGC
TATGGTGGTGTGATTATCGGTTTGGTTCGATACAGTCTGAAGAAGTGGCAGAGCTCTTAACTACCTGACTACA
CCTATTCTGTCTTTGGGATGGCACTGGGTGTGCCAAATCAACATCATGATGAAACCGAGACTGCCACTAGAGA
ATGTTGTCTTTGAGGAAGAATACCAAGAACAGTCAACTGAGGCAATCCAAGCTTATGACCGTGTTCAGGCTGACT
30 ATGCTGGGGCGCGTGGCACCACAAGCTGGAGTCAGCGCTAGCAGAACAGTTTGGTCAAGCTGAACCAAGCTCAA
CTAGAAAAATCTTGACAGAAAGAAATTATTGTAG

35 MTETIKLKAHTSVRRFKEQEIQVDLNEILTAQMASSWKNFQSYSVTVRSQEKDALYELVPQEAIRQSAVFLLFV
GDLNRAEKGARLHTDTFQPGVEGLLISSVDAALAGQNALLAAESLGYGGVIIGLVRYKSEEAELFNLPDYTSVFG
MALGVPNQHDMKPRPLENVVFEEYQEQSTEAIQAYDRVQADYAGARATTSWSQRLAEQFGQAEPSSTRKNLEQK
KLLZ

ID38 729bp

40 ATGACAGAAATTAGACTAGAGCAGTCAGTTATGCCTATGGTCAGGAGAGGATTTTAGAGGATATCAACCTACAG
GTGACTTCAGGGCAAGTGGTTTCCATCCTAGGCCCAAGTGGTGTGGAAAGACCACCTCTTAACTAATCGCTG
GGATTTTGAAGTTTCACTCAGGGAGAATTGCTTGTATGGTGAAGAAAATCCCAAGGGGCGCGTGAGTTATATGT
TGCAAAAGGATCTGCTCTTGGAGCACAAGACGGTGTGGAAATATCATTCTGCCCTCTTGATTCAAAAGGTGG
ATAAGGCAGAAAGCTATTTCCGAGCGGATAAAATCTTGGCAGCTTCCAGCTGACAGCTGTAAGAGACAAAGTATC
45 CTCATGAACCTTAGCGGTGGGATGCGCCAGCGTGTAGCCTTACTCCGGACCTACCTTTTGGGCACAAGCTCTTTCT
CTTAGATGAGGCCTTAGCGCCTTGGATGAGATGGAAGATGGAAGTCCAGCTTGGTATCTTGAGATTACAA
GCAGTTGCAGCTAACAACTGATCATACGCATAGTATTGAGGAGGCCCTCAATCTCAGCGACCGTATCTATATC
TTGAAAAATCGCCCTGGGCAGATTGTTTCAAGAAATTAAGTAGATTGGTCTGAAGATGAGGACAAGGAAGTCCAA
AAGATTGCCTACAAACGTCAAAATTTGGCGGAATTAGGCTTAGATAAGTAG

50 MTEIRLEHVSAYGQERILEDINLQVTSGEVVSILGPSGVGKTTLFNLIAGILEVQSGRIVLDGEENPKGRVSYMLQKDLL
LEHKTVLGNILPLLIQKVDKAEISRADKILATFQLTAVRDKYPHELSSGMRQRVALLRTYLFHKLFLLDFAFSALDE
MTKMELHAWYLEIHKQLQLTTLITHSIEEALNLSDRYILKNRPGQIVSEIKLDWSEDEKEVQKIAKYRQILAEGLDK
Z

ID39 2433bp

55 ATGAACTATTCAAAAGCATTGAATGAATGTATCGAAAGTGCCTACATGGTTGCTGGACATTTGGAGCTCGTTATC
TAGAGTCGTGGCACTTGTGATTGCCATGTCTAATCACAGTTATAGTGTAGCAGGGGCACTTTAAATGATTATCC
GTATGAGATGGACCGTTTGAAGAAGGTGGCTTTGGAACCTGACTGAAACGGACTATAGCCAGGATGAAACCTTAC
60 GGAATTTGCCGTTCTCCCGTCTTTGACAGGTTCTTTTGTATGAAGCAGAGTATGTAGCGTCAGTGGTCCATGTAAG
GTACTAGGGACAGAGCAGCTCTATGCGATTTTGCATGATAGCAATGCCTTGGCGACTCGTATCTTGGAGAGG
GCTGGTTTTTCTTATGAAGACAAGAAAGATCAGGTCAAGATTGCTGCTCTTCGTCGAAATTTAGAAGAACGGGCA
GGCTGGACTCGTGAAGATCTCAAGGCTTTACGCCAACGCCATCGTACAGTAGCTGACAAGCAAAATCTATGGCC
AATATGATGGGCATGCCGAGACTCCTAGTGGTGTCTCGAGGATTATACGCATGATTGACAGAGCAAGCGCGT
65 TCTGGCAAGTTAGAACCAGTCATCGGTGGGACAAGGAAATCTCACGTATGATTCAAATCTTGAGCCGGAAGACT

AAGAACCAACCTGTCTTGGTTGGGGATGCTGGTGTTCGGGAAACACGCTCTGGCGCTTGTGTTCTGCCACGCTATTG
 CTAGTGGTGACGTGCGCTGCGGAAATGGCTAAGATGCGCGTGTTAGAAGCTTGAATGATGTCGTTGCAGGGA
 CACGCTTCCGTTGGTGAATTTGAAGAACGCATGAATAATATCATCAAGGATATTGAAGAAGATGCCAAAGTCATCC
 TCTTATCGATGAACCTCCACCATCATGGTTCTGGTAGCGGGATTGATTCGACTCTGGATGCGGCCAATATCTT
 5 GAAACCAGCCTTGGCGCGTGGAACCTTTGAGAACGGTTGGTGCCACTACTCAGGAAGAATATCAAAAACATATCGA
 AAAAGATGCGGCACTTTCTCGTCGTTTCGCTAAAGTGACGATTGAAGAACCAAGTGTGGCAGATAGTATGACTAT
 TTACAAGGTTTGAAGCGCATCTTATGAGAAACATCACCGTGTACAAATCACAGATGAAGCGGTTGAAACACGCGT
 10 TAAGATGGTCTATCGTTATTTAACCATGCTGCTACTTGCCAGACTCTGCTATCGATCTCTTGGATGAGGCGGACGA
 ACAGTGCACAAAATGAAGCAAGCATGTAAAAGCAGACGATTGAGTTGAGTCCAGCTGACAAGGCCCTGATGGAT
 GGCAAGTGGAAACAGGCGACGCTAATCGCAAAAGAGAGGAAGTACCTGCTCAAAAGACTTGGTGACAGA
 GTCTGATATTTTGACCACTTGAGTCGTTGTGAGGAATCCCAAGTCAAAAACGACTCAACCGGATGCTAAGAA
 TATTTAAATCTTGAAGCAGAACTCCATAAACCGGTTATCGGTCAAGATCAAGCTGTTTCAAGCATATGCGGTCGA
 15 TTCGCCGCAACCAAGTCAGGATTGCGAGTCATAAGCGTCCGATTGGTTCTTTATGTTCTTAGGGCTACAGGTGT
 CGGGAACCACTGAATTAGCCAAGGCTTGCGAGAAGTCTTTTTGACGACGAATCAGCCCTTATCCGCTTTGATATG
 AGTGAGTATATGGAGAAATTTGACAGTATGCTGTCTCAACGGAGCTCTCCAGGCTATGATGATATGAAGAAGT
 GGGGAGTTGACAGAGAAGATTCGCAATAAACCCCTATTCGGTCTCTCTTTGATGAGGTAGAGAAGGCCACCCA
 GATATCTTTAATGTTCTCTTGACGTTCTGGATGACGGTGTCTTGACAGATGAAGGACGCAAGGTCGATTTTT
 20 CAAATACCATTTATCATTATGACATCGAATCTAGGTGCGACTGCCCTTCGTGATGATAAGACTTGGTGTGGGG
 TAAGGATATTCGTTTGAACAGGAAAAATATGAAAAACGCATGTTTGAAGAACTGAAAAAGCTTATAGACCGGA
 ATTCATCAACCGTATTGATGAGAAGGTGGTCTTCATAGCCTATCTAGTATCATATGACAGGAAGTGGTGAAGATT
 ATGGTCAAGCGTTTGTAGTGGCAAGTTTGAAGTGAAGGCAATGACTTGAAATCAAGCTTCAGCTGAAATTTG
 TAGCAATCAAGGATATGACCCAGAGATGGGAGCTCGCCCACTTCGCAACCACTCGCAACAGCAAGTGGAGGAC
 AAGTTGGCAGAACTTCTCTCAAGGAGATTAGTGGCAGGCAGCACTTAAGATTGGTGTCAAAGCAGGCCAG
 25 TTAATTTGATATTGCATAA

 MNYSKALNECIESAYMVAGHFGARYLESWHLIAMSNSHSYVAGATLNDYPYEMDRLEEVALELTETDYSQDETFT
 LPFSRRLQVLFDEAEYVASVHVAKVLGTEHVLYAILHDSNALTRILERAGFSYEDKKDQVKIAALRRNLLEERAGWTR
 EDLKLALRQRHRTVADQNSMANMMGMPQTSGGLEDYTHDLTEQSRGKLEPVGIRGDKEISRMQILSRKTKNPNVLV
 GDAGVGKTALALGLAQRIASGDVPAEMAKMRVLELDLMNVVAGTRFRGDFEERMNNIUKDIEEDGQVLFIDELHTM
 30 GSGSIDSTLDAANILKPALARGTLRTVGATTQEYQKHEKDAAALSRFAKVTIEEPSVADSMITLQGLKATYKHHVR
 QITDEAVETAVKMAHRYLTSRHLPSAIDLLDEAAATVQNKAKHVKADDSLPADKALMDGKWQAQLIAKEEV
 PVYKDLVTESDILTSLRSLGIPVQKLQTQDAKKYLNLEAELHKRVIGQDQAVSSIRAIRRNQGSYFHEKRGVDFLGP
 TGVGKTELAKALAEVLFDDSEALIRFDMSEYMEKFAASRLNAPPYVGYEEGGELTEKVRNKPYSVLLFDEVEKAHP
 35 DIFNVLLQVLDGVLTDQSKRKYDFSNTHIMTSNLGATALRDDKTGVFGAKDIRFDQENMEKRMFEELKAYRPEFIN
 RIDEKVVFHSLSSDHMQVYKIMVPLVASLTEKGIDKLQASALKLLANQGYDPEMGARPLRRTLQTEVEDKLAELL
 LKGDVLVAGSTLKIGVKAGQLKFIDIAZ

ID40 1998bp

 ATGAAGAAACATGGAAAGTGTTTTAACGCTTGTAAACAGCTCTTGTAGCTGTTGTGCTTGGCTGAGTCAAG
 GAAGCTGCTCTAAAGACAACAAAGAGGCGAGAACTTAAGAAGTTGACTTTATCTAGACTGGACACCAATACCA
 ACCACACAGGGCTTTATGTTGCCAAGGAAAAAGGTTATTTCAAAGAAAGTGGAGTGATGTTGATTGAAATGTC
 40 CACCAGAAGAAAGTTCTTCTGACTTGGTTATCAACGGAAAGGCACCATTTGCAAGTGTATTTCAAAGACTACATGGC
 TAAGAAATTTGAAAAAGGAGCAGGAATCACTGCGGTTGCAGCTATTGTTGAACAAATACATCAGGAATCATCTC
 TCGTAAATCTGATAATGTAAAGCAGTCCAAAGAACTTGGTTGGTGAAGAAATATGGGCAATGGAATGACCAACTGA
 45 ACTTGCTATGTTGAAAACCTTGGTGAATCTCAAGGTGGAGACTTTGAGAAGGTTGAAAAAGTACCAAAATACGA
 CTCAAACTCAATCACACCGATTGCCAATGGCGTCTTTGATACTGCTTGGATTACTACGTTGGGATGGTATCTCTT
 GCTAAATCTCAAGGTGTAGATGCTAACTCATGTACTGTAAGAACTATGCAAGGAGTTGACTACTATTCCACGAC
 50 TTATCATCGCAACACGACTATCTGAAAGATAACAAAGAAGAAGCTCGCAAGTCAATCAAGCCATCAAAAAA
 GGCTACCAATATGCCATGGAACATCCAGAGAAGGCTGCAGATATTCTCATCAAGAATGCACCTGAATCAAGGAA
 AAACGTGACTTTGTCAATGAACTCAAAAAATCTTGCAAAAGAAATACGCAAGGCAAGGAAAAATGGGGTCAA
 TTTGACGCAGCTCGCTGGAATGCTTTCTCAAAATGGGATAAAGAAATGGTATCTTAAAGAAAGACTTGACAGAC
 AAAGGCTTACCAACGAATTTGTGAAATAA

 MKKTWKVFLTLVTLVAVVLVACGQGTASKDNKEAELKKVDFILDWTPNTNHTGLYVAKEKGYFIRKEKPGVVDLKL
 55 PEESDDL VINGKAPFAVYFQDYMAKKLEKGAGITAVAAIVEHNTSGIIRKSDNVSSPKDLVGKXYGTWNPTELAML
 KTLVESQGGDFEKVEKVPNNDSNSITPIANGVFDTAWIYYGWDGILAKSQGVANDFMVYKDYVKEFDYYSPIIANNND
 YLKDNDKEARKVIAKKGYYQYAMEHPHEAADILIKNAPELKEKRDVFIESQKYLSEYASDKEKWGFDAARWNAFY
 60 KWDKENGILKEDLTDKGFTNEFVKZ

ID41 762bp

 TTGATGAGAACTTGAGAAGTATACTGAGACGACATACATGCTTATTGGGCTTTCTCGGAGTATTGTCAATCTGGC
 AGTAGGACGGTTTTCTTAACTCTCCCAAGGTTATCTCTGCGACACCTCTGAAATCTCCAGCCCTTTGTTGCT
 65 GACAGAGAATTTCTCTGCGACCATAGCTGGCGCAGCTTGAGAGTGCTTTACTGGGGCTGATTTTGGGAGTTTGA

- 5 TTGCTGTCTTATGGCTGTGCTCATGGATAGTTTGACTTGGCTCAATGACCTGATTTACCTATGATGGTGGTCATT
CAGACCAATCCGACCATTTGCCATAGCTCCTATCCTGGTCTTGTGGCTAGGTTATGGGATTTTGGCCAAAGATTGTCT
TGATTATCTTAACGACAACCTTTCCCATCATCGTTAGTATTTTGGACGGTTTTAGGCATTGGCACAAGGATATGCT
GACCTTGTTTAGTCTGATGCGGGCCAAGCCTTGGCAAACTCTGTGGCATTTTAAAATCCAGTTAGCCTGCCTTAC
TTTTATGCAGGTCTGAGGGTCAGTGTCTCTACGCCCTTATCACAACCTGTGGTATCTGAGTGGTTGGGAGGTTTTG
AAGGCTTGGTGTTTATATGATTCACTCTAAAAAAGTGTTCAGTATGATACCATGTTTGCCATTATTATCTGGTG
TCGATTATCAGTCTTTTGGGTATGAAGCTGGTCGATATCAGTGAAAAATATGTGATTAATGGAACGTTCTGATG
- 10 MMRNLRSLRRHISLLGFLGVLISWQLAGFLKLLPKFILPTPLEILQPFVRDREFLWHHSWATLRVALLGLGLVLIACLM
AVLMDSLTWLNDLYPMVMVVIQTIPTIAIPILVLWGLYGLPKIVLILTTTFPIVSILDGFRHCDKMDLTLFSLMRAKP
WQILWHFKIPVSLPYFYAGLRVSVSYAFITTVVSEWLGGEGLGVYMIQSKKLFQYDTMFJHILVSIISLLGMKLVDSIE
KYVIKWKRSZ
- 15 ID42 372bp
- 20 TTGATTTTAACTCTATTTGCTGTATGATAAGGGAAAAGAAAGGGGACAGATATGGCTTTTACCAATACCCACA
TGGATCTGCTAGTTTGGTATTGTTACCAGCTTGCTGATGACATCATTGACTCTTTTGGTATATCATCGACCAT
TTCTTAAAAAATGTCTTTGAATTGGAAGAAGAACTCGAGTTTCAATTGCTTAATAACCAAGGAAAGATTACCTTCC
ACTTTTCAAGTCAACACCTCCCTACAGCCATTGATTTTGACTTTAACCATCCTTTTCGACCCTCGTTATCCCCAAGA
GTACTGGTTTTAGACATGGACGGTAGAGAAACTATCCTCCTCCAGAAGAAAATGACCTATTTTAA
- 25 MIFNPICCMIREKKGDRDMAFTNTHMRSASFGIVTSLPDDIISFWYIIDHFLKNVFELEEELEFQLLNNQGKITTFHSSQ
HLPTAIDFDNFHFDPRYPFRVLVLDMDGREILLPEENDLPZ
- 30 ID43 1569bp
- 35 ACAGCGGTGTCATTCTATCTATTTTAAAGAAAAGTAATAATCAATTGTTAAAAATAGTAAAAAATTGGAGGTTCTG
ATGAAAATTTTGTTCCTAATGAGGTATTCAGTATTCGTAATAAAGGTGGGACTTGCTCGGTACTATTGGCAA
TTTCAATTTTGGGAAGCCAAGGTATTTATCGGATGAAGTTGTTACTAGTTCTTCCCGATGGCTACAAAAGAGTC
TTCTAATGCAATTACTAATGATTTAGATAATTCACCAACTGTTAATCAGAATCGTTCTGCTGAAATGATTGCCTCT
AATTCAACCACTAATGGTTTAGATAATTCGTTAAGTGTTAATAGCATCAGCTCTAATGGTACTATTGTTCCAATT
CACAATTAGACAACAGACAGTTGAATCTACAGTAACATCTACTAATGAAAATAAGAGTTATAAGGAAGATGTTA
TAAGTGACAGAATTATCAAAAAAGAAATTTGAAGATACTGCTTTAAGTGTAAGAGATTATGGTGCAGTAGGTGATG
GGATTCTATGATGATCGACAAGCAATTCAAGATGCAATAGATGCTGCAGCTCAAGGGCTAGGTGGAGGAAATGTAT
35 ATTTTCTGAAGGAACTTATTTAGTAAAAGAAATGTTTTTTAAAAAGTCATACACACTTGAATGAGAA
AGCTACAATTCTAAATGGTATAAATATTAAGAATCACCTTCCATTGTTTTATGACAGGTTTATTACGGATGAT
GGTGCGCAAGTAGAATGGGGCCCAACAGAAGATATTAGTTATTCTGGTGGTACGATTGATATGAACGGGTGCTTTG
AATGAAGAAGGAACTAAAGCAAAAAATCTACCACTTATAAATCTTCAGGTGCAATTTGCTATTGGGAATTCAAAT
40 AACGTAATATAAAAAATGTAACATTCAAGGATAGTTATCAAGGCGATGCTATTCAAATTCAGGTTTCGAAAAAT
GTATTAGTTGATAATTCTCGTTTCTTGGGCAAGCCTTACCCAAAACGATGAAGGATGGGCAATCATAAGTAAGG
AGAGCATTGAGATTGAACCATTAAGTAAAAAGGTTTTCCTTATGCCTTGAATGATGATGGGAAAAAATCTGAAA
ATGTGACTATTCAAAATTCCTATTTTGGCAAAAGTGATAAATCTGGGGAATTAGTAACAGCAATTGGCACACACTA
TCAAACATTGTCGACACAGAACCCTCTAATATTAATAATCAAAATAATCAATTTGATAACATGATGTATGACGGT
45 GTACGTTTTACAGGATTCAGTATGATTAATCAAAGGAAATCGCTTGTATAAGAAAGTTAAAGGAGAGAGTGTA
CATTATCGAGAAAGCGGAGCAGCTTAGTAAATGCTTATAGCTATAAAAACTAAAGACCTATTAGATTTAAAT
AAACAGGTGGTTATCGCCGAAAAATATATTTAATATTGCCGATCCTAAAACAAAAGCGATACGAGTTGCAAAAGAT
AGTGACAGATGTTTAGGAAAAGTATCAGATATTACTGTAACAAAAATGTAATTAATAAATCTAAGGAAACA
GAACAACCAATATTGAATTATTACGAGTTAGTGATAATTTAGTAGTCTCAGAGAATAGT
- 50 QRCHSIYFKKSNNQLLKIVKKLEVLKMYFVPNEVFSIRKLKVGTCVLLAISILGSQGILSDEVVTSPPMATKESSNAITN
DLDNSPTVNQNRSAEMIASNSTTNGLDNSLSVNSISSNGTIRSNSQLDNRTVESTVTSTNENKSYKEDVISDRIKKEFEDT
ALSVKDYGAVDGIHDDRQAIQDAIDAAAQGLGGGNVYFPEGTYLVKEIVFLKSHTHLELNEKATILNGINIKNHPISIVF
MTGLFTDDGAQVEWGPTEDISYSGGTIDMNGALNEEGTKAKNLPLINSSGAFAGNSNNVTIKNVTFKDSYQGHAIQIA
55 GSKNVLVDNSRFLGQALPKTMKDGQIISKESIQIEPLTRKGFYPALNDDGKKSENVTIQNSYFGKSDKSGELVTAIGHY
QTLSTQNPSNIQNNHFDNMMYAGVRFGTFTDVLKGNRFDKKVKGESVHYRESGAALVNAYSYKNTKDLLDLNKQ
VVAENIFNIADPKTKAIRVAKDSAELCKVSDITVTKNVINNNSKETEOPNIELLRVSDNLVVSNS
- 60 ID44 324bp
- 65 GTGATGAAAGAACTCAGCTATTTAAAGGTGTTCTTGAAGGTGTGTCTTGATATGATTGGTCAAAAAGAGCGG
TATGTTATGAGTTGGTTGAGCTTTGCGAGAGGCTGGATTTGATACTATCGTTCCAGGAATTTATCCTTTGTT
GCAAAAGTTAGAAAAAATCAATGGATAAGAGGCGACATGCGCCCTGCGCCAGATGGTCCAGATCGGAAGTATTT
TTCATTAATGAAAGAAAGGAGAAGAGCGTGTCTCAGTCTTTTGCAACAAATGGGACGATTGAGTCAAAAAGTAGA
AGGGATTAAGAAATGGGGTTAA

5

10

20

25

30

35

35

40

60

11

65

5 CTTGGTGAAAAACAAGCTAAGGTCCGTAACCAACAAATCGGTTTTGTCTTTACGACAGTTCTTTCTTCTATCGA
AGCTCAATGCTCTGCAAAATGTAGAAATTGCCCTTGATTTACGCAGGAGTTTCGTCTTCAAAACGTCGCAAGTTGGC
TGAGGAATATTTAGACAAGGTTGAATTGACAGAACGTAGTCACCATTTACCTTCAGAATTATCTGGTGGTCAAAA
GCAACGTGTAGCCATTGCGCGTGCCTTGGTAAACAATCCTTCTATTATCCTAGCGGATGAACCGACAGGAGCCTTG
GATACCAAAACAGGTAACCAAAATTATGCAATTATTGGTTGATTTGAATAAAGAAAGGAAAAACCATTATCATGGTA
ACGCATGAGCCTGAGATTGCTGCCTATGCCAAACGTCAGATTGTCAATTCGGGATGGGGTCATTTCTGCTGACAGTG
CTCAGTTAGGAAAGGAGGAAAACTAA

10 MMKQLISLKNIFRSYRNGDQELQVLKNINLEVNEGEFVAIMGPSGSGKSTLMNTIGMLDTPSTGEYYLEGQEVAGLGEK
QLAKVRNQIQGFVQFFLLSKLNALQNVLEPLIYAGVSSSKRRRLAEEYLDKVELTERSHHLPSELSSGGQKQRVAIARA
LVNPNPILADEPTGALDTKGNQIMQLLVLDLNKEGKTIIMVTHEPEIAAYAKRQIVIRDGVISSDAQLGKEENZ

ID49 1200bp

15 ATGAAGAAAAAGAAATGGTAAAGCTAAAAAGTGGCAACTGTATGCAGCAATCGGTGCTGCGAGTGTAGTTGTATTG
GGTGCTGGGGGGATTTTACTCTTTAGACAACCTTCTCAGACTGCTCTAAAAGATGAGCCTACTCATCTTGTGTTG
CCAAGGAAGGAAGCGTGGCCTCTCTGTTTTATTGTGAGGGACAGTAACAGCAAAAAATGAACAAATATGTTTTATT
TTGATGCTAGTAAGGGTGATTTAGATGAAATCCTTGTCTTGTGGCGATAAGGTCAGCGAAGGGCAGGCTTTAGT
20 CAAGTACAGTAGTTCAGAAGCGCAGGCGGCTATGATTCAGCTAGTCGAGCAGTAGCTAGGGCAGATCGTCATAT
CAATGAACTCAATCAAGCACGAAATGAAGCCGCTTCAGCTCCGGCTCCACAGTTACCAGCGCCAGTAGGAGGAGA
AGATGCAACGGTGCAAGGCCAACTCCAGTGGCTGGAAATCTGTTGCTTCTATTGACGCTCAATTGGGTGATGCC
CGTGATGCGCGTGACAGATGCTGCGGCGCAATTAAGCAAGGCTCAAAGTCAATTGGATGCAACAACTGTTCTCAGT
ACCTTAGAGGGAAGTGTGGTGAAGTCAATAGCAATGTTTCTAAATCTCCAACAGGGGCGAGTCAAGTTATGGTT
CATATTGTGACCAATGAAATTTACAAGTCAAGGGAGAATTGTCTGAGTACAATCTAGCCAACTTTCTGTAGGTC
25 AAGAAGTAAGCTTTACTTCTAAAGTGTATCCTGATAAAAAATGGACTGGGAAATTAAGCTATATTCTGACTATCC
TAAAAACAATGGTGAAGCAGTAGTCCAGCAGCCGGAATAATACAGGTTCTAAATACCTTTATACTATTGATGT
GACAGGCGAGGTTGGTGATTTGAAACAAGGTTTTCTGTCAACATTGAGGTTAAAGCAAACTAAGGCTATTCTT
GTTCTGTAGCAGTCTAGTAATGGATGATAGTAAAAATTATGTCTGGATTGTGGATGAACAACAAAAGGCTAA
30 AAAGTTGAGGTTTCATTGGGAAATGCTGACGCAGAAAAATCAAGAAATCACTTCTGGTTTAAACGAACGGTGCTAAG
GTCAATCAGTAATCCAACATCTTCTTGAAGAAGGAAAAAGGTTGAAGGCTGATGAAGCAACTAATTAG

35 MKKKNGKAKKWQLYAAIGAASVVVLGAGGILLFROPSTALKDEPHTLVVAKESVASSVLLSGVTYAKNEQYVYFD
ASKGDLDEILVSVGDKVSEQALVKYSSSEAQAAYSASRAVARADRHINELNQARNEAASAPAPQLPAPVGGEDATV
QSPTPVAGNSVASIDAQLGDARDARADAAQLSKAQSLDATTVLSTLEGTVEVNSNVSKSPTGASQVMVHVSNEN
LQVKGELSEYNLANLSVGOEVSFTSKVYPDKKWTGLSYSDYPKNNGEASPAAGNNTGSKYPYTTIDVTGEVGLKQ
GFSVNIEVSKTKAILVPVSSLVMDDSKNYVWVDEQQAQKAKKVEVSLGNADAENQEITSGLTNGAKVISNPTSSLEEGKE
VKADEATNZ

ID50 759bp

40 ATGTCACGTAAACCATTATCGCTGGTAACTGGAAAAATGAACAAAAATCCAGAAGAAGCTAAAGCATTCTGTTGAA
GCAGTTGCATCAAAAACCTTCTTCATCAGATCTTGTGAAGCAGGTATCGCTGCTCCAGCTCTTGATTGACAACTG
TTCTTGCTGTTGCAAAAGGCTCAAACTTAAAGTTGCTGCTCAAACTGCTACTTTGAAAAATGCAGGTGCTTTTAC
45 TGGTGAAACTAGCCCAAGTTTTGAAAGAAATCGGTACTGACTACGTTGTTATCGGTCACTCAGAACGCGGTGA
CTACTTCCATGAAACTGATGAAGATATCAACAAAAAAGCAAAAGCAATCTTTCGGAACGGTATGCTTCCAATCAT
CTGTTGTGGTGAACTCACTTGAACCTTACGAAGCTGGTAAAGCTGCTGAATTCTGAGGTGCTCAAGTATCTGCTGCA
TTGGCTGGATTGACTGCTGAACAAGTTGCTGCCTCAGTTATCGCTTATGAGCCAATCTGGGCTATCGGTACTGGTA
AATCAGCTTACAAAGACGATGCACAAAAATGTGTAAGTTGTTGCTGACGTTGTAGCTGCTGACTTTGGTCAAG
AAGTCGACAGCAAAAGTTCTGTTCAATACGGTGGTTCTGTTAAACCTGAAAAATGTTGCTTCATACATGGCTTGCCC
-50 AGACGTTGACGGTGCCCTTGTAGGTGGTGCCTCACTGAAGCTGAAAGCTTCTTGGCTTGTGCTTGTGAAAA
TAA

55 MSRKPIAGNWKMNKNPEEAKAFVEAVASKLPSSDLVEAGIAAPALDLTTVLAVAKGSLKVAQAQNCYFENAGFTG
ETSPQVLKEIGDYVIGHSERRDYFHETDEINKKAKAIFANGMLPIICCGESLETYEAGKAAEFVGAQVSAALAGLTA
EQVAASVIAYEPIWAIPTGKSASQDDAQKMKVVRDVVAADFGQEVADKVRVQYGGSVKPNVASYMACPDVDGAL
VGGASLEAESFLALLDFVKZ

ID51 1473bp

60 TTGAAAAACAAAATTGGATTAGCAAGTATCTGTTTACTAGGCTTGGCAACTAGTCATGTCGCTGCAAAATGAACTG
AAGTAGCAAAAACCTTCGACAGGATACAACGACAGCTTCAAGTAGTTCAGAGCAAAATCAGTCTTCTAATAAAACGC
AAACGAGCGCAGAAGTACAGACTAATGCTGCTGCCCACTGGGATGGGGATTATTATGTAAGGATGATGGTTCTA
AAGCTCAAGTGAAATGGATTTTGAACAACTACTATAAGGCTTGGTTTTATATTAATTACAGATGGTCTACTCGCA
65 GAATGAATGGCATGGAATTAACCTGAAATCAGGTGGATATATGGCCCAAAACGAGTGGATCTATGACAGTAA
TTACAAGAGTTGTTTTATCTCAAGTCAGATGGGGCTTATGCTCATCAAGAAATGGCAATTGATTGAAAAAATGTTG

TACTACTTCAAGAAGTGGGGTTACATGGCTAAAAGCCAATGGCAAGGAAGTTATTTCTTGAATGGTCAAGGAGCT
ATGATGCAAAATGAATGGCTCTATGATCCAGCCTATTCTGCTTATTTTTATCTAAAATCCGATGGAACCTATGCTA
ACCAAGAGTGGCAAAAAGTGGGCGGCAAAATGGTACTATTTCAAGAAGTGGGGCTATATGGCTCGGAATGAGTGGC
AAGGCAACTACTATTTGACTGGAAGTGGTGGCCATGGCGACTGACGAAGTGATTATGGATGGTACTCGCTATATCTT
5 TGGCGCCTCTGGTGAGCTCAAAGAAAAAAGATTGAATGTCGGCTGGGTTACAGAGATGGTAAGCGCTATTT
CTTTAATAATAGAGAAGAACAGTGGGAACCGAACATGCTAAGAAAGTCATTGATATTAGTGAGCACAATGGTCG
TATCAATTGGTGAAGGTTATTGATGAGAAGCAAGTGGTGGTTCATTGTTCTAGTTATAGCGGTAA
AGAAGACAAGGAATTGGCGCATAACATTAAGGAGTTAAACCGTCTGGGAATTCCTTATGGTGTCTATCTCTATAC
10 CTATGTGAAAAATGAGACCGTGGTGGAGAGTGACGCTAAACAGACCATTGAACCTATAAAGAAATACAATATGAAC
CTGTCTTACCCTATCTATTATGATGTTGAGAATTGGGAATATGTAATAAGAGCAAGAGAGCTCCAAGTGATACA
GGCACTTGGGTTAAAAATCATCAACAAGTACATGGACACGATGAAGCAGGCGGGTTACAAAATGTGTATGTCTAT
AGCTATCGTAGTTTATTACAGACGCTTAAAAACCCAGATATTTTAAACATGTAACTGGGTAGCGGCCTATA
CGAATGCTTTAGAATGGGAAACCTCATTATTCAGGAAAAAAGGTTGGCAATATACCTCTTCTGAATACATGA
15 AAGGAATCCAAGGCGCGTAGATGTCAGCGTTTGGTATTAA

MKTKIGLASICLLGLATSHVAANETEVAKTSQDTTASSSEQNQSSNKTQTSAEVQTNAAAHWDGDYVYKDDGSKAQ
SEWIFDNYKAWFYINSDGRYSQNEWHGNYLKSQGYMAQNEWIYDSNYKSWFYLKSDGAYAHQEWQLIGNKWYY
FKKWGYMAKSQWQGSYFLNGOGAMMQNEWLYDPAYSAFYLKSDGTANQEWQKVGKWWYFKKWGYMARNE
20 WQGNYYLTGSGAMATDEVIMDGTRYIFAASGELKEKKDLNVGVVHRDGRYFFNNREEQVGEHAKKVIDISEHNG
RINDWKVIDENEVDGVVRLGYSGKEDKELAHNIKELNRLGIPYGVLYTYAENETDAESDAKQTELKKNYNNLSY
PIYDVENWEYVYNSKRAPSDGTWVKIINKYMDTMKQAGYQNVVYYSRLLQTRLKHPDILKHVNVWAAVTNAL
EWENPHYSKKGWQYTSSEYMKGIQGRVDVSVWYZ

ID52 774bp

ATGAAAAAATTTGCCAACCTTATCTGGGACTGGTCTTCTGGTCTCTACCTGCCTATCTTTTACTTGATTGGCTA
TGCCTTTAATGCTGGTGATGATATGAATAGCTTTACAGGTTTTAGCTGGACTCAGTTTGAAACCATGTTTGGAGAT
GGGAGACTCATGCTGATTTTGGCTCAGACATTTTCTGGCCTTCTATCAGCCTTGATAGCGACCATTATCGGGA
30 CTTTGGTGCCATTACATCTACCACTCTCGTAAGAAATACCAAGAGCCCTTCTATCACTCAATAATATCCTCAT
GGTTGGCGCTGACGTTATGATTGGTGCTAGCTTCTGATTCTCTTACCCAACCTCAAGTTTTCACTTGGCTTTTGA
CCGTTCTATCTAGTCAGTGGCCTTCTCCATTCTATCGTGGTCTTGATGGTCTTGCTCGACTCAAGGAAATGAA
TGGCGACATGATTCTATGCGGCTATGACTTGGGAGCTAGTCAATTCAGATGTTCAAGGAAATCATGCTTCTTAC
CTGACTCCGTCTATCATTACTGGTTATTTATGGCCTTACCTATTCGTTAGATGACTTTGCCGTGACCTTCTTTGT
35 AACAGGAAATGGCTTTTCAACCTATCAGTCGAGATTTACTCTCGTCTCGCAAGGGGATTTCCTTAGAAATCAAT
GCCCTGTCTGCTAGTCTTCTCTTATGATTATCTAGTTGTAGGTTATTACTTTATCTCTCGTGAGAAGGAGGA
GCAAGCATGA

MKKFANLYLGLVFLVLYLPIFYLIGYAFNAGDDMNSFTGFSWTHFETMFGDGRMLMLLAQTFFLAFLSALIATITGFGA
IYIYQSRKKYQEAFLSLNNILMVAPDVMIGASFLILFTQLKFLSLGFLTVLSSHVAFSIPVVLMLVPLRKEMNGDMIHAA
40 YDLGASQFQMFKEIMLPYLTPTSITGYFMAFTYSLDDFAVTFVTGNGFSTLSVEIYSRARKGISLEINALSALVFLFSIILVV
GYFISREKEEQAZ

ID59 1071bp

ATGAAAAAATCTATTCATTTTATAGCAGGAATTGCAGCGATTATCCTTGTCTTGTGGGAATTGCGACTCATTAG
ATAGTAAAAATCAATAGTCGAGATAGTCAAAAATTTGGTTATCTATAACTGGGGAGACTATATCGATCCTGAACTCTT
GACTCAGTTTACAGAAGAAACAGGAATCAAGTTCAGTACGAGACTTTTACTCCAACGAAGCCATGTACACTAA
GATAAAGCAGGGTGGAACGACCTACGATATTGCCATTCCAAGTGAATACATGATTAACAAGATGAAGGACGAAG
50 ACCTCTTGGTCCGCTTGATTATTCAAAAATGAAGGAATCGAAAATATCGGACCAGAGTTTCTCAACCACTCCTT
TGACCCAGGTAATAAATTCTCCATCCCTTACTTCTGGGAAACCTTAGGAATTGTCTACAACGAAACCATGGTAGAT
GAAGCGCTGAGCATTGGGATGACCTTTGGAAGCCGAGTATAAGAATTCTATCATGCTCTTTGATGGGGCGCGT
GAGGTGCTGGGACTAGGACTCAATCCCTCGGCTACAGCCTCAACTCCAAGGATCTGCAGCAGTTGGAAGAGACA
GTGGATAAGCTCTACAACTGACTCCAATATCAAGGCTATCGTTGCGGACGAGATGAAGGGCTATATGATTTCAG
AATAATGTTGCAATCGGCGTACCTTCTCTGGTGAAGCCAGCCAAATGTTAGAAAAAATGAAAAATCTACGTTAT
55 GTGGTACCGACAGAGGCCAGCAATCTTTGGTTTGAATATGGTCAATCCCAAAACAGTAAAAAACCAAACTCA
GCCTATGCCTTTTCAACCTTATGTTGAAACCTGAAAAATGCTCTCAAAATGCGGAGTATGTCGGCTATTCAACAC
CAAACCTACCAGCGAAGGAATTGCTCCAGAGGAAACAAAGGAAGATAAGGCCTTCTATCCCGATGTTGAAACCA
TGAAACACCTAGAAGTTTATGAGAAATTTGACCATAAATGGACAGGGAATATAGCGACCTCTTCTACAGTTTA
60 AAATGTATCGGAAGTAG

MKKIYSFLAGIAAJILVLWGIATHLDSKINSRDSQKLVIYNWGDYIDPELLTQFTEETGIQVQYETFDSDNEAMYTKIKQGG
TTYDIAIPSEYMINKMKDEDLLVPLDYSKIEGIEINIGPEFLNQSFDPGNKFSIPYFWGTLGIVYNETMVDPEHWDLLW
KPEYKNSIMLFDGAREVLGLGLNSLGYSLNSKDLQLEETVDKLYKLTPNIKAIVADEMKGYMIQNNVIAIGVTFSGEAS
65 QMLEKNENLRYVVPTEASNLWFDNMVIPKTVKNQNSAYAFINFLKPENALQNAEYVGYSTPNLPAKELLPEETKED
KAFYDPVETMKHLEVYEFKDHKWTGKYSDFLQFKMYRKZ

ID61 1851bp

5 ATGAATAAAAACTAACAGATTATGTGATTGATCTGGTGGAAATTTTAAATAAACAAACAAAGCAGGTTTTCTGG
 GGAATATTTGATATTTTCAGTATGGTGGTTTCCATCATTGTATCTTATATTTTATTTATGGGCTGATTAATCCAGC
 ACCTGTTGACTACATTATCTATACGAGTTTGGCCTTCCTGTTCTATCAATTGATGATTGGTTTTTGGGGGTGAACG
 CGAGCATTAGTCGTTACAGCAAGATTACGGATTTCATGAAAACTTTTTTGGTGTGACTGCTAGCAGTGTCTTGTG
 ATATAGTATCTGTTATGCCTTCTTGCCACTCTTCTCCATCCGTTTCATCAITCTCTTTATCTTGTGAGTACCTTCTT
 10 GATTTTATTGCCACGGATTACTTGGCAGTTAATCTACTCCAGACGCAAAAAAGGTAGTGGTGTGGAGAACCCG
 TCGGACCTTCTTGATTGGTGCCGGTGTGGTGGGGCTCTTTTATGGATAAGTTACCAACATCCAACAGTGAATTA
 GAACGTGGTCGGTATTTTGGATAAGGATTCTAAGAAAAAGGGTCAAAAACTTGGTGGTATTCTCTGTTTTGGGCTCTT
 ATGACAATCTGCCTGAATTAGCCAAACGCCATCAAATCGAGCGTGTATCGTTGCGATTCCGTCGCTGGATCCGTC
 AGAATATGAGCGTATCTTGAGATGTGTAATAAGCTGGGTGTCAAATGTTACAAGATGCCTAAGGTTGAAACTGT
 15 TGTTACGGCTTACCAAGCAGGTAAGCTTCCAAAAAATTGATATTACGGACCTTTTGGGTGCTCAGGAAATC
 CGTCTTGACGAATCGCGTCTGGGTGCAGAACTGACAGGTAAAGCCATCTTAGTCACAGGAGCTGGAGGTTCAATC
 GGTTCGAAATCTGTCGTCAAGTTAGTCGCTTCAATCCTGAACGCATTGTCTGCTCGGTATGGGAAAACTCAA
 TCTACCTTGTATCATGAATTGATTCTGAAGTTCCAAGGATTGATTATGTACTGTGATTGCGGACATTCAGA
 CTATGATCGTTTGTGCAAGTCTTTGAGCAGTACAAACCTGCTATTGTTTATCATGCGGCAGCCCAAGCATGTT
 20 CCTATGATGGAGCGCAATCCAAAAAGAGCCTTCAAAAAAATATCCGTGGAACCTTCAATGTTGCTAAGGCTGTT
 GATGAAGCTAAAGTGTCTAAGATGGTTATGATTTGCAGAGATAAGGCAGTCAATCCACCAAAATGTTATGGGAGCA
 ACCAAGCGCGTGGCGGATTGATTGCTACTGGCTTAAACCAACGTAGCCAATCAACCTACTGTGCAGTTCGTTTTG
 GGAATGTTCTTGGTAGCCGTGGTATGTCATTCCAGTCTTTGAACGTGAGATTGCTGAAGGTGGGCTGTAACCGT
 GACAGACTTCCGTATGACCCGTACTTTATGACCATTCCAGAAGCTAGCCGTCTGGTTATCCATGCTGGTGCTTAT
 25 GCCAAAGATGGGGAAGTCTTTATCCTTGATATGGGCAAAACAGTCAAGATTTATGACTTGGCCAAGAAGATGGTG
 CTTCTAAGTGGCCACACTGAAAGTGAAATTCGAATCGTTGAAGTTGGAATCCGCCAGGTGAAAACTCTACGAA
 GAACTCTTGGTATCAACCGAACTCGTTGATAATCAAGTTATGGATAAGATTTTCTTGGTAAGGTTAATGTCATGC
 CTTTGAATCCATCAATCAAAGATTGGAGAGTTCGCCACTCTCAGTGGAGATGAGTTGAAGCAAGCTATTATCG
 CCTTGTCTAATCAAACAACCCACATTGAATAA

30 MNKCLTDYVIDLVEILNKQKQVFWGIFDIFSMVSVIIVSYLYGLINPAPVDYIITYSLAFLFYQLMIGFWGLNASISRY
 SKITDFMKIFFGVTAASSVLSYSICYAFLPLFSIRFIILLSTFLILLPRITWQLIYSRRKKGSGDGEHRRFTFLIGAGDGGALF
 MDSYQHPTSELELVGILDKDSKKKGQKLGIPVLGSYDNLPELAKRHQIERVIVAPSLDPSEYERILQMCNKLGVKCYK
 MPKVETVVQGLHQAGTFQKIDITDLLGRQIEIRLDESRLGAELTGKILVTGAGGSIGSEICRQVSFRNPERIVLLOHGEN
 35 SIYLVYHELIRKFQGDYYPVVIADIQDYDRLLQVFEQYKPAIVYHAAAHKHVPMERNPKAEAFKNINRGTYNVAKAVID
 EAKVSKMVMISTDKAVNPPNVMGATKRVAEIIVTFNQSRQSTYCAVRFGNVLSRGSVIPVERQIAEGGPVTVDFR
 MTRYFMTIPEASRLVIHAGAYAKDGEVFILDMGPKPKIYDLAKKMVLLSGHTESEIPIVEVGIRPGEKLYEELLVSTELV
 DNQVMDKIFVGKVNVMPLSINQKIGEFRTLSGDELKQAIHAFANQTHIEZ

ID101 1338bp

40 ATGATTGAACCTTTATGATAGTTACAGTCAAGAAAGTCGAGATTTACATGAAAGTCTAGTCGCTACTGGTCTTTCTC
 AACTTGGAGTGGTCATCGATGCAGATGGTTTTCTGCCTGATGGTCTGCTTTCTCCTTTTACCTATTATCTAGGTTAC
 GAGGATGGAAAACTCTCTATTTTAAATCAAGTTCCTGTTTTCAGATTTTTGGGAAATTTTAGGAGATAATCAGCTCG
 CTTGTATTGAAGATGTGACGCAGGAGAGGGCTGTCTTTCATTATGCTGATGGAATGCAGGCTCGCTTGGTTAAACA
 45 GGTAGACTGGAAAGACCTAGAAAGGTCGAGTACGTCAGGTTGACCACTACAATCGCTTCGGAGCTTGTGTTGTAC
 AACGACTTATAGCGCAGATAGCGAGCCGATTATGACAGTTTACCAAGATGTCAATGGTCAACAAGTTTACTGGA
 AAACCATGTGACGGGTGATATCTTATTGACTTTGCCAGGTCAGTCCATGCGTTACTTTGCAAAATAAGTTGAATTT
 ATCACCTTCTTTTGCAAGATTTGGAAATAGATACCAGTCAGCTTATCTTAACTACTAGCGACTCTTTCTTGGT
 50 TTCTTCCATCATCCAGATAAATCTGGCTCGGATGCTTGGTATGGCAGGAACCTCTCTATGATGCCATTCCAGGT
 AATATGCAGTTGATTTTGGAAAGTGATAATGTGCGTACTAAGAAGATCATCTTCCAAATAAGGCGACTTATGAG
 CGCGCTTTAGAGTTAACTGACGAGAAATACCATGATCAGTTTGTGCACTTGGGTTATCATTACCAGTTCAAACGTG
 ATAATTTCTAAGACGAGATGCCTTAACTTTGACCAATTCAGATCAGATTGAGCAAGTAGAAGCAATCGCAGGAG
 CCTTGCCTGATGTCACTTTCCGTATTGACGCGGTGACAGAGATGTCTTAAAGCTCTTAGACATGCTTTGCTATCCT
 55 AATGTGGCCCTTTACCAGAACGCTAGTCCACAGAAGATTGAGGAGCTGTATCAACTGTGGATATTTACTTGGATA
 TAAACCACAGTAATGAGTTGCTACAGGCAGTGCCTGACGGCCTTTGAGCACAATCTCTTGATTCTTGGCTTAAATCA
 GACGGTGCACAATAGACTTTATATCGCTCCAGACCATCTATTGAAAGTAGTGAAGTTGCTGCTTTGGTTGAGACC
 ATTAATTTGGCCCTTTTTCAGATGTTGATCAATGCGTCAGGCACTTGGCAACAAGGCCAACATGCAAAATTATGTTG
 ACTTGGTGAGATATCAGGAAACCATGCAAACTGTTTTAGGAGGCTAA

60 MIELYDSYSQESRDLHESLVATGLSQLGVVIDADGFLPDGLLSPFTYYLYGYEDGKPLYFNQVPVSDFWELGDNQSACIE
 DVTQERAVIHYADGMQARLVKQVDWKDLEGRVRQVDHYNRFGACFATTTYSADSEPIMTVYQDVNGQVYLLNHHV
 TGDILLTLPGQSMRYFANKVEFITFLQDLEIDTSQILFNLTATPFLVSFHHPKSGSDVLVWQEPYDAIPGNMQLILES
 65 DNVRTKIIPNKATYERALELTDEKYHDQFVHLGYHYQFKRDNFLRRDALILTNSDQIEQVEALAGALPDVTFRIAAYT
 EMSSKLLDMLCYPNVALYQNASPQKIQLYQLSDIYLDINHNSNELLQAVRQAFEHNLILGFNQTVHNRLYIAPDHLFE
 SSEVAALVETIKLALSDVDQMRQALGKQGQHANYVDLVRYQETMQTVLGGZ

ID102 1512bp

5 ATGACAATTTACAATATAAATTTAGGAATTGGTTGGGCTAGTAGCGGTGTTGAATACGCTCAAGCCTATCGTGCTG
GTGTTTTTCGGAAATTAATCTGTCTCTAAGTTTATCTTTACAGATATGATTTTAGCCGATAATATTCAGCACTTA
ACAGCCAATATTGGTTTTGATGATAATCAGGTTATCTGGCTTTATAATCATTTACAGATATCAAAATTCACCTTA
CTAGCGTGACAGTGGATGATGCTCTGGCTTACTTTGGTGGTGAAGAAAGTCACAGAGAAAAAATGGCAAGGTTT
TACGTGATTTCTTTTTGACCAAGATAAGTTTGTAACCTGTTATTTGGTTGATGAGAACAAAGGACTTGGTTCAACA
10 TGCCGAGTATGTTTTAAGGGAACCTGATTGCGAAGGATTACTTTCTTATACGCGTTATTGTAGCGAGTATTTT
GCTCCCAAGGACAATGTTGCAGTCTTATACCAACGAACTTTTATAATGAAGACGGGACTCCAGTCTATGATATCT
TGATGAATCAAGGGAAGGAAGAAGTTTATCATTTCAAGGATAAGATTTTCTATGGAAGCAAGCTTTTGTGCGTG
CCTTTATGAAATCTTTGAATTTGAATAAGTCTGATTTGGTCATTCTCGATAGGGAGACAGGTATTGGACAGGTTGT
GTTTGAGGAAGCACAGACAGCACATCTAGCGGTAGTTGTTTCATGCGGAGCATTATAGTGAAATGCTACAAATGA
15 GGACTATATCCTTTGGAATAACTATTATGACTATCAGTTTACCAATGCAGATAAGGTTGACTTCTTTATCGTGTCT
ACTGATAGACAAAATGAAGTTCTACAAGAGCAATTTGCCAAATATACTCAGCATCAGCCAAAGATTGTTACCATT
CCTGTAGGCAGTATTGATTCCTTGACAGATTCAAGTCAAGGGCGCAAAACCTTTTATTGATTACGGCTTCACGTC
TTGCCAAAGAAAAGCACATTGATTGGCTTGGAAGCTGTGATTGAAGCTCATAAGGAGTTACCGGAACTAACCT
TTGATATCTATGGTAGTGGTGGAGAAGATTCTGCTTAGAGAAATTTTGCAAAATCATCAGGCAGGACTATAT
20 CCAACTCAAGGGGCATGCGGAACCTTTCGAGATTATAGCCAGTATGAGGTCTACTTAACGGCTTCTACCAGCGA
AGGATTTGGTCTGACCTTGATGGAAGCTATTGGTTTCAGGTTACCTCTAATTGGTTTTGATGTGCTTATGGTAATC
AGACCTTTATAGAGGATGGGCAAAATGGTTATTGATTCCAAGTTTCATCTGACCATGTAGAAAGACCAATCAAGC
AAGCTTATGCCGCTAAGATTGTCAATTGTATCAAGAAAATCGTTTGAAGCTATGCGTGCTCTATTCTTACCAAT
TGCAGAAGGCTTCTTGACCAAGAAAATTTAGAAAAGTGAAGAAAACAGTAGAGGAGGTGCTCCATGATTGA

25 MTIYNINLIGIWASSGVEYAQAYRAGVFRKLNLSKFIFDMLADNIQHLTANIGFDDNQVIWLYNHFTDKIAPTSVT
VDDVLA YFGGEESHREKNGKVL RVFFDQDKFVTCYLVDENKDLVQHA EYVFKGNLRKDYFSYTRYCSEYFAPKDN
VAVLYQRTFY NEDGTPVYDILMNQKKEEVYHFKDKIFYGKQAFVRAF MKSLNLNKS DVLDR ETGIGQVVFEEAQTA
HLAVV VHA EHYSENATNEDYILWNNYDYQFTNADKVDF FVSTDRQNEVLQEQFAKYTQHQP KIVTPVGSIDSLTDS
30 SQGRKPFSLITASRLAKEKHIDWL VKAVIEAHKELPELTFDIYSGGEDSLREIHANHQAEDYIQLKGHAELS QIYSQYE
VYLTASTSEGFLTLMEAGSGLPLIGFDPVYGNQTFIEDGQNGYLPSSSDHVEDQIKQAYAAKICQLYQENRLEAMRA
YSYQLAEGFLTKEILEKWKTVEEVLHDZ

35

ID103 2292bp

40 ATGTCCTCTCTTTCCGGATCAAGAATTAGTAGCTAAAACAGTAGAGTTTCGTCAGCGTCTTTCCGAGGGAGAAAAGTC
TAGACGATATTTTGGTTGAAGCTTTTGCTGTGGTGCCTGAAGCAGATAAGCGGATTTTAGGGATGTTTCTTATGA
TGTTCAAGTCATGGGAGCTATTGTCATGCACTATGGAATGTTGCTGAGATGAATACGGGGGAAGGTAAGACCTT
GACAGCTACCATGCCTGTCTATTTGAACGCTTTTTCAGGAGAAGGAGTGATGGTTGTGACTCTAATGAGTATTTA
TCAAAGCGTGATGCCGAGGAAATGGGTCAAGTTTATCGTTTTCTAGGATTGACCATTGGTGTACCATTTACGGAAG
45 ATCCAAAGAGGAGATGAAAGCTGAAGAAAAGAAAGCTTATCTATGCTTCGGATATCATCTACACAACCAATAGTA
ATTTAGGTTTTGATTATCTAAATGATAACCTAGCCTCGAATGAAGAAGGTAAGTTTTTACGACCGTTTAACTATGT
GATTATTGATGAAATTGATGATATCTTGCTTGATAGTGACAAAACCTCTGATTATTGCGGGTTCTCCTCGTGTTT
AGTCTAATTACTATGCGATCATTGATACACTTGTAAACAACCTTGGTGAAGGAGAGGATTATATCTTTAAAGAGGA
GAAAGAGGAGGTTTGGCTCACTACTAAGGGGGCAAGTCTGCTGAGAATTTCTAGGGATTGATAATTTATACAA
50 GGAAGAGCATGCGTCTTTGCTCGTCAATTTGGTTTATGCGATTGAGCTCATAAGCTCTTTACTAAAGATAAAGGAC
TATATCATTCGTGGAATGAGATGGTACTGGTTGATAAGGGAACAGGGCGTCTAATGGAATGACTAACTTCAA
GGAGGTCTCCATCAGGCTATTGAAGCCAAGGAACATGTCAAATTTCTCTGAGACGCGGGCTATGGCCTCGATC
ACCTATCAGAGTCTTTTAAAGATGTTTAAAGATATCTGGTATGACAGGGACAGGTAAGGTCGCGGAAAAAGAG
TTTATTGAAACTTACAATATGTCTGTAGTACGCATTCCAACCAATCGTCCGAGACAACGGATTGACTATCCAGATA
55 ATCTATATATCACTTTACCTGAAAAAGTGTATGCATCCTTGAAGTACATCAAGCAATACCATGCTAAGGGAAATCC
TTTACTCGTTTTGTAGGCTCAGTTGAAATGTCTCAACTCTATTCTGCTCTCTTGTTCGTGAAGGGATTGCCATA
ATGTCCTAAATGCTAATAATGCGGCGCGTGAGGCTCAGATTATCTCCGAGTCAGGTGAGATGGGGGCTGTGACAG
TGGCTACCTCTATGGCAGGACGTGGTACGGATATCAAGCTTGGTAAAGGAGTCGACAGGCTTGGGGGCTTGATTG
TTATTGGGACTGAGCGGATGGAAGTCAGCGGATCGACCTACAAATTCGTGGCCGTTCTGGTCTGACGGGAGATC
60 CTGGTATGAGTAAATTTTTGTATCCTTAGAGGATGATGTTTCAAGAAAATTTGGTCCATCTTGGGTGCATAAAAA
GTACAAAGACTATCAGGTTCAAGATATGACTCAACCGGAAGTATTGAAAGGTCGTAATACCGGAACTAGTCGA
AAAGGCTCAGCATGCCAGTGATAGTCTGGAAGTTTCAGCAGCTCGTCAGACTCTGGAGTATGCTGAAAGTATGAA
TATACAAAGGATATAGTCTATAAAGAGAGAAATCGTCTAATAGATGGTTCTCGTGACTTAGAGGATGTTGTTGTG
GATATCATTTAGAGATATACAGAAAGGAGTACGGGTGATCCTATGCTAGTCGTGAATTTGTTTCACTTTATTG
65 TGACCAATATTAGTTTTCATGTTAAAGAGGTTCCAGATTATATAGATGTAAGTACGACAAAACCTGCAAGTTCGTAGCTT
TATGAAGCAGGTGATTGATAAAGAACTTTCTGAAAAGAAAGAAATTAATCAACATGACTTATATGAACAGTT

10

15

20

25

35

40

45

50

55

60

65

GLQAGFVQGDVVRPQMLKESDVVISDLVPGYYPDDAVASRHQVASSQEHTYAHLLMEQGLKYLKSDGYAIFLAPSD
LLTSPQSDLLKEWLKEEASLVAMISLPENLFANAKQSKTIFILQKKNEIAVEPFVYPLASLQDASVLMKFENFQKWTQ
TEIZ

5 ID110 1902bp

ATGATTATTTTACAAGCTAATAAAATTGAACGTTCTTTTGCAGGAGAGGTTCTTTTCGATAATATCAACCTGCAGG
TTGATGAACGAGATCGGATTGCTCTTGTGGGAAAAATGGTGCAGGTAAGTCTACTCTTTTGAAGATTTTAGTTGG
AGAAGAGGAGCCAACTAGCGGAGAAATCAATAAGAAAAAGATATTTCTCTGTCTTACCTAGCCCAAGATAGCCG
10 TTTTGAGTCTGAAAAATACCCTACGATGAAATGCTTCATGTCTTTAATGATTTGCGTGGACGGAGAGACAACTG
CGTCAGATGGAGCTGGAGATGGGTGAAAAAGTCTGGTGAGGATTTGGATAAACTGATGTCAGATTATGACCGCTTA
TCTGAGAAATTTTCGCCAAGCAGGTGGCTTTACCTATGAAGCTGATATTCGAGCGATTTTGAATGGATTCAAGTTTG
ACGAGTCTATGTGGCAGATGAAAAATTGCTGAGCTTTCTGGTGGTCAAAATACTCGTTTGGCACTTGCCAAAAATGCT
15 CCTTGAAAAAGCCCAATCTCTTGGTCTTGGACGAGCCAACTAACCACTTGGATATTGAAACCACTCGCTGGCTAGA
GAATTACTTGGTAACTATAGCGGTGCCCTCATTATCGTCAGCCACGACCGTTATTTCTTGGACAAGGTTGCGACA
ATTACGCTAGATTGACCAAGCATTCCTTGGATCGCTATGTGGGGAATTAATCTCGTTTGTGCAATTGAAGGAGC
AAAAGCTAGTTACTGAGGCAAAAACTATGAAAAGCAACAGAAAGAAATCGCTGCTCTGGAAGACTTTGTCAATC
GCAATCTAGTTCTGCTTCAACGACTAAACGCTGCTCAATCTCGCCGTAAACCACTAGAAAAATGGAGCGTTTGG
20 ACAAGCCTGAAGCTGGCAAGAAAGCAGCCAACTGACCTTCCAGTCTGAAAAACGTCGGGCAATGTTGTTTGA
CTGTTGAAAAATGCAGCTGTTGGCTATGACGGGGAAGTCTTGTCAACCTATCAACCTAGATCTTCGTAAGATGAA
TGCTGTGCTATCGTTGGTCCAAATGGTATCGGCAAGTCAACCTTTTCAAGTCTATTGGGACCGAGATTCCTTTT
ATCAAGGGAGAAAAAGCGCTTGGCGCTAATGTTGAGGTTGGTTACTATGACCAAAACCAAGCAAGCTGACACCA
AGTAATACGGTGCTGGATGAACCTGGAATGATTTCAACTGACACCAGAAGTTGAAATCCGCAACCGTCTTGGG
GCCTTCTCTTTTCTCAGGAGATGATGTTAAAAATCAGTCGGCATGCTATCTGGTGGCGAAAAAGCTCGTTTGCTTT
25 TAGCTAAATTGTCTATGGAACCAATAACTTTTGTATTCTGGATGAGCCGACCAACCACTTGGATATTGATAGTAA
GGAAGTGCTAGAAAAATGCCTTGATTGACTTTGATGGAACCTTGTCTGTTGTGAGTCATGATCGTTACTTTATCAAT
CGTGTGGCAACTCATGTTTGGAAATGTCTGAGAATGGTTCAACTCTTACCTTGGAGATTACGACTACTATGTTG
AGAAGAAAGCAACAGCAGAAATGAGTCAGACTGAGGAAGCTTCAACTAGCAATCAAGCAAGGAAGCAAGTCCA
GTCAATGACTATCAGGCCAGAAAGAAAGTCAAAAAAGAGTTCGCAAACTCATGCGACAAATCGAAAGTCTAGA
30 AGCTGAAATTGAAGAGCTAGAAAGTCAAGGCCAAGCCATTCTGAACAAATGTTGGAACCAACGATGCCGACA
AACTCATGGAATTACAGGCTGAGCTGGACAAATCAGCCATCGTCAGGAAGAAGCTATGCTTGAGTGGGAAGAAT
TATCAGAGCAGGTGTAA

MIILQANKIERSFAGEVLFNDINLQVDERDRIALVGKNGAGKSTLLKILVGEEPTSGEINKKKDISLSYLAQDSRFESENT
35 IYDEMLHVFNDLRRTERQLRQMELEMGESGEDLDKLMSDYDRLSENFRQAGGFTYEADIRAILNGFKFDESMWQMK
IAELSGGQNTRLALAKMLLEKPNLLVLEPTNHLDIETIAWLENYLVNYSALIIVSHDRYFLDKVATITLDTLKHSLDR
YVGNYSRFVELKEQKLVTEAKNYEKQKEIAALEDVFNRLVRASTTKRAQSRKQLEKMERLDPKPEAGKKAANMTF
40 QSEKTSGNVVLTVENAAVGYDGEVLSPINLDRKMNVAIVGPNIGKSTFKISVDQIPFIKGEKRFGANVEVGYDQ
TQSKLTPSNTVLDELWDFKLTPVEIRNRLGAFLSFGDDVKKSVGMLSGGEKARLLAKLSMENNFLILDEPTNHL
DIDSKEVLNALIDFDGTLFVSHDRYFINRVATHVLESENGSTLYLGDYDYVEKKATAEMSQTTEASTSNQAKEAS
PVNDYQAQKESQKEVRKLMRQIESLEAEIELESQSQAISEQMLETNDADKLMELQAEIDKISHRQEEAMLEWEEELSEQ
VZ

45 ID111 1179bp

ATGAATCGCTATGCAGTGCAGTTGATTAGCCGTGGGGCTATCAATAAAATGGGAAATATGCTCTATGATTATGGA
AATAGTGTCTGGTTGGCTTCTATGGGGACTATAGGACAGACAGTTTTAGGAATGTATCAGATTCTGAGCTCGTCA
CATCTATTCTCGTCAATCCCTTTGGCGGAGTTATTTAGACCGTTTTTCTCGTCGTAAGATTTAATGACGGCAGAT
50 CTGTTTGTGGGATTCTTTGTCTGGCTATTTCTTTCATAAGGAATGATAGCTGGATGATTGGCGCTTTGATTGTTGC
TAACATTGTGCAAGGCTATTGCTTTTGCCTTTTCTCGCACAGCCAATAAAGCTATCATAACTGAAGTGGTGGAGAAA
GATGAGATTGTGATCTATAATCTCGCTTAGAGCTGGTTTGCAGGTTGTAGGTGTTAGCTCTCCTGTTCTTCTCTT
CCTTGTTTTACAGTTTGCAAGTCTCCATATGACGCTACTGCTAGACTCGCTGACTTTTTTCATTGCTTTTGTCTAG
TGGCTTCTCTTCCAAAAGAGGAAGCAAAAGTTCAAGAGAAAAAGGCTTTTACTGGGAGAGATATTTTGTAGATA
TCAAGGATGGGTTACACTATATCTGGCATCAGCAAGAAATTTTCTTCTTTTGTGCTGCTAGCTTCCAGCGTTAATTT
55 CTTTTTGCAGCTTTTGAATTTCTACTTCCCTTTTCAATCAGCTTTACGGGTCAGAAAGGAGCCTATGCAAGTATTT
TAACTATGGGGGCTATTGGTTCCATCATTTGGGGCTCTTCTAGCTAGTAAAAATTAAGCTAATATTTATAATCTTTT
GATTTTACTGGCTTTGACAGGTGTCGGAGTTTTATGATGGGATTACCACTTCCAACCTTTCTTTCTTTCTGGA
ATTTAGTTTGTGAATTGTTATGACGATTTTAAATATTCATTTTACTCAAGTACAAACCAAGGTTGAGAGCGAA
60 TTTCTTGGAAAGAGTACTGAGTACAAATTTTACCTAGCTATTCTATTATGCCTATTGCAAAAGGATTATGACAGT
CTTGCCAAGTGTCCATCTTTATCTTTCTTGATTATTGGACTTGGAGTTGTAGCCTTATATTTCTTACTGCTCGGAT
ATGTTGCAACTCATTTGAAAAATTGATATAA

MNRYAVQLISRGAINKMGNMLYDYGNSVWLASMTIGQTVLGMVQISELVTSLVNPFGGVISDRFSRRKILMTADLV
65 CGILCLAISFIRNDSWMIGALIVANTVQALAFASRTANKAITVEVKEDEIVIYNSRLELVQVVGSSPVLVSLVLFQFASL
HMTLLDLSLTFIAFVLVAFLPKEAKVQEKKAFTGRDIFVDIKDLHYIWHQOEIFFLLLVASSVNFFFAAFEFLPFNS

QLYGSEGA YASILT MGAIGSIH GALLASKIKANIY NLLILLALTGVGVFMMGLPLPTFLSFSGNLVCELFMTIFNIHFFTQV
QTKVESEFLGRVLSTIFTLAILFMPLAKGFMTVLPVSHLYSFLIIGLVVALYFLALGYVRTHFEKLIZ

ID113 2466bp

5 ATGCAAAATCAATTAATGAATTAACGAAAAATGCTGGAATTTTCCAGCAAAAACAAAAAATAAAAAATCA
GCTAGACCTGGCAAGAAAGGTTCAAGTACCAAAAAATCTAAAAACCTTAGATAAGTCAGCCATTTTCCAGCTATT
TTACTGAGTATAAAAGCCTTATTTAACITACTCTTTGTAAGGAGGAATGTTGGGAGCTGGGATTG
10 CTTTGGGATACGGAGTGGCCTTATTTGACAAGGTTCCGGTGCCTCAGACAGAAGAAATGGTGAATCAGGTCAAGG
ACATCTCTTCTATTTTACAGAGATTACCTATTCGGACGGGACGGTGATTGCTTCCATAGAGAGTGATTGTTGCGCAC
TTCTATCTCATCTGAGCAAATTCGGAATCTGAAGAAGGCTATCATTGCGACAGAAGATGAACACTTTAAAGA
ACATAAGGGTGTAGTACCCAAGGCGGTGATTGCTGCGACCTTGGGAAAATTTGTAGGTTTGGGTTCTCTAGTGGG
15 GGTCAACCTTGACCCAGCAACTAATTAACAGCAGGTGGTTGGGGATGCGCCGACCTTGGCTCGTAAGGCGGCA
GAGATTGTGGATGCTCTTGCCTTGGAAACGCGCCATGAATAAAGATGAGATTTTAAACGACCTATCTCAATGTGGCTC
CCTTGGCGGAAAATAAAGGGACAGAATATTGCAAGGGCTCGGCAAGCAGCTGAGGGAATTTTGGTGTAGATG
CCAGTCAGTTGACTGTTCTCAAGCAGCAATTTTAGCAGGACTTCCACAGAGTCCCATTACTCTCTCTATGA
AAACTCTGGGAGTTGAAGAGTGATGAAGACCTAGAAAATTTGGCTTAAGACGGGCTAAGGCAGTTCTTACAGTAT
GTATCGTACAGGTGCATTAAAGCAAGACGAGTATTCTCAGTACAAGGATTATGACCTTAAACAGGACTTTTACC
20 ATCGGGCAGGTTACAGGAATTTACGAGACTATTTATACTTTACAACCTTGGCAGAAGCTCAAGAAGCTATGTAT
GACTATCTAGCTCAGAGAGACAATGTCTCCGCTAAGGAGTTGAAAAATGAGGCAACTCAGAAGTTTATCGAGAT
TTGGCAGCCAAGGAAATTTGAAAATGGTGGTTATAAGATTACTACTACCATAGATCAGAAAAATCTTCTGCCATG
CAAAGTGCGGTTGCTGATTATGGCTATCTTTAGACGATGGAACAGGTCGTGTAGAAGTAGGGAATGTCTTGATG
GATAACCAAACAGGTGCTATTTAGGCTTTGTAGGTGGTCGTAATTATCAAGAAAAATCAAAATAATCATGCCTTTG
25 ATACCAAACGTTCCGACGCTTCTACTACCAAGCCCTTGGCTACGGTATTGCTATTGACAGGGCTTGATGGG
AAGTGAACGATTCTATCTAATCTCAACAACTTTGCTAATGGCAATCCGATTATGTATGCTAATAGCAAGGG
AACAGGAATGATGACCTTGGGAGAAGCTCTGAATATTCTGGAATATCCCTGCTTACTGGACCTATCGTATGCTC
CGTGAAGGGTGTGATGTCAAGGGTTATATGGAAGATGGGTTACGAGATTCTGAGTACGGTATTGAGAGC
TTGCCAATGGGTGGTGGTATTGAAGTCACAGTTGCCAGCATACCAATGGCTATCAGACCTTAGCTAATAATGGA
30 GTTATCATCAGAACGATGTGATTCAAAGATTGAAGCAGCAGATGGTAGAGTGGTGTATGAGTATCAGGATAAA
CCGGTTCAAGTCTATTCAAAGCTACTGCGACGATTATGCAAGGATTGCTACGAGAAGTTCTATCTCTCGTGTGA
CAACAACCTTCAAGTCTAAGCTGACTTCTTTAAATCTACTCTGGCTAATGCAGATTGGGAGAGCTGGTAC
AACCAACCAAGACGAAAAATATGTGGCTCATGCTTTCGACACCTAGATTAAACCTAGGTGGCTGGATTGGGATGA
TGATAATCATTCTATTGTACGTAGAGCAGGTTATTCTAATACTCTAATTACATGGCTCATCTGGTAAATGCGATT
35 CAGCAAGCTTCCCAAGCATTGGGGGAACGAGCGCTTTGCTTTAGATCCTAGTGTAGTGAAATCGGAAGTCTTG
TAGGAAACAGGTCAAAAAACAGAGAAGGTTTCTGTTGAAGGAAAAGAGTAGAGGTACAGGTTCCGACTGTTACC
AGCTATTGGGCTAATAAGTCAGGAGCGCCAGCGACAAGTTATCGCTTTGCTATTGGCGGAAGTGATGCGGATTAT
CAGAATGCTTGGTCTAGTATTGTGGGGAGTCTACCAACTCCATCCAGCTCCAGCAGTTCAAGTAGTATTCTAGCG
ATAGCAGTAACCTCAAGTACTACACGACCTTCTTCTCAAGGGCGAGACGATAA

40 MQNQLNELKRKMLEFFQKQKNKKSARPKKGSSTKSKTLDKSAIFPAILLSIKALFNLLFVLGFLGGMLGAGIALGY
GVALFDKVRVPQTEELVNQVKDISSIEITYSDGTVIASIESDLLRTSISSEIQUENLKKAILATEDEHFKEHKGVVPKAVIR
ATLGKFVGLGSSSGSTLTQQLIKQVVGDAPTLARKAAEIVDALALERAMNKDEILTYLVNAPFGRNNKQGNIAGA
RQAAEGIFGVDA SQLTYPQAAFLAGLPSPITSPYENTGELKSDLEDLEIGLRRAKAVLYSMYRTGALSKEYSQYKDY
45 DLKQDFLPSGTVTGISRDYLYFTTLAEAQERMYDYLAQRDNVSAKELKNEATQKFYRDLAAKEENGKYKITTTIDQKI
HSAMQSAVADYGYLLDDGTGRVEVGNVMDNQTGAILGFVGGRNQYQENQNNHAFDTRSPASTTKPLLYAGLAIDQG
LMGSETILSNYPNPFANGNPIMYANSKGTGMMTLGEALNYSWNIPAYWYRMLREKGVDPVKGYMEKMGYIEPEYGIE
SLPMGGGIEVTVAQHTNGYQTLANNGVYHQHVISKIEAADGRVVEYQDKPVQVYSKATATIMQGLLREVLSSRVTT
TFKSNLTSLNPTLANADWIGKTGTTNQDENMWMMLSTPRLTLGGWIGHDDNHSLSRRAGYSNNSNYMAHLVNAIQQA
50 SPSIWGNERFALDPSVVKSEVLKSTGQKPEKVSVEGKEVEVTGSTVTSYWANKSGAPATSYRFAIGGSDADYQNAWSSI
VGS LPTPSSSSSSSSSSSSSSSSSSSTRPSSSRARRZ

ID114 1974bp

55 ATGAAAAAATTTTATGTAAGTCCAATTTTCTATTCTAGTAGGATTGATTGCGTTTGGAGTCTTATCCACTTTCAT
TATTTTGTATAATAATCTGTTGACGGTTTAAATTTGTTTCTTTTGTAGGAGGCTATGTTTTTATTTAAGAA
ACTGAGAGTGCAATTATACAAGGAGTGATGAGAACAGATACAGTATGTAAACCAACCAAGCGGAAGAAAGTTTGAC
AGCTCTATTGGAACAGATGCCTGTAGGTGTTATGAAATTGAATTTATCTTCTGGAGAGGTTGAGTGGTTAATCCC
TATGCTGAATGATTTTGACCAAGGAAGATGGTGATTTTGATTAGAAGCTGTTCAAACGATTATCAAGGCTTCAG
60 TAGGAAATCCGTTACTTATGCAAGCTTGGTGAGAAGCGTTATGCTGTTTATGATGGATGCTTCTCCGGTGT
GTATTTGTAGATGTATCCAGGGAACAAGCCATAACAGATGAATTGGTAACAAGTAGACCAGTGATTGGGATTGT
CTCTGTGGATAATTATGATGATTTGGAGGATGAAACTTCTGAGTCAGATATTAGTCAAAATCAATAGTTTGTAGCT
AATTTTATACAGAGTTTTCAGAAAAACATGATGTTTCTCGTGGGTAAGTATGGATCGATTATCTATTATAC
TGACTACACGGTGCTTGAGGGCTTGATGAATGATAAATTTCTGTTATTGATGCTTTCAGAGAAGAGTCGAAACAG
65 AGACAGTTGCCCTTGACCTTAAGTATGGGATTTCTATGGCGATGGAATCATGATGAGATAGGGAAGGTTGCTT
TGCTCAATTTGAACTTGGCTGAAGTACGTGGTGGCGACCAAGGTGGTTGTTAAGGAAAACGACGAAACGAAAAATC

5 CAGTTTATTTTGGTGGTGGGCTGCTGCTTCAATCAAGCGTACACGGACTCGTACGCGCGCTATGATGACAGCTAT
TTCAGATAAGATTTCGGAGTGTAGATCAGGTTTTGTAGTCGGTCACAAAAATTTAGACATGGATGCTTTGGGCTCT
GCTGTAGGTATGCAGTTGTTCCGCAGCAATGTGATTGAAAAATAGCTATGCTCTTTATGATGAAGAACAAATGTCTC
10 CAGATATTGAACGAGCTGTTTCATTCATAGAAAAAGAGGAGTTACGAAGTTGTTGCTGTTAAGGATGCAATGG
GGATGGTGACCAATCGTTCTTTGTTGATTCTTGTAGACCATTCAAAGACAGCCTTAACATTATCAAAAGAAATTTTA
TGATTTATTTACCCAAACCATTGTTATTGACCACCATAGAAGGGATCAGGATTTTCCAGATAATGCGGTTATTACT
TATATCGAAAGTGGTGAAGTAGTGCCAGTGAAGTTGTAACGGAATTGATTCAAGTTCCAGAAATCTAAGAAAAAT
CGTTTGAGTCGTATGCAAGCAAGTGTCTTGATGGCTGGTATGATGTTGGATACTAAAAATTTCACTCGCGAGTAA
15 CTAGTCGGACATTTGATGTTGCTAGCTATCTCAGAACGCGCGGAAGTGATAGTATTGCTATCCAGGAAATCGCTGC
GACAGATTTTGAAGAAATATCGTGAGGTCAATGAACATTATTTACAGGGGCGTAAATAGGTTGAGATGTAATA
GCAGAGGCTAAGGACATGAAATGCTATGATACAGTTGTTATTAGTAAGGCAGCAGATGCCATGTTAGCCATGTCA
UGTATTGAAGCGAGTTTGTCTTGGCAAGAAATACACAAGGATTTATCTCTATCTCAGCTCGAAGTCGTAGTAAAC
TGAATGTACAACGAGTATGGAAGAGTTAGGCGGTGGAGGCCACTTTAATTTGGCAGCAGCTCAAATTAAGATG
20 TAACCTTGTGAGAAGCAGGTGAAAACTGACAGAAATGTATTAAATGAAATGAAGGAAAAGGAGAAAGAAGAA
TGA

MKKFYVSPFIPILVGLIAGVLTSTFIIVNNLLTVLILFLVGGYVFLFKLRVHYTRSDVEQIQYVNHQAEESLTALLE
QMPVGVMLNLSSGEVEWFPYAEILITKEDGDFLEAVQTIKASVGNPSTYAKLGEKRYAVHMDASSGVLYFVDVS
25 REQAITDELVTSRPVIGIVSVNDYDDLEDETSDESISQINSFVANFISEFSEKHMMSRRVSMDFYLFYDVTYVLEGLMN
DKFSVIDAFREESKQRQLPLTSMGFSYGDGNHDEIGVALLNLNLAEVRGGDQVVKENDETKNPVYFGGSAASIK
RTRTRTRAMMTAISDKIRSVQVFFVGHKNLMDALGSAVGMQLFASNVNIENSYALYDEEQMSPDIERAVSFIEKEGV
TKLLSVKDAMGMVNTNRSLLILVDHSTALTLSKEFYDLFTQTTVIDHRRDQDFPDNAVITYIESGASSASELVTELIQFQ
NSKKNRLSRMQASVLMAGMMLDTKNFTSRVTSRTFDVASYLRTGRSDSIAIQEIAATDFEYREVNELILQGRKLGSDV
30 LIAEAKDMKCYDTVVISKAADAMLAMSGIEASFVLAKNTQGFISISARSKLNQVRIMEELGGGGHFNLAQAQKDV
LSEAGEKLTEIVL NEMKEKEKEEZ

ID115 663bp

30 ATGAAGTCTGTTTATGTGGGCAGACTATGAAGACTGTTTAACTTTTATAGTCTCTTACTTCTGAGGAATGATG
ACTCTTGTCTTTGTTTCAAGTGTGATTCTACTTTTGAAGAATTGGGAAGAGAACTGTCCAAATTTGATGAAAA
AGAGTTGTCAACAAAGTGTCAAGATTGTCACTTTGGTGTAAAGAGGGAGTTGAAGTCAGTCATAGAGCGATTTT
TACTTACAATCAAGCTATGAAGGATTTTTCAGTCGGTATAAGTTGATGGAGACTTCTGTTAAGAAAAAGTTTTC
35 GCTTCATTTTAAAGTGAGGAGTTGAAAAAGTACAAAGAGTATCAATTTGTTGTAATTTCCCTAAGTCCTGATAGAT
ATGCTAATAGAGGATTTAATCAGGTTGAGGGCTTGGTAGAGGCAGCAGGCTTGGATATCTGGATTTATTAGAGA
AAAGAGAAGAGAGCCAGTTCTTCTAAAAATCGTTCAGAGCGCTTGGGACAGAACTTCTTCTTTATTTAAAA
GTGGAGTCACTATTCTAAAAAAATCTACTTATAGATGATATCTATACTACAGGAGCAACTATAATCGTGTAA
GAACTGTTGGAAGAAGCTGGTCTAAGGATGTAACAACTTTCCCTTGAAGATGA

40 MKCLLCGQTMKTVLTFSSLLLLRNDSDCLDCDSTFERIGEENCPCNMKTELSTKCQDCQLWCKEGVEVSHRAIFTY
NQAMKDFFSRYKFDGDFLLRKVFASFLSEELKKYKEYQFVVIPLSPDRYANRGFNQVEGLVEAAGFEYLDLLEKREER
ASSSKNRSERLGTLPFFIKSGVTIPKKILLIDDIYTTGATINRVKKLLEEAGAKDVKTFSLVZ

ID116 1299bp

45 ATGAAAGTAAATTTAGATTATCTCGGTGCTTTATTTACTGAGAATGAATTAACAGAAGAAGAACGTCAGTTGGCG
GAGAAACTTCCAGCAATGAGAAAGGAGAAAGGGGAACTTTTCTGTCAACGCTGTAATAGTACTATTCTAGAAGAA
TGGTATTTGCCATCGGTGCTTACTATTGTGAGAGTGTCTGCTGATGAAGCGAGTCAGAAGTGATCAAACTTTAT
ACTATTTTCCGCAGGAGGATTTTCCAAAGCAAGATGTTCTCAATGGCGCGGCCAATTAACCTCTTTTCAAGAGAA
50 GGTGTGAGAGGGATTGCTTCAAGTAGTAGACAAGCAAGCAAAAGCAACCTTAGTTCATGCGGTAAACAGGAGCTGGAAA
GACAGAAATGATTTATCAAGTAGTGCTAAAGTGATCAATGCGGGTGGTGCAGTGTGTTGGCTAGTCTCGCAT
AGATGTTTGTGTTGAGCTGTACAAGCGCCTGCAACAGGATTTTCTTGGCGGATAGCTTTGCTACATGGAGAATCG
GAACCTTATTTTGAACACCACTAGTTGTTGCAACAACCCATCAGTTATTGAAGTTTATCAAGCTTTTGAATTGCT
GATAGTGGATGAAGTAGATGCTTTTCTTATGTTGATAATCCATGCTTTACCACGCTGTCAAGAATAGTGTAAG
55 GAGAATGGATTGAGAATCTTTTAAACAGCGACTTCGACCAATGAGTTAGATAAAAAAGGTCCGTTTAGGAGAACTA
AAAAGACTGAATTTACCGAGACGGTTTATGGAATCCGTTGATTATCCAAAACCAATTTGGTTATCGGATTTTA
ATCGCTACTTAGACAAGAATCGTTTGTCAACAAAGTTAAAGTCTATATTGAGAAGCAGAGAAAGACAGCTTATC
CGTTACTCATTTTGTCTCAGAAATTAAGAAAGGGGAGCAGTTAGCAGAAATCTTACAGGAGCAATTTCCAAATG
AGAAAAATGGCTTTGTATCTTCTGTAAACAGAGGATCGATTAGAGCAAGTACAAGCTTTTGGAGATGGAGAACTGA
60 CAATACTTATCAGTACGACAATCTTGGAGCGCGGAGTTACCTTCCCTTGTGTGGATGTTTTCGTAGTAGAGGCCAA
TCATCGTTTGTGTTACCAAGTCTAGTTTGAATTCAGATTGGTGGACGAGTTGGACGAAGCATGGATAGACCGCAGGA
GATTTGCTTTTCTTCATGATGGGTTAAATGCTTCAATCAAGAAGGCGATTAAGGAAATTCAGATGATGAATAAGG
AGGCTGGTCTATGA

65 MKVNL DYLGRLFTENELTEERQLAEKLPAMRKEKGKLFQRCNSTILEEWYLPIGA Y Y CRECLLMKRVRSQDTLYYF
PQEDFPKQDVLKWRGQLTPFQEKVSEGLLQVVDKQKPLVHAVTGAGKTEMITYQVAVKVINAGGAVCLASPRIDVCL

ELYKRLQQDFSCGIALHGESEPYFRTPLVVATTHQLLKIFYQAFDLLIVDEVDAFPYVDNPMLYHAVKNSVKENGLRIF
LTATSTNELDKKVRLEGELKRLNLPFRFHGNPLIPKPIWLSDFNRYLDKNRLSPKLKSYIEKQRKTAAYPLLFASEBKKE
QLAEILQEOPNEKIGFVSSVTEDRLEQVQAFRDGELITLISTILERGVTFPCVDVFVVEANHRLFTKSSLIQIGGRVGRS
MDRPTGDLFFHDGLNASIKKAIKEIQMMNKEAGLZ

5

ID117 870bp

ATGCAAATTCAAAAAAGTTTTAAGGGGCAGTCTCCCTATGGCAAGCTGTATCTAGTGGCAACGCCGATTGGCAAT
CTAGATGATATGACTTTTCGTGCTATCCAGACCTTGAAAGAAGTGGACTGGATTGCTGCTGAGGATACGCCGAAT
ACAGGGCTTTTGCTCAAGCATTGACATTCCACCAAGCAGATCAGTTTTTCATGAGCACAATGCCAAGGAAAAA
ATTCCTGATTTGATTGGTTTCTTGAAAGCAGGGCAAAGTATTGCTCAGGTCTCTGATGCCGTTTTCCTAGCATTT
CAGACCTGGTCATGATTTAGTTAAGGCAGCTATTGAGGAAGAAATTGCAGTTGTGACAGTTCCAGGTGCTCTGC
AGGAATTTCTGCCTTGATTGCCAGTGGTTTAGCGCCACAGCCACATATCTTTACGGTTTTTACCGAGAAAAATCA
GGTCAGCAGAAGCAATTTTTGGCTTGAAAAAAGA'TATCTGAAACACAGATTTTTATGAATCACCTCATCGTG
TAGCAGACACGTTGGAAAAATATGTTAGAAGTCTACGGTGACCGCTCCGTTGTCTTGGTCAGGGAATTGACAAAA
TCTATGAAGAATACCAACGAGGTACTATCTCTGAGTTATTAGAAAGCATTGTGTAAGCGCCACTCAAGGGCGAAT
GTCTTCTCATTGTTGAGGGTGCCAGTCAGGGTGTGGAGGAAAGGACGAGGAAGACTTGTTCGTAGAAATTCAAA
CCCGCATCCAGCAAGGTGTGAAGAAAAACCAAGCTATCAAGGAAGTCGTAAGATTACCAGTGAATAAAAGTC
AGCTCTACGCTGCCTACCACGACTGGGAAGAAAAACAATAA

10

15

20

MOIQKSFQSPYKLYLVATPIGNLDDMTFRAIQTLEKVDWIAAEDTRNTGLLLKHFDISTKQISFHEHNAKEKIPDLI
GFLKAGQSIAQVSDAGLPSISDPGHDLVKAAIEEIAVVTVPASAGISALIASGLAPQPHIFYGLPRKSGQQKQFFGLKK
DYPETQIFYESPHRVADTLENMLEVYGDERSVVLVRELTKIYEYQRTISELLESIAETPLKGECLLIVEGASQGVEEKDE
EDLFVEIQTRIQQGVKKNQAIKEVAKIYQWNKSLYAAHYDWEKQZ

25

ID118 345bp

ATGATAAAGAAAGGAAAGGGCTGTTTTATGGACAAAAAGAATTATTTGACGCGCTGGATGATTTTTCCCAACAA
TTATTGGTAACCTTAGCCGATGTGGAAGCCATCAAGAAAAATCTCAAGAGCCTGGTAGAGGAAAAATACAGCTCTT
CGCTTGGAAAAATAGTAAGTTGCGAGAACGCTTGGGTGAGGTGGAAGCAGATGCTCCTGTCAAGGCCAAGCATGTT
CGCGAAAGTGTCCGTCGTATTTACCGTGATGGATTTACGATGTGAATGATTTTTATGGACAACGTCGAGAGCAGG
ACGAAGAATGTATGTTTTGTGACGAGTTGTTATACAGGAGTAA

30

35

MIKKGKGCFFMDKKELFDALDDFSQQLVTLADVEAIKKNLKSLEVENTALRLENSKLRERLGEVEADAPVKAKHVRES
VRRIYRDGFHVCNDFYQRRREQDEECMFCDellyREZ

ID119 639bp

ATGTCAAAGGATTTTTAGTCTCTCTTGAGGGACCAGAGGGAGCAGGCAAGACCAGTGTTTTAGAGGCTCTGCTA
CCAATTTTAGAGGAAAAAGGAGTAGAGGTGTTGACGACCCGTGAACCTGGCGGAGTCTTGATTGGGGAGAAGATT
CGGGAAGTGATTTTGGATCCAAGTCATACTCAGATGGATGCTAAAACAGAGCTACTTCTCTATATTGCCAGTCGCA
GACAGCATTGGTGGAAGAAAGTTCTTCCAGCCCTTGAAGCTGGCAAGTTGGTCATCATGGATCGTTTTATCGATAG
TTCTGTGCTATCAGGGATTTGGTCTGGCTTAGATATTGAAGCCATTGACTGGCTCAATCAGTTTGGCAGAGAT
GGCCTCAAACCCGATTTGACACTCTATTTGACATCGAGGTGGAAGAAGGGCTGGCTCGTATTGCTGCTAATAGTG
ACCGCGAGGTTAATCGTTTGGATTGGAAGGGTGGACTTGCATAAAAAAGTTTCGTAAGGCTACCTTTCTCTCT
GGATAAAGAGGGAAATCGCATTGTCAAGATTGATGCTAGTCTCCCTTTGGAGCAAGTTGTGGAACTACCAAGGC
TGTCTTGTGTTGACGGAATGGGCTTGCCAAATGA

40

45

50

MSKGFLVSLEGPEGAGKTSVLEALLPILEEKGVLEVTREPGGVLIGEKIREVILDPSTQMDAKTELLYIASRRQHLVE
KVLPALEAGKLVIDRFDSSVAYQGFGRGLDIEAIDWLNQFATDGLKPDLTLYFDIEVEEGLARIAANSREVNRLDL
EGLDLHKVRQGYLSLLDKEGNRIVKIDASLPLEQVVETTKAVLFDGMGLAKZ

ID120 408bp

ATGGTAGAACAAAGAAAAATCAATTACCATGAAAGATGTTGCTTTAGAAGCAGGAGTTAGTGTGGAACTGTTTCA
CGTGTAATTAATAAAGAAAAAGGCATTAAGAAAGTAACCTTGAAAAAAGTGGAAACAAGCGATTAAAACTTTGAAT
TACATTCCAGATTACTACGCTAGAGGAATGAAAAAAATCGAACAGAAACGATTGCAATCATTTGTACCAAGTATC
TGGCATCCCTTCTTTTCAAAATTTGCTATGCTATGTTGAAAAATGAAGTCTATAAGAGAAATAACAAATTACTCTTAT
GTTCTATCAATGGTACAATAGAGAGCAAGACTATCTGGAGATGTTGCGTCATAATAAAGTTGATGGAGTGGTTG
CCATTACCTATAGGCCAATTGAACATTACTTGACGTGAGGAATCCCTTTGTTAGTATTGACCGCACATACTCAGA
GATTGCCATTCTTGTGTTTCA

55

60

65

MVEQRKSTITMKDVALEAGVSVGTVSRVINKEKGIVELTKKVEQAIKTLNYPDYARGMKKNRTETIAIIVPSIWHPPF
SEFAMHVENEVYKRNNKLLCSINGTNREQDYLEMLRHNKVDGVVAITYRPIEHLTSGIPFVSIDRTYSEIAPCVS

ID121 285bp

5 ATGAATATATTTAGAACAAGAATGTTAGTTTATGATAAAAACAGAGATGCATAGGCATTTGAAGTTATGGGATTTG
ATTTTGTGGGTATCGGAGCCATGGTAGGGACAGGCGCTTTACAATCACAGGTAAGTGCAGCTGCAACACTTGGCTG
GCCCAGCCCTAGTGATTTCAATCGTTATTTCTGCTTGTGTGGGATTATCAGCCCTCTTTTTGCAGAATTTGCC
TCGGAGTACCCGCTACAGGAGGTGCCTATAGTTACCTCTATGCTATCTTAGGAGAATTCCTGCGCTGGTGGCTG
GTTGGTTAACCATGATGGAGTTCATGACAGCCATATCAGGCGTAGCTTCGGGTGGGACAGCTTATTTTAA

10 MNIFRTKNVSLDKTEMRHLKLWDLILLGIGAMVGTGVFTTGTAAATLAGPALVISIVISALCVGLSALFFAEFASRPV
ATGGAYSYLAILGEPPAWLAGWLTMMEFMTAISGVASGWAAAYF

ID124 1311bp

15 ATGAAATCAAGAGTAAAGGAAACGAGTATGGATAAAATTGTGGTTCAAGGTGGCGATAATCGTCTGGTAGGAAGC
GTGACGATCGAGGGAGCAAAAAATGCAGTCTTACCCTTGTGGCAGCGACTATTCTAGCAAGTGAAGGAAAGACC
GTCTTGCAGAAATGTTCCGATTTTGTGCGATGCTTTATTATGAATCAGGTAGTTGGTGGTTTGAATGCCAAGGTTG
ACTTTGATGAGGAAGCTCATCTTGTCAAGGTGGATGCTACTGGCGACATCACTGAGGAAGCCCCCTTACAAGTATG
TCAGCAAGATGCGCGCTCCATCGTTGTATTAGGGCAATCCTTGCCCGTGTGGGTATGCCAAGGTATCCATGCC
20 AGGTGGTTGTACGATTGGTAGCCGTCTATTGATCTTCATTTGAAAGGTCTGGAAGCTATGGGGTTAAGATTAGT
CAGACAGCTGGTTACATCGAAGCCAAGGCAGAACGCTTGCATGGTGCTCATATCTATATGGACTTCCAAAGTGTG
GTGCAACGCAGAACTTGATGATGGCAGCGACTCTGGCTGATGGGTGACAGTGATTGAGAATGCTGCGCGTGAGC
CTGAGATTGTTGACTTAGCCATTCTCCTTAATGAAATGGGAGCCAAGGTCAAAGGTGCTGGTACAGAGACTATAA
CCATTACTGGTGTGAGAACTTCATGGTACGACTCACAATGTAGTCCAAGACCGTATCGAAGCAGGAACCTTTAT
GGTAGCTGCTGCCATGACTGGTGGTGATGCTTGATTGAGACGCTGTCTGGGAGCAACCCGCTCCCTTGATTGCC
25 AAGTTACTTGAAATGGGTGTTGAAGTAATTGAAGAAGACGAAGGAATTCGTGTTCTCACTAGAAAAATCTA
AAAGCTGTTTCAATGTGAAACCTTGCCCCACCCAGGATTTCCAACAGATATGCAGGCTCAATTTACAGCCTTGATGA
CAGTTGCAAAAGGCGAATCAACCATGGTGGAGACAGTTTTCGAAAATCGTTTCCAAACCTAGAAGAGATGCGCCG
CATGGGCTTGCACTTCTGAGATTATCCGTGATACAGCTCGTATTGTTGGTGACAGCCTTTCAGGGAGCAGAAGTT
30 CTTTCAACTGACCTTCGTGCCAGTGGCGCTTGATTTTGACAGGTTTGGTAGCACAGGAGAACTGTGGTCGTA
AATTGGTTCACTTGGATAGAGGTTACTACGGTTTCCATGAGAAGTTGGCGCAGCTAGGTGCTAAGATTACGGGAT
TGAGGCAAGTGATGAAGATGAATAA

35 MKSRVKETSMDKIVVQGGDNRLVGSVTIEGAKNAVLPLAATILASEGKTVLQNPILSDVFIMNQVVGGLNAKVDFD
EEAHLVKVDATGDITEEAPYKYVSKMRASIVVLGPILARVGHAKVSMPPGCTIGSRPIDLHLKGLEAMGVKISQTAGYIE
AKAERLHGAIHYMDFPSVGATQNLMMAAATLADGVTVIENAAAREPEIVDLAILLNEMGAKVKAGTETTTITGVEKLHG
TTHNVVQDRIEAGTFMVAAMTGGDVLIRDAVWEHNRPLIAKLLMGVEVIEDEGIRVRSQLENLKAHVHKTLPHP
GFPTDMQAQFTALMTVAKGESTMVETVFENRFQHLEEMRRMGLHSEIIRDTARJVGQPLQGAEVLSTDLRASAALLJL
TGLVAQGETVVGKLVHLDRGYGFHEKLAQLGAKIQRIEASDEDEZ

ID125 1101bp

40 ATGTTATTAGCGTCAACAGTAGCCTTGTCAATTTGCCCAGTATTGGCAACTCAAGCAGAAGAAGTCTTTGGACTG
CACGTAGTGTGAGCAAAATCCAAAACGATTGACTAAAACGGACAACAAAACAAGTTATACCGTACAGTATGGTG
45 ATACTTTGAGCACCATTGCAGAAGCCTTGGGTGTAGATGTACAGTGCTTGCGAATCTGAACAAAATCACTAATAT
GGACTTGATTTTCCAGAACTGTTTGTGACAACGACTGTCAATGAAGCAGAAGAAGTAACAGAAGTTGAAATCCA
AACACCTCAAGCAGACTCTAGTGAAGAAGTGACAACTGCGACAGCAGATTTGACCACTAATCAAGTGACCGTTGA
TGATCAAACTGTTACAGTTGCAGACCTTTCTCAACCAATTGCAGAAGTTACAAAGACAGTGATTGCTTCTGAAGAA
GTGGCACCATCTACGGGCACCTTCTGTCCCAGAGGAGCAACGACCGAAACAACCTCGCCAGTTGCAGAAGAAGCT
50 CCTCAGGAAACGACTCCAGCTGAGAAGCAGGAAACACAAACAAGCCCTCAAGCTGCATCAGCAGTGGAAGCAAC
TACAACAAGTTCAGAAGCAAAAGAAGTAGCATCATCAATGGAGCTACAGCAGCAGTTTCTACTTATCAACCAGA
AGAAACGAAAGTAATTTCAACAACCTACGAGGCTCCAGCTGCGCCCGATTATGCTGGACTTGCAAGTACAAAATC
TGAAAATGCAGGTCTTCAACCACAAACAGCTGCCTTTAAWGAAGAAATTGCTAACTGTTTGGCATTACATCCTTT
AGTGGTTATCGTCCAGGAGACAGTGGAGATCACGGAAAAGGTTTGGCTATCGACTTTATGGTACCAGAACGTTCA
55 GAATTAGGGGATAAGATTGCGGAATATGCTATTCAAAATATGGCCAGCCGTGGCATTAGTTACATCATCTGGAAA
CAACGTTTCTATGCTCCATTGATAGCAAAATATGGGCCAGCTAACACTTGGAAACCAATGCCAGACCGTGGTAGT
GTGACAGAAAATCACTATGATCACGTTTACGTTTCAATGAATGGATAA

60 MLLASTVALSFAPVLATQAEVLTARSVEIQNDLTKTDNKTSTYTVQYGDTLSTIAELGVDVTVLANLNKITTMDL
IFPETVLTITVNEAEVTEVEIQTPQADSSEVTTATADLTNNQVTVDDQTVQVADLSQPIAEVTKTVIASEEVPSTGTS
VPPEQTETTRPVAEEAPQETTPAEKQETQTSQAASAVEATTTSSAEKEVASSNGATAAVSTYQPEETKVISTTYEAPA
APDYAGLAVAKSENAGLQPTAAFKKLLTCLALHPLVVIVQETVEITEKVWLSTLWYQNVQNZGIRLRNMLFKIWP
65 VALVTSSGNNVSMHLSIANMGQLTLGTQCQTVVZQKITMITFTFQZMD

ID126 1281bp

5 TTGTTTAAGAAAAATAAAGACATTCTTAATATTGCATTGCCAGCTATGGGTGAAAACCTTTTGCAGATGCTAATGG
GAATGGTGGACAGTTATTTGGTTGCTCATTTAGGATTGATAGCTATTTTCAGGGGTTTCAGTAGCTGGTAATATTAT
CACCATTTATCAGGCGATTTTCATCGCTCTGGGAGCTGCTATTTCCAGTGTTATTTCAAAAAGCATAGGGCAGAAA
GACCAGTCGAAGTTGGCCTATCATGTGACTGAGGCGTTGAAGATTACCTTACTATTAAGTTTCCTTTTAGGATTTT
10 TGTCATCTTCGCTGGGAAAGAGATGATAGGACTTTTGGGGACGGAGAGGGATGTAGCTGAGAGTGGTGGACTGT
ATCTATCTTTGGTAGGCGGATCGATTGTTCTCTTAGGTTAATGACTAGTCTAGGAGCCTTGATTCTGTGCAACGCA
TAATCCACGCTCTGCCTCTCTATGTTAGTTTTTATCCAATGCCTTGAATATTTCTTTTCAAGCTAGCTATTTTGT
TCTGGATATGGGGATAGCTGGTGTGCTTGGGGGACAATTGTGTCTCGTTGGTTGGTCTTGTGATTTTGTGGTCAC
AATTAAACTGCCTTATGGGAAGCCAACTTTTGGTTAGATAAGGAACTGTTGACCTTGGCTTTACCAGCAGCTGG
15 AGAGCGACTTATGATGAGGGCTGGAGATGTAAGTATGCTTGCCTTGGTCTGTTCTTTGGGACGGAGGCACTGCT
GGGAATGCAATCGGAGAAGTCTTGACCCAGTTAACTATATGCCTGCCTTGGCGTCTACGGCAACGGTCTATG
CTGTTGGCCCGAGCAGTTGGAGAGGATGATTGGAAGAGATTGCTAGTTTGAGTAAACAAACCTTTTGGCTTCTC
TGTTCTCATGTTGCCCTGTCTTTAGTATATATGCTTGGGTGTACCATTAACTCATCTCTATACGACTGATTCT
20 CTAGCGGTGGAGGCTAGTGTCTAGTGACACTGTTTCACTACTTGGGACCCCTATGACGACAGGAACAGTCATCT
ATACGGCAGTCTGGCAGGGATTAGGAAATGCACGCCCTCCCTTTTATGCGACAAGTATAGGAATGTGGTGTATCC
GCATTGGGACAGGATATCTGATGGGGATTGTGCTTGGTTGGGGCTTGCCTGGTATTTGGGCAGGGTCTCTCTGGA
TAATGGTTTTCGCTGGTTATTTCTACGCTATCGTTACCAGCGCTATATGAGCTTGAAGGATAG

LFKKNKDILNIALPAMGENFLQMLMGMVDSYLVAHLGLAISGVSVAGNITTYQAIFFALGAAISSVSKSIGQKDQSKLA
YHVTEALKITLLLSFLLGFLSIFAGKEMIGLLGTERDVAESGGLYLSLVGGSIIVLLGLMTSLGALIRATHNPRPLPVVSL
25 SNALNLFSSLAIFVLDMDIAGVAWGTIVSRVLVGLVILWSQLKLPYGKPTFGLDKELLTLALPAAGERLMMRAGDVIHA
LVVSFGTEAVAGNAIGEVLTQFNYPAGFVATATVMLLARAVGEDDWKRVASLSKQTFWLSFLMLPLSFSIYLVGP
LTHLYTDSLAVEASVLVTLFSLGTPMTTGTVIYTA VVWQGLGNARLPFYATSIGMWCIRGTGYLMGIVLGWGLPGIW
AGSLLDNGFRWFLRYRYQRYMSLKGZ

ID127 894bp

30 GTGGGAAGAATTATCAGAGCAGGTGTAAAGATGGAACATCTTGGAAAAGTATTTCTGTAATTTTGAACAAGTGGA
AATTATCTTTAAAGGAAGCAGCAGGCGAATCCTGCTCTACCTCTCAGTTATCTCGCTTTGAGCTTGGGGAGTCTG
ACCTGGCAGTCTCCCGTTTCTTTGAGATTTTGGATAACATTCATGTAACAATCGAAAAATTCATGGATAAGGCAAG
35 GAATTTTCATAATCATGAACATGTGTCTATGATGGCAGAGATTATCCCACTTTACTATTCAAACGATATTGCAGGT
TTTCAAAGCTTCAAAGAGAACAACCTTGAAGAGTCTAAGAGTTCGACGACTCCCCCTTTATTTTGAAGTGAAGTGA
TTTTGCTACAAGGTCTGATTTGTCAAAGAGATGCGAGTTATGATATGAAGCAGGATGATTGGGTAAGGTAGCAG
ATTATCTCTTCAAACAGAGAAGTGGACCATGTATGAGTTGATTCTTTTGGTAACCTCTATAGTTTCTACGATGT
40 AGACTATGTCACTCGGATTGGTAGAGAAGTTATGGAGAGGGAGGAATTTTACCAAGAGATTAGTCGCCATAAGAG
ATTAGTGTGATTTTGGCCCTCAATTGTTACCAGCATTGTTAGAGCATTCTTCTTTTATAATGCCAACTATTTTG
AGGCTTATACAGAGAAGATTATTGACAAAGGTATTAAGCTTTATGAGCGTAATGTTTCCATTATTTAAAGGTTT
TGCTTATATCAAAAAGGACAGTGTAAAGAAGGCTGTAAGCAGATGCAAGAGGCCATGCATATTTTGTATGTGT
AGGTCTTCCAGAGCAAGTAGCCTATTATCAGGAACACTACGAAAAATTTGTCAAAGTTAA

50 VGRIRAGVKMEHLGKVFREFRTSGNYSLEAAGESCSTSQLSRFELGESDLAVSRFFEILDNIHVTIENFMDKARNFHN
HEHVSMMQAIIPLYSNDIAGFQKLQREQLKSKSSTPLVFELNWILLQGLICQDASYDMKQDDLKGKVADYLFKTEE
WTMYELILFNLYSFYDVYVTRJGREVMEREFFYQEISRHKRLVLILALNICYQHLEHSSFYNNANYFEAYTEKIIDKGI
KLYERNVPHYLKGFALYQKGQCKEQMAMEHIFDVLGLPEQVAYYQEHYEFVKSZ

TABLE 3**ID1 1068bp**

5 ATGTCTAACATTCAAAACATGTCCCTGGAGGACATCATGGGAGAGCGCTTGGTCGCTACTCCAAGTACATTATTC
AAGACCGGGCTTTGCCAGATATTCGTGATGGGTGGAAGCCGGTTCAGCGCCGTATTCTTTATTCTATGAATAAGGA
TAGCAATACTTTTGACAAGAGCTACCGTAAGTCGGCCAAAGTCAGTCGGGAACATCATGGGGAATTTCCACCCACA
CGGGGATTCTTCTATCTATGATGCCATGGTTCGTATGTCACAGAACTGGAAAAATCGTGAGATTCTAGTTGAAATG
10 CACGGTAATAACGGTTCTATGGACGGAGATCCTCCTGCGGCTATGCGTTATACTGAGGCACGTTTGTCTGAAATTG
CAGGCTACCTTCTCAGGATATCGAGAAAAAGACAGTTCCTTTTGCATGGAACCTTGACGATACGGAGAAAGAAC
CAACGGTCTTGCCAGCAGCCTTTCCAAACCTCTTGGTCAATGGTTCGACTGGGATTTCCGGCTGGTTATGCCACAGA
CATTCTCCCCATAATTAGCTGAGGTCATAGATGCTGCAGTTTACATGATTGACCACCCAACCTGCAAAGATTGAT
AAACTCATGGAATCTTGCCTGGACGAGCTTCCTACAGGGGCTATTATTCAGGGTCGTGATGAAATCAAGAAA
15 GCTTATGAGACTGGGAAAGGGCGCGTGGTTGTCGTTCCAAGACTGAAATTGAAAAGCTAAAAGGTGGTAAGGAA
CAAAATCGTTATTATTGAGATTCTTATGAAATCAATAAGGCCAATCTAGTCAAGAAAAATCGATGATGTTTCGTGTTA
ATAACAAGGTAGCTGGGATTGCTGAGGTTCTGATGAGTCTGACCGTGATGGTCTTCGTATCGCTATCGAATCTAA
GAAAGACGCTAATACTGAGCTTGTCTCAACTACTTATTTAAGTACACCGACCTACAAATCAACTACAATTTAAT
ATGGTGGCGATTGACAAATTCACACCTCGTCAGGTTGGATTGTTCCAATCCTGTCTAGCTATATCGCTCACCCTCG
20 AGAAGTGA

MSNIQNMSLEDIMGERFGRYSKYTIQDRALPDIRDGLKPVQRRLYSMNKDSNTFDKSYRKSASVGNIMGNFHPHGD
SIYDAMVRMSQNWKNREILVEMHGNNGSMGDPPAAMRYTEARLSEIAGYLLQDIEKKTVPFAWNFDTEKEPTVLP
AAFPNNLLVNGSTGISAGYATDIPPHNLAVIDAAVYIMDHPTAKIDKLMEFLPGPDFPTGAIHQGRDEIKKAYETGKGRV
25 VYRSKTEIEKLKGGKEQIVIIIEIPYEINKANLVKKIDDVRVNNKVAGIAEVRDESDRDGLRIELKKDANTELVNLFLK
YTDLQINYNFMVAIDNFTPRQVGLFQSCLAISLTVEKZ

ID12 684bp

30 ATGCCGACATTAGAAATAGCACAAAAAACTGGAGTTCATTAAGAAGGCAGAGAATATTACAATGCCTTGTGT
ACAAATATACAGTTGAGCGGAGATAAACTAAAAGTAATTTCCGTTACTCTGTAAACCTGGGGAAGGAAAAACA
ACTACTTCCATAAATATAGCATGGTTCGTTTCCGCGTGCAGGCTATAAACTCTTTTGATCGATGGCGATACTCGAA
ATTCAGTTATGTTAGGAGTTTTTAAATCTCGTGAATAAATTACAGGGCTAACAGAAATTTTATCTGGGACAGCTGA
35 TTTATCTCACGGTTTATGTGATACAAATATTGAAAAATTTTGTAGTTCAATCGGGATCTGTATCACCAAAACCT
ACAGCCTTGTACAAAGTAAAAATTTTATGATGATGTTGAAACATTGCGTAAATATTTTGATTATATCAATTATTG
ATACACCGCCTATTGGAATTGTTATTGATGCGGCAATTATCACTCAAAGTGTGATGCGTCCATCTTGGTAAACAGC
AACAGGTGAGGCGAATAAACGTGATATCCAAAAAGCGAAACAACAATTAACAAAAACAGGGAACTGTTCTAG
GAGTTGTTTTAAATAAATTGGATATCTCGGTTAATAAGTATGGAGTTTACGGTTCTATGGAATTTATGGTAAAAA
ATAA

40 MPTLEIAQKKLEFIKKAEEYNNALCTNIQLSGDKLVISVTSVNPGEKTTTSINIAWSFARAGYKTLIDGDRNSVML
GVFKSREKITGLTEFLSGTADLSHGLCDTNIENLFVQSGSVSPNPTALLQSKNFNDMIETLRKYFYDIIDTPPIGIVIDAA
IITQKCDASILVTATGEANKRDIQAKQQLKQTGKFLGVVLNKLDSVKNYGVYGSYGNYGKKZ

ID13 1182bp

45 ATGGAGGCAAATATGAAACATCTAAAAACATTTTCAAAAAATGGTTTCAATTATTAGTCGTTATCGTCATTAGCT
TTTTTAGTGGAGCCTTGGGTAGTTTTTCAATAACTCAACTAACTCAAAAAAGTAGTGTAACAACCTCTAACAACAA
TAGTACTATTACAAAACCTGCCTATAAGAACGAAAATTCACAAACACAGGCTGTTAACAAAGTAAAGATGCTGT
50 TGTTTCTGTTATTACTTATTCGGCAACACAGACAAAATAGCGTATTGGCAATGATGATACTGACACAGATTCTCAG
CGAATCTCTAGTGAAGGATCTGGAGTTATTTATAAAAAAGATGATAAAGAAGCTTACATCGTCACCAACAATCAC
GTTATTAATGGCGCCAGCAAAAGTAGATATTCGATTGTCAGATGGGACTAAAGTACCTGGAGAAATTTGTCGGAGCT
GACACTTTCTGATATTGCTGTCTCAAAATCTCTTCAGAAAAAGTGACAACAGTAGCTGAGTTTGGTGATTCTA
GTAAGTTAACTGTAGGAGAAAACGCTATTGCCATCGGTAGCCGTTAGGTTCTGAATATGCAAAATACTGTCACTCA
55 AGGTATCGTATCCAGTCTCAATAGAAATGTATCCTTAAATCGGAAGATGGACAAGCTATTTCTACAAAAGCCAT
CCAACTGATACTGCTATTAACCCAGGTAACCTGCGCGCCCACTGATCAATATTCAAGGGCAGGTTATCGGAAT
TACCTCAAGTAAAAATTGCTACAAATGGAGGAACATCTGTAGAAGGTCTTGGTTTCGCAATTCCTGCAAAATGATGCT
ATCAATATTATTGAACAGTTAGAAAAAACGAAAAAGTGACGCGTCCAGCTTTGGGAATCCAGATGGTTAATTTA
TCTAATGTGAGTACAAAGCAGATCAGAAAGACTCAATATTCAGTAATGTTACATCTGGTGTAATTGTTTCGTTCCG
60 TACAAAGTAATATGCCTGCCAATGGTCACCTTGAATAATACGATGTAATTACAAAAGTAGATGACAAAGAGATTG
CTTCATCAACAGACTTACAAAGTGTCTTTACAACCTTCTATCGGAGACACCATTAAGATAACCTACTATCGTAA
CGGGAAGAAGAACTACCTCTATCAAACTTAAACAAGAGTTCAGGTGATTAGAATCTTAA

65 MEANMKHLKTFYKKWFQLLVVIVISFFSGALGSFSITQLTKSSVNNNSNNNSTTTQTA YKNENSTTQAVNKVKDAVVSV
ITYSANRQNSVFGNDDTDTDSQRISSESGVYKKNDEAYIVTNNHVINGASKVDIRLSDGTVPGEIVGADTFSDIAV
VKISSEKVTVAEFGDSSKLTGGETAIAIGSPLGSEYANTVTQGIVSSLNRNVSLKSEDQAIJTKAIQTDTAIPNGNSGGP

LINIQGVIGITSSKIATNGGTSVEGLGFAIPANDAINIEQLEKNGKVTRPALGIQMVNLSNVSTSDIRRLNIPSNVTSQVIV
RSVQSNMPANGHLEKYDVITKVDDKEIASSTDLSQALYNHSIGDTIKITYRNGKEETTSIKLNKSSGDLESZ

ID15 939bp

5 ATGGCAGAAATTTATCTAGCAGGTGGTTGTTTTGGGGCCTAGAGGAATATTTTTACGCATTTCTGGAGTGCTAG
AAACCAAGTGTGGCTACGCTAATGGTCAAGTCGAAACGACCAATTACCAGTTGCTCAAGGAAACAGACCATGCAG
AAACGGTCCAAGTGATTACGATGAGAAGGAAGTGTCACTCAGAGAGATTTACTTTATTATTTCCGAGTTATCGA
10 TCCTCTATCTATCAATCAACAAGGGAATGACCGTGGTCGCCAATATCGAACTGGGATTTATTATCAGGATGAAGC
AGATTTGCCAGCTATCTACACAGTGGTGCAGGAGCAGGAACGCATGCTGGGTCGAAAGATTGCAGTAGAAGTGGA
GCAATTACGCCACTACATTCTGGCTGAAGACTACCACCAAGACTATCTCAGGAAGAATCCTTCAGGTTACTGTCAT
ATCGATGTGACCGATGCTGATAAGCCATTGATTGATGCAGCAAATATGAAAAGCCTAGTCAAGAGGTTGTTGAAG
GCCAGTCTATCTGAAGAGTCTTATCGTGTACACAAGAAGCTGCTACAGAGGCTCCATTACCAATGCCTATGACC
15 AAACCTTTGAAGAGGGGATTTATGTAGATATTACGACAGGTGAGCCACTCTTTTTGCCAAGGATAAGTTTGCTTC
AGGTTGTGGTTGGCCAAGTTTTAGCCGTCGGATTTCCAAAGAGTTGATTCAATTATACAAGGATCTGAGCCATGGA
ATGGAGCGAATTGAAGTTCGTTCTCGTTCAGGCAAGTGTCACTTGGGTCATGTTTTACAGATGGACCGCGGGAGT
TAGGCGGCCTCCGTTACTGTATCAATCTGCTCTTTACGCTTTGTGGCCAAGGATGAGATGGAAAAAGCAGGATA
TGGCTATCTATTGCCTTACTTAAACAAATAA

20 MAEIYLAGGCFWGLEEYFSRISGVLETSVGYANGQVETNNYQLKETDHAETVQVIYDEKEVSLREILLYFRVIDPLSI
NQGNDRGRQYRTGIYYQDEADLPAIYTVVQEQERMLGRKIAVEVEQLRHYLAEDYHQDYLRKNPSGYCHIDVTD
DKPLIDAANYEKPSQEVKASLSEESYRVTEAATEAPFTNAYDQTFEEGIYVDITTEPLFFAKDKFASGCCWPSFSRPI
SKELIHYKDLSHGMERIEVRSRSGAHLGHVFTDGPRLGGLRYCINSASLRFVAKDEMEKAGYGYLLPYLNKZ

ID17 870bp

25 ATGAAGATTATTGTACCTGCAACCAGTGCCAATATCGGGCCAGGTTTTGACTCGGTGGTGTAGCTGTAACCAAGT
ATCTTCAAAATTGAGGTCTGCGAAGAACGAGATGAGTGGCTGATTGAACACCAGATTGGCAAATGGATTCCACATG
30 ACGAGCGTAATCTTGTCTCAAAATCGCTTTGCAAAATTGACAGACTTGCAACCAAGACGCTTGAAATGACCA
GTGATGTCCCTTTGGCGCGCGGTTTGGGTTCTTCAGCTCGGTTATCGTTGCTGGGATTGAAGTACGCCAACCACT
GGGTCAACTCACTTATCAGACCATGAAAAATGCGATTAGCGACCAAGATTGAAGGGCATCCTGACAAATGTGGC
TCCAGCCATTTATGGTAATCTCGTTATTGCAAGTTCTGTTGAAGGGCAAGTCTCTGCTATCGTAGCAGACTTTCCA
GAGTGTGATTTTCTAGCTTACATTCAAACTATGAATTACGTACTCGCGACAGCCGTAGTGTCTTGCTTAAAAAAT
35 TGTCTTATAAGGAAGCTGTTGCTGCAAGTTCTATCGCCAAATGTAGCGGTTGCTGCTTGTGGCAGGAGACATGGT
GACCGCTGGGCAAGCAATCGAGGGAGACCTTCCATGAGCGCTATCGTCAGGACTTGGTAAGAGAATTTGCGAT
GATTAAGCAAGTGACCAAGAAATGGGGCCTATGCAACCTACCTTTCTGGTGTGGGCGGACAGTTATGGTTCT
GGCTTCTCATGACAAGATGCCAACAAATTAAGGCAGAAATGGAAAAGCAACCTTTCAAAGGAAAACCTGCATGACTT
GAGAGTTGATACCAAGGTGTCGCTGTAGAAGCAAAATAA

40 MKIIVPATSANIGPGFDSVGVAVTKYLQIEVCEERDEWLIEHQIGKWIPHDERNLLKIALQIVPDLPRLKMTSDVPLA
RGLGSSSSVIVAGIELANQLGQLNLSDEKLQLATKIEGHPDNVAPAIYGNLVIASSVEGQVAIVADFPCEDFLAYIPNY
ELRTRDSRSVLPKKLSYKEAVAASSIANVAVAALLAGDMVTAGQAEIGDLFHERYRQDLVREFAMIKQVTKENGAYAT
YLSGAGPTVMVLASHDKMPTIKAELKQPFKGLHDLRVDTQGVREAKZ

ID20 564bp

45 ATGAAATATCAGGATTACATCTGGGATTTAGGTGGAACCTTTACTGGATAATTATGAAACTTCAACAGCTGCATTTG
TTGAAACATTGGCACTGTATGGTATCACACAAGACCATGACAGTGTCTATCAAGCTTTAAAGGTTTCTACTCCTTT
50 TGGCATTGAGACATTCGCTCCCAATTTAGAGAATTTTTAGAAAAGTACAAGGAAAATGAAGCCAGAGAGCTTGA
ACACCCGATTTTATTGAAGGAGTTTCTGACCTATTGGAAGACATTTCAAATCAAGGTGGCCGCTATTTTTTGGTC
TCTCATCGAAATGATCAGGTTTTGGAAATTTAGAAAAAACCCTCTATAGCAGCTTATTTTACAGAAAGTGGTGA
CTAGCTCAGGCTTTAAGAGAAAGCCAAATCCCGAATCCATGCTTTATTTAAGAGAAAAGTATCAGATTAGCTCTG
55 GTCTTGTCATTGGTGATCGCCGATTGATATCGAAGCAGGTCAAGCTGCAGGACTTGATACCCACTTGTTTACCAG
TATCGTGAATTTAAGACAAGTATTAGACATATAA

MKYHDIYIDLGGTLLDNYETSTAFAFVETLALYGITQDHDSDVYQALKVSTPFAIETFAPNLENLEKYKENEARELEHPI
LFEGVSDLLEDISNQGRHFLVSHRNDQVLEILEKTSIAAYFTEVVTSSSGFKRKPENPESMLYLRKYQISSGLVIGDRPID
IEAGQAAGLDTHLFTSIVNLRQVLDIZ

ID21 1875bp

60 ATGACAGAAGAAATCAAAAATCTGCAGGCACAGGATTATGATGCCAGTCAAATTCAGTTTATGAGGGCTTAGAG
GCTGTTTCGATGCGTCCAGGGATGTACATTGGATCAACCTCAAAAAGAGGCTTCCACCATCTAGTCTGGGAAATTG
65 TTGATAACTCAATTGACGAGGCCTTGGCAGGATTTGCCAGCCATATTCAAGTTTTATTGAGCCAGATGATTCGAT
TACTGTTGTGGATGATGGGCGTGGTATCCAGTCGATATTCAGGAAAAAACAGGCCGCTCCTGCTGTTGAGACCGT

CTTTACAGTCCTTCACGCTGGAGGAAAGTTCCGGCGGTGGTGATACAAGGTTTCAGGTGGTCTTCACGGGGTGGG
GTCGTCAGTAGTTAATGCCCTTTCCACTCAATTAGACGTTTCATGTTCAAAAAATGGTAAGATTCATTACCAAGAA
TACCGTCGTGGTCATGTTGTCGAGATCTTGAAATAGTTGGAGATACGGATAAAACAGGAACAACTGTTCACTTC
ACACCGGACCCAAAAATCTTCACTGAAACAACAATCTTTGATTTTGATAAAATTAATAAACGGATTCAAGAGTTG
5 GCCTTTCTAAATCGCGGTCTTCAAATTTCAATTACAGATAAGCGCCAAGGTTTGGAAACAAACCAAGCATTATCATT
ATGAAGGTGGGATTGCTAGTTACGTTGAATATATCAACGAGAAACAAGGATGTAATCTTTGATACACCAATCTATA
CAGACGGGTGAGATGGATGATATCACAGTTGAGGTAGCCATGCAGTACACAACCTGTTACCATGAAAAATGTCATGA
GTTTCGCCAATAATATTCATACCCATGAAGGTGGAAACACATGAACAAGGTTTCCGTACAGCCTTGACAGCTGTTAT
CAACGATTATGCTCGTAAAAATAAGTTACTGAAAGACAATGAAGATAATTTAACAGGGGAAGATGTTCCGGAAGG
10 CTTAACTGCAGTTATCTCAGTTAAACACCCAAATCCACAGTTTGAAGGACAAACCAAGACCAAAATGGGAAATAG
CGAAGTGGTCAAGATTACCAATCGCCTCTTCAGTGAAGCTTTCTCCGATTTCCTCATGGAATAACCAAGATTGCC
AAACGTATCGTAGAAAAAGGAATTTTGCTGCCAAGGCTCGTGTGGCTGCCAAGCGTGCAGTGAAGTCAACGCT
AAAAATCTGTTTGGAAATTTCCAACTTCCAGGGGAACTAGCAGACTGTTCTTCTAATAACCCGTGCTGAAACAG
15 AACTCTTCACTCGTGAAGGAGACTCAGCTGGTGATCAGCCAAATCTGTCGTAACCGTGAGTTTCAGGCTATCCT
TCCAATTCGCGGTAAAGATTTTGAACGTTGAAAAAGCAAGTATGGATAAGATTCTAGCCAACGAAGAAATTCGAT
TCTTTTACAGCCATGGGAACAGGATTTGGCGCAGAAATTTGATGTTTCGAAAGCCGTTACCAAAAACTCGTTTGG
ATGACCGATGCCGATGTCGATGGAGCCACATTCTGACCTTCTTTAACCTTGATTATCGTTATATGAAACCAA
TCCTAGAAGCTGGTTATGTTTATATTGCCCAACCACCAATCTATGGTGTCAAGGTTGGAAGCGAGATTAAGAATA
TATCCAGCCGGGTGCAGATCAAGAAATCAAACCTCAAGAAGCTTTAGCCCGTTATAGTGAAGGTCGTACCAAAACC
20 GACTATTCAGCGTTATAAGGGGCTAGGTGAAATGGACGATCATCAGCTGTGGGAAACAAACCATGGATCCCGAACA
TCGCTTGATGGCTAGAGTTTCTGTAGATGATGTGCAGAAGCAGATAAAATCTTTGATATGTTGA

MTEEIKNLQAQDYDASQIQVLEGLEAVRMRPGMYIGSTSKEGLHHLVWEIVDNSIDEALAGFASHIQVFIEPDDSTIVVD
DGRGIPVDIQEKTGRPAVETVFTVLHAGGKFGGGYKVSGLHGVSSVVALSTQLDVHVHKNKGIHYQEYRRGHV
25 VADLEIVGDTDKTGTTHFTPDPKIFTEITTFDFDLNKRQELAFNLRLQISTDKRQGLEQTKHYHYEGGIA SYVEYI
NENKDVIFDTPITDGEDDITVEVAMQYTTGYHENVMSFANNIHTHEGGTHEQGFRTALTRVINDYARKNKLKLDN
EDNLTGEDVREGLTAVISVKHPNPQFEGQTKLGNSEVVKITNRLFSEAFSDFLMENPOIAKRIVEKILAAKARVAAC
RAREVTRKKSGLAISNLPGKLADCSNNPAETELFIVEGDSAGGSAGSRNREFQAILPIRGKILNVEKASMDKILANEEI
30 RSLFTAMGTGFGAEFDVSKARYQKLVMTDADVDGAHIRTLLLTLYRYMKPILEAGYVYIAQPPYGVKVGSEIKEYI
QPGADQEIQLQELARYSEGRTKPTIQRYKGLGEMDDHQLWETTMDEHRLMARVSVDDVQKQKSLICZ

ID54 1446bp

ATGAGTAGACGTTTTAAAAAATCACGTTACAGAAAGTGAAAGCGAAGTGTTAATATAGTTTTGCTGACTATTATT
TATTGTTAGTTTGTGTTTTTATTGTTCTTAATCTTAAGTACAATATCCTTGCTTTTAGATATCTTAATCTAGTGGTAA
35 CTGCGTTAGTCTACTAGTTGCCTTGGTAGGGTACTCTTGATTATCTAAAAAAGCTGAAAAGTTTACTATTITTT
CTGTTGGTGTTCTCTATCCTTGTGAGCTCTGTGTCGCTCTTTCAGTACAGCAGTTTGTGGAGTACCAATCGTTT
AAATGCGACTTCTAATTACTCAGAATATTCAATCAGTGTGCTGTTTTAGCAGATAGTGAGATCGAAAAATGTTACG
CAACTGACGAGTGTGACAGCAGCAGCTGGGACTAATAATGAAAATATTAGAAATTAAGTATATCAAGTCA
40 AGTCAGAATACCGATTGACGGTCAACAGAGTTCGTCTTACTTGGCAGCTTACAAGAGTTTGATTGCAGGGGAG
ACTAAGGCCATTGTCCTAAATAGTGTCTTTGAAACATCATCGAGTCAAGATATCCAGACTACGCATCGAAGATA
AAAAAGATTTATACTAAGGGATTCACTAAAAAAGTAGAAGCTCCTAAGACGCTAAGAGTCAGTCTTTCAATATC
TATGTTAGTGGAAATTGACACCTATGGTCTTATAGTTCCGGTGTGCGGATCAGATGTCAACATCCTGATGATGTCA
45 ATCGAGATACCAAGAAAATCCTCTTGACCAACAACGCCACGTGATGCTATGTACCAATCGCAGATGGTGAAATA
ATCAAAAAGATAAATTGACTCATGCGGGCATTTATGGAGTTGATTGCTCCATTACACCTTAGAAAAATCTCTATGG
AGTGGATATCAATTACTATGTGCGATTGAACCTCACCTTCGTTTTTGAATGATTGATTTGTTGGTGGAATTGATG
TTTATAATGATCAAGAATTTACTGCCCATACGAATGGAAGTATTACCTGCAGGCAATGTTTCATCTTGATTCAGA
ACAGGCTCTCGGTTTTGTTGAGCGCTACTCCCTAGCAGATGGCGATCGTGACCGCGGGCGCCATCAACAAAA
50 GGTGATTGTGGCTATCCTTCAAAAATTAACGTCAACCGAAGTGCTGAAAAATTATAGTACGATCATTAATAGCTTT
CAAGATTCTATCCAAACAAATATGCCACTTGAGACCATGATAAATTTGGTCAATGCTCAGTTAGAAAGTGGAGGG
AATTATAAAGTAAATCTCAAGATTAAAGGGACAGGTGGATGATCTTCTTCTTATGCAATGCCAGACAGTA
ACCTCTATGTGATGGAATAGATGATAGTATTAGCTGTAGTTAAAGCAGCTATACAGGATGTGATGGAGGGTA
GATGA

MSRRFKKRSQKVKRSVNIVLLTIYLLVCFLLFIKYNILAFRYLNLVVTALVLLVALVGLLLIYKKAKEFTIFLLVFS
ILVSSVSLFAVQQFVGLTNRLNATSNYSEYSIVAVLADSEJENVTLQTSVTAPTGTNNENIQKLLADIKSSQNTDLTVNQ
SSSYLAAYKSLIAGETKAIVLNSVFENIESEYDPYASKIKKIYTKGFTKKVEAPKTSKSQSFINIYVSGIDTYGPISVSRS
NLMVTYNRDTKILLTTTPRDAYVPIADGGNNQKDKLTHAGIYGVDSSTHTLENLYGVNDINYVRLNFTSFLKLIDLLGG
IDVYNDQEFTHAHTNGKYYPAGNVHLDEQALGFVRERYSLADGDRDRGRHQKQVIVAILQKLTSTEVLNKYSTIINSLQ
60 DSIQTNMPLETMINLVNAQLESGGNYKVNSQDLKGTGRMDLPSYAMPDSNLVYMEIDSSLA VVKAAIQDVMEGRZ

ID55 732bp

5 ATGATAGACATCCATTGCGCATATCGTTTTTGATGTAGATGACGGTCCCAAGTCAAGAGAGGAAAGCAAGGCTCTC
 TTGGCAGAATCCTACAGACAGGGGGTGGCAACCATTTGTTTCTACCTCTCACCGTCGCAAGGGCATGTTTGAAACTC
 CGGAAGAGAAGATAGCAGAAAACTTTCTTCAGGTTCCGGGAAATAGCTAAGGAAGTGGCGAGTGACTTGGTCATTG
 CTTACGGGGCTGAAATTTATTACACACCAGATGTTCTGGATAAGCTGGAAAAAAGCGGATTCCGACCCTCAATG
 ATAGTCGTTATGCCTTGATAGAGTTTAGTATGAACACTCCTTATCGCGATATTCATAGCGCCTTGAGCAAGATCTT
 10 GATGTTGGGAATTACTCCAGTCATTGCCACATTGAGCGCTATGATGCTCTTGAAAAATATGAAAAACGCGTTGGA
 GAACTGATCGATATGGGCTGTTACACGCAAGTAAATAGTTACATGTCCTCAAAACCCAAACTTTTGGCGAACGTT
 ATAAATTCATGAAAAAAGAGCTCAGTATTTTTAGAGCAGGATTGGTTCATGTCATTGCAAGTGATATGCACAA
 TCTAGACGGTAGACCTCCTCATATGGCAGAAGCATATGACCTTGTTACCCAAAAATACGGAGAAGCGAAGGCTCA
 GGAACTTTTTATAGACAATCCTCGAAAAATTGTAATGGATCAACTAATTTAG

15 MIDHSHVFDVDDGPKSREESKALLAESYRQGVRTIVSTSHRRKGMFETPEEKIAENFLQVRELAKEVASDLVIAYGAEI
 YYTPDVLDKLEKKRIPTLNDSTRYALIEFSMNTPYRDIHSLSKILMLGITPVIAHIERYDALENNEKRVRELIDMGCTYQV
 NSSHLVKPKLFGERYKFMKKRAQYFLEQDLVHVIASDMHNLDRPPHMAEAYDLVTQKYGEAKAQELFDNPRKIVM
 DQLIZ

ID58 3990bp

20 TTGATTTATATAATCGCTATCAATATAACAATGCAATCAGGAGGTTTTGCAATGAAACATGAAAAACAACAGCGT
 TTTTCTATTGTAATACGCTGTAGGAGCAGCTTCTGTTCTAATTTGGATTTGCTTCCAAGCAGAGCTGTTGCGA
 CCGTAGGAGTTACTCTACTACTACAGAAAAACCAACCGACCATCCATACGGTTTTCTGATTCCCTCAATCATCCGA
 AAATCGGACTGAGGAAACACCTAAAGCAGTGCTTCAACCAGAAGCTCCAAAACTGTAGAAACAGAACTCCAG
 CTACTGATAAGGTAGCTAGTCTTCCAAAAACAGAAAGAAACCAAGAGGAAGTTAGTTCAACTCCTAGTGATA
 25 AAGCAGAAGTGGTAACCTCAACTTCTGCTGAAAAAGAACTGCTAATAAAAAAGGCAGAAAGCTAGCCCTAAA
 AAGGAAGAAGCGAAAGAGGTTGATTCTAAAGAGTCAAATACAGACAAGACTGACAAGGATAAACCAAGCTAAAAA
 AGATGAAGCGAAAGCAGAGGCTGACAAACCGGCAACAGAGGCAGGAAAGGAACGTGCTGCAACTGTAATGAAA
 AACTAGCGAAAAAGAAAATTGTTTCTATTGATGCTGGACGTAATATTTCTCACCAGAACAGCTCAAGGAAATCA
 TCGATAAAGCGAAACATTATGGCTACACTGATTTACACCTATTAGTCGGAAATGATGGACTCCGTTTCAATGTTGGA
 30 CGATATGAGCATCAGCTAACGGCAAGACCTATGCCAGTGACGATGTCAAACGCGCCATTGAAAAAGGTACAAA
 TGATTATTACAACGATCCAAACGGCAATCACTTAACAGAAAGTCAAATGACAGATCTGATTAATATGCCAAAGA
 TAAAGGTATCGGTCTCATTCCGACAGTAAATAGTCTGGACACATGGATGCGATTCTCAATGCCATGAAAGAATT
 GGGAAATCCAAAAACCTAATCTTATGCTATTTTGGGAAGAAATCAGCCCGTACTGTCGATCTTGACAACGAACAAGC
 35 TGTCGCTTTTACAAAAGCCCTTATCGACAAGTATGCTGCTTATTTCCGCGAAAAAGACTGAAATCTTCAACATCGGA
 CTTGATGAATGCGCAATGATGCGACAGATGCTAAAGGTTGGAGTGTGCTTCAAGCTGATAAATACTATCCAAAC
 GAAGGCTACCTGTAAAAGGCTATGAAAAATTTATGCTACGCCAATGACCTCGCTCGTATTGTAAAAATCGCAC
 GGTCTCAAACCAATGGCTTTAACGACGGTATCTACTACAATAGCGACACAAGCTTTGGTAGTTTGGACAAAGAC
 ATCATCGTTTCTATGTGGACTGGTGGTTGGGAGGCTACGATGTGCTTCTTAAACTACTAGCTGAAAAAGGTC
 40 ACCAAATCCTTAATACCAATGATGCTTGGTACTACGTTCTTGGACGAAACGCTGATGGCCAAGGCTGGTACAACT
 CGATCAGGGGCTCAATGGTATTAACCAACACCAATCACTTCTGTACCAAAAAACAGAAGGAGCTGATATCCCAAT
 CATCGGTGGTATGGTAGCTGCTTGGGCTGACACTCCATCTGCACGTTATTACCATCACGCCTCTTCAAACTCATG
 CGTCATTTTGCAAAATGCCAACGCTGAATACTTCGACGCTGATTATGAATCTGCAGAGCAAGCACTTAACGAGGTA
 45 CCAAAAGACCTGAAACCGTTATACTGCAGAAAGCGTCACGGCCGTAAGAAAGCTGAAAAAGCTATTCCGCTCTCTC
 GATAGCAACCTTAGCCGTGCCCAACAGATACGATTGATCAAGCCATTGCTAACTTCAAGAACTGTCAACAAC
 TTGACCCTCACGCCTGAAGCTCAAAAAAGAAAGAGCTAAACGCTGAGGTTGAAAAACTTGCCAAAAACAAGGT
 AATCTCAATCGATGCTGGACGCAATACTTTACTCTGAACACGCTCAAACGCATCGTAGACAAGGCCAGTGAGCT
 50 CGGATATTTGATGTCCATCTCTTCTAGGAAATGACGGACTTCGCTTTCTACTCGATGATGACCATTTGCC
 AACGGAACCACTATGCTAGTGATGACGTTAAAAAAGCTATTATCGAAGGAACTAAAGCTTACTACGACGATCCA
 AACGGTACTGCACTAACACAGGCAGAAAGTAACAGAGCTAATTGAATACGCTAAATCTAAGGACATCGGTCTCATC
 CCAGCTATTAACAGTCCAGGTACATGGATGCTATGCTGGTTGCCATGGAAAAATTAGGTATTAATAATCTCTCA
 55 GCCCACTTTGATAAAGTTTCAAAAACACTATGGACTTGAAAAACGAAGAGCGATGAACCTTTGTAAGGCCCTC
 ATCGGTAAATACATGGACTTCTTTGACGTTAAAAACAAAGATTTTCAACTTTGGTACTGACGAATACGCCAACGAT
 GCGACTAGTGCCCAAGGCTGGTACTACCTCAAGTGGTATCAACTCTATGGCAATTTGCCGAATATGCCAACACC
 CTCGACGCTATGGCCAAAGAAAGAGGGCTTCAACCAATGGCCTTCAACGATGGCTTCTACTATGAAGACAAGGAC
 60 GATGTTTCAGTTTGACAAAGATGTCTTGAATTTCTACTGGTCTAAAGGCTGGTGGGGATATAACCTCGCATCACTC
 AATACCTAGCAAGCAAGGCTATAAATCTTGAATACCAACGGTGACTGGTACTACATTCTTGGTCAAAAAACAG
 AAGATGGTGGTGGTTTCTCAAGAAAGCTATTGAGAATACTGGAAGAAACACCACTTCAATCAACTAGCTTCTACCA
 AATATCTGAAAGTAGATCTTCCAACAGTCGGAAGTATGCTTCAATCTGGGCAGATAGACCAAGCGCTGAATACA
 AGGAAGAGGAAATCTTGAACCTCATGACTGCCTTTGCAGACCACAACAAAGACTACTTTCGTGCTAATTAATG
 65 CTCTCCGCGAAGAAATAGCTAAAATCTTCAAACTTAGAAGGATATAGTAAAGAAAGCTTGGAGCCCTTGACG
 CAGCTAAAAACAGCTCTAAATTACAACCTCAACCGTAATAAACAAAGCTGAGCTTGACACGCTTGTAGCCAACTAA
 AAGCCGCTCTTCAAGGCTCAAAACAGCTGTAACCTATTTCAGGAAGCTAGATGAAAAATGAAGTGCTGCAATG
 TTGAACACAGACCAGAACTCATCAAGAACTGAAGAAATTCATTGAAAGTTATCAAGAAAGAAATCTTAACCT
 TCCAGCCGGTCAGGAAAAATATTATCACAGCAGGAGTCAAAGGTGAACGAACCTATTACATCTCTGACTCACTG
 AAAATGGAAAAACAACAGAAACAGTCTTGATAGCCAGTAACCAAGAAAGTTATAAACCAAGTGGTTGAAGTT
 GCGGCTCCTGTAACCAAGGGTGATGAAGTGGTCTTGACCAACTACTGAGGTAAAAACCTAGACTGGATATC

5 CAAGAAGAAGAAATTCCATTTACCACAGTGACTTGTGAAAATCCACTCTTACTCAAAGGAAAAACACAAGTCATT
ACTAAGGGCGTCAATGGACATCGTAGCAACTTCTACTCTGTGAGCACTTCTGCCGATGGTAAGGAAGTAAAAACA
CTTGTAATAAGTGTGCTAGCACAGGAAGCCGTTACTCAAATAGTGAAGTCGGAAGTATGGTAACACATGTAGGC
GATGAAAACGGACAAGCCGCTATTGCTGAAGAAAAACCAAACTAGAAATCCCAAGCCAACCAAGCTCCATCAAC
TGCTCCTGCTGAGGAAAGCAAAGTTCTTCTCAAGATCCAGCTCCTGTGGTAACAGAGAAAAAACTTCTGTAAAC
AGGAACTCAGGATTCTGCAGGACTAGTAGTCGCAGGACTCATGTCCACACTAGCAGCCTATGGACTCACTAAAAAG
AAAAGAAGACTAA

10 MIYIAINITMQSGGFAMKHEKQQRFSIRKYAVGAASVLIGFAFQAQTVAADGVPTTTTENOPTIHTVSDSPQSENRTTE
TPKAVLQPEAPKTVETETPATDKVASLPKTEEPQEEVSTPSDKAEVVTPTSAREKETANKKAEESPKKEEAEKVDSE
SNTDKTDKDKPAKKDEAKAEADKPATEAGKERAATVNEKLAKKKTVIDAGRKYFSPEQLKEIIDKAKHYGYTDLHLL
VGNDGLRFMLDDMSITANGKTYASDDVKRAIEKGTNDYNDPNGNHLTESQMTDLINYAKDKGIGLIPTVNSPGHMD
AILNAMKELGIQNPFSYFGKKSARTVDLDNEQAVAFKALIDKYAAYFAKKTETIFNIGLDEYANDATDAKGSVLAQ
15 DKYYPNEGYPVKGYEKFLAYANDLARIVKSHGLKPMAFNDGIYNSDTSFGSFDKDIIVSMWTGGWGGYDVASSKLLA
EKGHQILNTNDAWYYVLGRNADGGQWYNLDQGLNGIKNTPTSPKTEGADIPHGGMVAAWADTPSARYSPSRLFKL
MRHFANANAIFYAADYESAEQALNEVPKDLNRYTAESVTAVKEAEKAIRSLDSNLSRAQQDITDQALAKLQETVNNLT
LTPEAQKEEEEAKREVEKLAKNKVISIDAGRKYFTLNQLKRIVDKASELGYSDVHLLGNDGLRFLDDMTTANGKTYA
20 SDDVKKAIIEGTKAYYDDPNGTALTQAEVTELIEYAKSKDIGLIPAINSPGHMDAMLVAMEKLGIKNPQAHFDKVSMTT
MDLKNEEAMNFMVYKALIGYMDFFAGKTKIFNFGTDEYANDATSAQGWYLLKWKYLYGKFAEYANTLAAMAKERGL
QPMFNDGFYFEDKDDVQFDKDVLSYWSKGWGYNLASPYLASKGYKFLNTNGDWYLLGQKPEDGGGFLKKAI
ENTGKTPFNQLASTKYPEVDLPTVGSMLSIWADRPSEYKEEEIFELMTAFADHNKDYFRANYNAREELAKIPTNLEG
YSKESLEALDAAKTALNYNLNRNKQAEIDTLVANLKAALQGLKPAVTHSGSLDENEVAANVETREPILITREIPEFVI
25 KKENPNLPAGQENIITAGVKGERTHYISVLTENGKTTETVLDQVTKVINQVVEVGAPVTHKGDESGLAPTEVVKPRL
DIQEEIIFFTVTTCENPLLLKGKTQVITKGVNGHRSNFYSVTSADGKEVKTLVNSVVAQEAQVTVQVEVGTMTVTHVGDE
NGQAAIAEEKPKLEIPSPAPSTAPAEESKVLQDPAPVVTTEKKLPETGTHDSAGLVVAGLMSTLAAAYGLTKRKEDZ

ID122 825bp

30 ATGAACAAAAAACAAGACAGACACTAATCGGACTGCTAGTGTTATTGCTTTTGTCTACAGGGAGCTATTATATC
AAGCAGATGCCGTCGGCACCTAATAGTCCCAAAACCAATCTTAGTCAGAAAAACAAGCGTCTGAAGCTCCTAGT
CAAGCATTGGCAGAGAGTGTCTTAACAGACGCAGTCAAGAGTCAAATAAAGGGGAGTCTGGAGTGGGAATGGCTC
AGGTGCTTTTATCGTCAATGGTAATAAAACAAATCTAGATGCCAAGGTTTCAAGTAAGCCCTACGCTGACAAATA
35 AACAAAGACAGTGGGCAAGGAACTGTTCCAACCGTAGCTAATGCCCTCTGTCTAAGGCCACTCGTCAGTACAA
GAATCGTAAAGAACTGGGAATGGTTCACCTCTTGGACTCCTCCAGGTGGCATCAGGTCAAGAATCTAAAGGG
CTCTTATACCCATGCAGTCGATAGAGGTCAATTGTTAGGCTATGCCTTAATCGGTGGTTGGATGGTTTGTATGCCT
CAACAAGCAATCTAAAAACATTGCTGTTCAGACAGCCTGGGCAATCAGGCACAAGCCGAGTATTGACTGGTC
AAAACTACTATGAAAGCAAGGTGCGTAAAGCCTTGGACCAAAACAAGCGTGTCCGTTACCGTGTAAACCCCTTACT
ACGCTTCAACGAGGATTAGTCCCTCAGCTTACAGATTGAAGCAAGTCTTCGGATGGAGAATTGGAATTCA
40 ATGTTCTAGTTCCTCAATGTTCAAAAGGGACTTCAACTGGATTACCGAACTGGAGAAGTAACCTGTAACCTCAGTAA

45 MNKKTROTLLIGLLVLLLLSTGSYYIKQMPSPNPKTNLSQKKQASEAPSQALAESVLTDAVKSQIKGSLEWNGSGAFTV
NGNKTNLDAKVSSKPYADNKTCTVGKETVPTVANALLSKATROKYKRNKETGNGSTSWTPPGWHQVKNLKGSYTHAV
DRGHLLGYALIGGLDGFDASTSNPKNIAVQTAWANQAQAEYSTGQNYYESKVRKALDQNKRVRYRVTLYYASNEDL
VPSASQIEAKSSDGELEFNVLVPNVQKGLQLDYRTGEVTVTZ

ID123 225bp

50 GTGCTAAGATTCAGCGGATTGAGGCAAGTGATGAAGATGAATAAGAAATCAAGCTACGTAGTCAAGCGTTTACTT
TTAGTCATCATAGTACTGATTTTAGGTACTCTGGCTCTAGGAATCGGTTTAAATGGTAGGTTATGGAATCTTGGGCA
AGGGTCAAGATCCATGGGCTATCCTGTCTCCAGCAAAATGGCAGGAATTGATTCAAAATTACAGGAAATTAG

VLRFSGLRQVMKMNKSSYVVKRLLLVIIVLILGTLALGIGLMVGYGILGKGQDPWAILSPAKWQELIHKFTGNZ

55

CLAIMS:

1. A *Streptococcus pneumoniae* protein or polypeptide having a sequence selected from those shown in table 1.
5
2. A *Streptococcus pneumoniae* protein or polypeptide having a sequence selected from those shown in table 2.
3. A protein or polypeptide as claimed in claim 1 or claim 2 provided in substantially pure form.
10
4. A protein or polypeptide which is substantially identical to one defined in any one of claims 1 to 3.
- 15 5. A homologue or derivative of a protein or polypeptide as defined in any one of claims 1 to 4.
6. An antigenic and/or immunogenic fragment of a protein or polypeptide as defined
20 in Tables 1-3.
7. A nucleic acid molecule comprising or consisting of a sequence which is:
 - (i) any of the DNA sequences set out in Table 1 or their RNA equivalents;
25
 - (ii) a sequence which is complementary to any of the sequences of (i);

- (iii) a sequence which codes for the same protein or polypeptide, as those sequences of (i) or (ii);
- (iv) a sequence which is substantially identical with any of those of (i), (ii) and (iii);
- (v) a sequence which codes for a homologue, derivative or fragment of a protein as defined in Table 1.
8. A nucleic acid molecule comprising or consisting of a sequence which is:
- (i) any of the DNA sequences set out in Table 2 or their RNA equivalents;
- (ii) a sequence which is complementary to any of the sequences of (i);
- (iii) a sequence which codes for the same protein or polypeptide, as those sequences of (i) or (ii);
- (iv) a sequence which is substantially identical with any of those of (i), (ii) and (iii);
- (v) a sequence which codes for a homologue, derivative or fragment of a protein as defined in Table 2.
9. The use of a protein or polypeptide having a sequence selected from those shown in Tables 1-3, or homologues, derivatives and/or fragments thereof, as an immunogen and/or antigen.

10. An immunogenic and/or antigenic composition comprising one or more proteins or polypeptides selected from those whose sequences are shown in Tables 1-3, or homologues or derivatives thereof, and/or fragments of any of these.
- 5 11. An immunogenic and/or antigenic composition as claimed in claim 10 which is a vaccine or is for use in a diagnostic assay.
12. A vaccine as claimed in claim 11 which comprises one or more additional components selected from excipients, diluents, adjuvants or the like.
- 10 13. A vaccine composition comprising one or more nucleic acid sequences as defined in Tables 1-3.
14. A method for the detection/diagnosis of *S.pneumoniae* which comprises the step of bringing into contact a sample to be tested with at least one protein or polypeptide as defined in Tables 1-3, or homologue, derivative or fragment thereof.
- 15 15. An antibody capable of binding to a protein or polypeptide as defined in Tables 1-3, or for a homologue, derivative or fragment thereof.
- 20 16. An antibody as defined in claim 15 which is a monoclonal antibody.
17. A method for the detection/diagnosis of *S.pneumoniae* which comprises the step of bringing into contact a sample to be tested and at least one antibody as defined in claim 15 or claim 16.
- 25 18. A method for the detection/diagnosis of *S.pneumoniae* which comprises the step of bringing into contact a sample to be tested with at least one nucleic acid

sequence as defined in claim 7 or claim 8.

19. A method of determining whether a protein or polypeptide as defined in
Tables 1-3 represents a potential anti-microbial target which comprises inactivating
5 said protein or polypeptide and determining whether *S.pneumoniae* is still viable.

20. The use of an agent capable of antagonising, inhibiting or otherwise
interfering with the function or expression of a protein or polypeptide as defined in
Tables 1-3 in the manufacture of a medicament for use in the treatment or
10 prophylaxis of *S.pneumoniae* infection

1 / 2




FIG. 1

2 / 2




FIG. 2